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Gene therapy consists of the intracellular delivery of genetic material to produce 
a therapeutic effect. One of the most common means used for transferring genes to cells 
are recombinant retroviruses because they infect a variety of cell types and they stably 
integrate the therapeutic gene into the genome of the target cell, resulting, in principle, in 
a long-term cure. Unfortunately, their success has been limited, in part because they fail 
to transfer enough genes to achieve a desired biological effect. In addition, it has proven 
difficult to achieve predictable and reproducible levels of gene transfer using this vector. 
Some of the major limitations of retroviral-mediated gene transfer that are responsible 
for low and variable levels of gene transfer have been identified. These limitations 
include the low probability of encounter between bioactive viruses and target cells, the 
presence of inhibitors of transduction in virus stocks, and the inefficient interactions 
between viral envelope proteins and their cognate cellular receptors.  
We developed a method that substantially enhances the efficiency of retroviral-
mediated gene transfer. The method consists of the combined addition of the cationic 
polymer Polybrene and the anionic polymer chondroitin sulfate C to retrovirus stocks 
prior to transduction. These polymers induced flocculation of virus particles into high 
molecular weight retrovirus-polymer complexes that incorporated more than 80% of the 
viruses and less than 0.3% of the proteins originally present in the stock. The complexes 
were not cytotoxic, did not reduce the stability of the viruses, and were large enough to 
sediment, delivering the viruses to the cells more rapidly than by simple diffusion.  
Increases in the rate of transport of viruses correlated with increases in the rate of 
transduction, as the polymers did not affect the efficiency of post-binding steps of 
transduction. 
 xii
The formation of virus-polymer complexes not only permitted accelerating the 
transport of viruses to cells, but also enabled concentrating virus stocks. Low speed 
centrifugation of the complexes for 5 min, followed by resuspension of the pellet in a 
reduced volume resulted in substantial enhancement of transduction. Additionally, given 
that the complexes selectively incorporated virus particles, we were able to purify stocks 
from inhibitors of transduction by removing the conditioned medium and resuspending 
the pellet in fresh cell culture medium. Purification increased the maximum level of gene 
transfer up to 186-fold and linearized the dose response curve, thereby simplifying 
attempts to obtain reproducible and predictable levels of transduction.   
When using high concentrations of purified viruses, the efficiency of gene 
transfer was dependent on the number of envelope proteins displayed on the surface of 
each virus particle. Viruses with a low number of envelope proteins transduced cells 
more efficiently than did viruses with a high number of envelope proteins, and allowed 
more integrations of the transgene per target cell. In contrast, when the number of 
envelope proteins per virus particle was high, transduction appeared to be limited by a 
reduction in availability of functional receptors for viruses pseudotyped with the same 
envelope. 
In summary, we have shown that the efficiency of retroviral-mediated gene 
transfer can be dramatically enhanced by inducing flocculation of retroviruses into 
polyelectrolyte complexes.  The complexes sediment onto cells, can be rapidly 
concentrated without inactivating the virus particles, and can be purified from inhibitors. 
Purified virus stocks can be used in smaller quantities than unprocessed stocks to 
achieve a desired level of gene transfer and reduces uncertainties about the relationship 
between the amount of virus used and the number of genes transferred. In addition, the 
efficiency of gene transfer, and potentially the number of transgene copies delivered per 
target cell, can be modulated by varying the number of envelope proteins that protrude 
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from a virus particle.  Taken together, these novel methods for processing retrovirus 
stocks and a better understanding of major limitations of transduction should simplify 
efforts to predict the outcome of retrovirus transduction protocols and should help to 











BACKGROUND AND OBJECTIVES 
 
1.1 Gene Therapy 
Gene therapy is the intracellular delivery of genetic material to achieve a 
therapeutic effect. It was initially conceived to treat simple inherited genetic disorders, 
but has since been expanded to a wide range of applications. Gene therapy is currently 
under investigation to treat complex acquired genetic disorders such as cancer and 
infectious diseases such as HIV, and has numerous applications in tissue engineering 
[1]. Unfortunately, in spite of the enormous potential that treating diseases at the genetic 
level holds, there have been relatively few successes to date in gene therapy clinical 
trials, largely due to limitations with the current generation of gene transfer vectors.  
Gene transfer vectors can be classified as viral and non-viral [1, 2]. Viral vectors are 
replication-incompetent derivatives of wild-type viruses that take advantage of the 
mechanism viruses have developed over millions of years to deliver genes in an efficient 
manner and that have been genetically engineered to deliver therapeutic genes to cells. 
Non-viral vectors include all other types of gene transfer vectors and typically involve the 
delivery of genetic material to cells as part of polymer or liposomal complexes or via 
physical methods (by disrupting the cell membrane by mechanical or electrical means). 
The delivery of genetic material for therapeutic applications can be conducted 
either in vivo or ex vivo. In the in vivo setting, gene delivery vectors are directly injected 
into the patient. In the ex vivo setting, tissue is removed from the patient, cells from this 
tissue are cultured in vitro, genetically modified, then selected, expanded and 
reimplanted back into the patient. The ex vivo delivery of genes allows for relatively 
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straightforward targeting of gene delivery vectors and optimization of the gene transfer 
conditions. However, this method is labor intensive, expensive and not applicable to 
tissues that cannot be removed and reimplanted (e.g. brain). On the other hand, in vivo 
delivery requires less manipulation of the tissue, but also requires specific targeting to 
the cells of interest. 
 
1.2 Recombinant retroviruses as gene delivery vectors 
Currently, recombinant retroviruses are the vector of choice for many gene 
therapy applications because they are able to permanently integrate their genome into 
the genome of the target cell, resulting, in principle, in a long-term cure [3, 4]. 
Retroviruses used for gene transfer are often derived from the Moloney murine leukemia 
virus (MLV) or from the human immunodeficiency virus type 1 (HIV-1), which are also 
classified as lentiviruses. The most significant functional difference between these two 
viruses is that recombinant retroviruses delivered from MLV can only infect cells that are 
actively dividing, whereas recombinant lentiviruses derived from HIV may be able to 
infect cells even if they are not dividing [5, 6], an important advantage for many in vivo 
gene therapy protocols [7, 8].  
Recombinant retroviruses for gene therapy are designed to adopt the natural 
ability of wild type retroviruses to integrate into the genome of the target cells. Wild-type 
retroviruses are composed of two copies of identical strands of genomic RNA that are 
enclosed within an icosahedral matrix of virus capsid proteins. The capsid proteins are in 
turn surrounded by a lipid bilayer membrane, from which envelope glycoproteins 
protrude. Recombinant viruses are structurally identical to wild-type viruses, but carry a 
genetically engineered genome (vector), which encodes for the therapeutic gene of 
interest and does not encode for viral genes required for replication. Due to this design, 
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recombinant retroviruses deliver genes to cells in a similar manner to that of wild type 
viruses, but are not able to self-replicate.  
Recombinant retroviruses are produced by a two-part system composed of a 
packaging cell line and a recombinant vector (Figure 1.1). The packaging cell line is 
engineered to express all the viral genes (gag, env and pol) required for the formation of 
infectious virus particles. The retroviral vector contains the gene of interest, regulatory 
sequences for gene expression and a packaging sequence (ψ) for recognition and 
packaging of the viral RNA genome in a virus particle. During virus production, 
packaging cell lines are incubated with cell culture medium for several hours. During this 
time, they express the viral proteins and transcribe the viral vector. The viral proteins 
recognize the ψ packaging sequence of the vector RNA and assemble it into viral 
particles that bud from the cell membrane. The virus-laden medium is then collected and 
used to transfer genes to target cells. 
The process of gene transfer (transduction) consists in incubating virus stocks 
with target cells and requires the completion of a series of complex steps that begins 
with the transport of the virus particles to the surface of the cells. Once a virus binds to 
the surface of a cell, envelope proteins that protrude from the virus specifically bind to 
cellular receptors. This triggers fusion of the lipid bilayers of the virus and the cell. Upon 
fusion, the RNA genome of the virus and associated virus proteins and enzymes are 
released to the cytosol of the cell. After the virus enters the cytosol, the RNA genome of 
the virus is reverse transcribed to DNA, which is transported to the nucleus and 
integrated into the chromosomal DNA of the host cell. Once integrated, the viral DNA is 
stable and inherited by daughter cells, and its expression leads to the synthesis of the 






















Figure 1.1 Production of recombinant retroviruses by packaging cell lines.  Recombinant 
retroviruses are produced by transfecting packaging cells, genetically modified to 
express all of the proteins necessary to form a retrovirus particle, with plasmid DNA that 
encodes the therapeutic gene(s) of interest, the regulatory sequences that drives their 
expression, and a packaging sequence that ensures the RNA genomes of the viruses 
are efficiently incorporated into the virus particles.  The virus capsid proteins self-
assemble around the RNA genomes that contain the packaging sequence, then bud 
from the surface of the cell into the surrounding cell culture medium.  In the process of 
budding, the virus particles incorporate a lipid bilayer, which contains the virus envelope 
proteins and other ‘passenger’ cellular proteins, from the plasma membrane of the cell. 
Transfection
Expression of 




















Figure 1.2 Transduction of target cells by recombinant retroviruses.  Cells are 
transduced by incubation with stocks of retroviruses.  Retroviruses diffuse to the surface 
of the cells, and then bind to them via poorly defined non-specific interactions between 
the surface of the virus and the cell.  The envelope proteins of the virus then interact with 
their cognate receptors on the surface of the cell. This interaction initiates fusion 
between the lipid bilayer of the virus and the plasma or endosomal membrane of the cell, 
and the subsequent release of the internal components of the virus to the cytosol.  In the 
cytoplasm, the RNA genomes of the viruses are reverse transcribed to DNA, then 
transported to the nucleus and integrated into the chromosomal DNA of the cell. The 
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1.3 Limitations of retroviral-mediated gene transfer 
Unfortunately, the use of recombinant retroviruses in the clinic has met with 
limited success, in part because retroviruses often transfer too few genes to cells to 
achieve a desired therapeutic effect [9]. In addition, it has proven difficult to achieve 
predictable and reproducible levels of gene transfer with retroviruses [10]. Some of the 
major limitations of retroviral-mediated gene transfer that are responsible for low and 
variable levels of gene transfer have been identified. In this section we will describe 
major limitations, as well as strategies that have been developed to overcome them. 
 
Low probability of encounter between infectious viruses and target cells 
The low probability of encounter between bioactive viruses and cells is due to the 
combined effect of rapid decay and slow transport of retrovirus particles. Retroviruses 
lose their activity with a half-life between 6 and 8 hours [11, 12] and their transport in 
solution is driven by diffusion, with a diffusion coefficient of 2 x 10-8 cm2/s [13]. 
Considering these parameters, it has been estimated that in a typical gene transfer 
protocol, just 10% of the total number of virus particles are able to diffuse, bind and 
successfully transduce cells before losing their bioactivity [12]. Binding of viruses to cells 
is the first interaction necessary for transduction. It does not require specific binding of 
viral envelope proteins to receptors on the surface of target cell as previously thought 
[14-17], but is mediated by non-specific interactions. Thus, efforts to enhance the 
efficiency of gene transfer have focused on developing methods to increase the rate of 
delivery of infectious viruses to the surface of the cells. These methods include 
centrifugation of the virus stocks over target cells, flow through filtration, tangential flow 
filtration, complexation of virus particles with agents that lead to sedimentation of viruses 
onto target cells, addition of low concentrations of cationic polymers, and coating of the 
tissue culture plate with fragments of fibronectin (where both viruses and cells appear to 
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rapidly bind and colocalize) [18-26]. These methods can only be used ex vivo and 
increase the concentration of viruses on the surface of the target cells.  
Other strategies to increase the number of binding events between infectious 
viruses and target cells have focused on increasing the concentration of virus particles in 
the stocks (Table 1.1). Concentration has been conducted by ultracentrifugation, low 
speed centrifugation (usually for several hours), ultrafiltration, incorporation of viruses 
into complexes that are easily pelleted, and association of viruses with paramagnetic 
particles that are concentrated using a magnetic field [24, 27-39]. These methods can be 
used to process virus stocks prior to transduction ex vivo or in vivo. 
Although most of these approaches have resulted in significant increases in gene 
transfer, often times fold enhancements have been lower than those expected. This can 
be in part explained by the presence of inhibitors of transduction, which are secreted by 
packaging cell lines as a byproduct of the virus production system [40, 41]. 
 
Presence of inhibitors in virus stocks 
During virus production, packaging cell lines secrete a variety of molecules into 
the cell culture medium, some of which act as inhibitors of transduction. The nature and 
concentration of these inhibitors depend on the producer cell line used. As a result, the 
inhibitory activity can substantially differ from stock to stock of the same virus [42]. Some 
of these inhibitors have been identified and include proteoglycans, glycosaminoglycans 
and free envelope proteins [41-43]. 
Glycosaminoglycans are long repeating linear anionic polymers of disaccharides, 
which can be covalently bound to a central protein core to form proteoglycans. The 
extent of inhibition by glycosaminoglycans is independent of the envelope of the virus 
[40, 44] and dependent on the charge of the polymer, its degree of sulfation and its 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































understood, but it has been shown that glycosaminoglycans decrease the rate of binding 
of virus particles to cells [40, 43, 44, 48]. Binding appears to be mediated by non-specific 
interactions between the surface of the virus and glycosaminoglycans expressed on the 
surface of the cells [48], or by interactions between glycosaminoglycans on the surface 
of the viruses and binding sites on fibronectin [26]. Hence, free glycosaminoglycans are 
likely to compete with cell-associated glycosaminoglycans for virus binding [44, 48] or 
with virus-associated glycosaminoglycans for binding to the cells through fibronectin 
[26]. 
On the other hand, soluble (free) viral envelope proteins are present in retrovirus 
stocks and inhibit transduction [42, 49-52]. During virus production, some of the 
envelope proteins are not incorporated into virus particles, but shed from packaging cells 
[51, 52]. Also, it is possible that free envelope sheds from virus particles.  Early studies 
suggested that the shedding of envelope proteins was a common phenomenon of 
retroviruses and lentiviruses [53-55], but more recent quantitative studies of the protein 
content of retroviruses and lentiviruses have demonstrated that envelope proteins are 
more stably associated with virus particles than previously thought and that lentiviruses 
shed few, if any, envelope proteins [56, 57].  Soluble viral envelope act as a competitive 
inhibitor of virus-associated envelopes for binding to cell receptors and thus interfere 
with the fusion step of transduction [42, 58].  
In order to purify virus stocks from inhibitors, various techniques have been 
developed. Some of the concentration procedures we mentioned previously can achieve 
purification of stocks from serum proteins and certain inhibitors [31, 45]. However, these 
techniques may also co-concentrate inhibitors with virus particles [59, 60], making it 
necessary to conduct multi-step processing of virus stocks. Procedures aimed 
exclusively at purifying virus stocks can be applied to concentrated stocks, and  include 
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anion exchange chromatography, hydroxyapatite chromatography and sucrose gradient 
centrifugation [27, 32, 35, 36, 61, 62].  
Most of the purification and concentration methods mentioned are time 
consuming, require elaborate pieces of equipment and result in the loss of a significant 
fraction of the viruses originally present in stock. As a result, multi step processes cause 
substantial loss of virus particles and require long processing times [32].  
 
Inefficient interactions between viral envelope proteins and cellular receptors 
The specific interaction between viral envelope glycoproteins and receptors on 
the surface of target cells is another major determinant of the efficiency of transduction. 
After viruses bind non-specifically to the surface of the cells [15-17, 48, 63], viral 
envelope glycoproteins interact with cell receptors, which mediates fusion and entry of 
the viral core. Envelope proteins consist of two subunits: the extracellular domain SU 
(gp70) and the transmembrane domain TM (Prp15E) [64, 65]. These two subunits result 
from cleavage of a single precursor protein, gPr80env, and remain associated after 
cleavage. The SU subunit mediates binding of the virus particle to cell receptors, while 
SU and TM act in conjunction to mediate fusion and entry of the virus inside the target 
cell [66, 67].  
The choice of the envelope protein is a major determinant of gene transfer, as 
the specific interaction with cell receptors determines the range of cells that a virus can 
or cannot transduce (the tropism of the virus). In order to target specific cells in gene 
therapy protocols, the wild type envelope of a virus can be replaced with one from 
another virus to form a pseudotyped virus (a virus composed of proteins from more than 
one virus) [68, 69]. Commonly used envelope proteins include the amphotropic, 
ecotropic, 10A1, gibbon ape leukemia virus (GALV) and the vesicular stomatitis virus G 
(VSV-G) protein. During virus production, these proteins are transported to the surface 
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or to intracellular compartments of packaging cells, where they are incorporated into 
virus particles. This incorporation has been thought to take place at the plasma 
membrane, during budding of the virus [70, 71]. However, recent evidence suggests that 
colocalization of the envelope and other viral proteins occurs in the cytoplasm [72, 73] 
In addition to tropism, the choice of the envelope determines the efficiency of 
gene transfer [33, 74]. In fact, low expression of receptors has been shown to correlate 
with poor transduction [51, 75-80]. In some cases, transduction has been enhanced by 
inducing overexpression of receptors through manipulation of the cell culture medium. 
For example, the amphotropic receptor (Pit-2) and the gibbon ape leukemia virus 
receptor (Pit-1) are upregulated by incubation of the cells in phosphate depleted medium 
or in the presence of phorbol 12-myristate 13-acetate (PMA) [76, 81-83]. In 
hematopoietic stem cells, these receptors can be upregulated by incubation of the cells 
with cytokines [77, 80, 84]. Alternatively, it is possible to overexpress the receptor by 
transfecting the cells with the gene encoding for it [77, 83]. Slight upregulation of 
receptors that are normally expressed at low levels has been shown to translate in major 
increases in gene transfer [77]. However, this type of manipulation of target cells is not 
always suitable for gene therapy applications. First, most of these procedures require ex 
vivo treatment of the cells. Second, these treatments can potentially result in an altered 
phenotype of the target cells after reimplantation into the body.  
The efficiency of envelope-receptor interactions not only depends on the number 
of cell receptors, but can also be altered by varying the number of envelope 
glycoproteins per virus. The number of envelope proteins on the surface of a virus 
depends on the level of expression of these proteins by packaging cells [42, 85]. It also 
depends on the recognition of the envelope by the viral core during assembly of the virus 
particles [73, 86, 87].  Envelopes from a single virus form oligomers and act 
cooperatively to achieve efficient fusion [65, 87, 88]. Higher concentrations of virus-
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associated envelope proteins have been shown to correlate with higher rates of 
transduction [85]. Although the exact mechanism of fusion is not clear, it has been 
proposed that binding of multiple envelope proteins to multiple receptors creates a 
tighter binding that leads to faster fusion [85, 89]. In agreement with this idea, increasing 
the fluidity of the plasma membrane by increasing the temperature or by incubating cells 
with a detergent, has been shown to increase viral infectivity [90]. This is probably due to 
the fact that a more fluid membrane permits rapid mobilization of receptors to the site of 
virus binding, thereby providing multiple binding sites for multiple envelope proteins of a 
virus particle.  
While several studies have shown that increasing the number of envelopes per 
virus increases transduction , other studies suggest that there is an optimum level of 
envelope expression that maximizes transduction [42].  In fact, an increase in the 
expression of viral envelope may correlate with an increase in shedding of free envelope 
from packaging cells, and thereby with an increase in inhibitory activity in the virus 
stocks. Also, it is possible that an excess of viral envelopes associate with non-functional 
virus particles and compete with envelopes from functional viruses for binding to cell 
receptors [42]. A better understanding of how adjusting the level of envelope expression 
can be used to maximize or control the efficiency of transduction is required to develop 
safe and efficient viral vectors. 
 
1.4 Thesis objectives  
The objectives of this thesis were to enhance the efficiency of transduction, and 
to improve the reproducibility and predictability of gene transfer using recombinant 
retroviruses as gene delivery vectors. To accomplish these objectives, we pursued the 
following aims:  
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1) Develop and characterize a method to overcome the major extracellular rate-
limiting steps of gene transfer.  
2) Determine the extent to which increasing the rate of transport of viruses to cells 
enhances gene transfer. 
3) Determine the extent to which the composition of the medium in virus stocks 
affects the efficiency of transduction, and evaluate the effect that purifying 
viruses from inhibitors in the conditioned medium has on gene transfer. 
4) Examine of the relationship between the level of gene transfer and the number of 
envelope proteins that are incorporated per retrovirus particle when high doses of 
purified virus stocks are used to transduce cells 
 
1.5 Organization of the thesis 
In chapter one, we briefly introduce gene therapy and the use of recombinant 
retroviruses as gene delivery vectors. A major emphasis is placed on limitations of 
retroviral-mediated gene transfer.  
In chapter two, we develop a method to substantially increase the efficiency of 
retroviral-mediated gene transfer. The method consists of inducing aggregation 
(flocculation) of virus particles with charged polymers, which results in the formation of 
high molecular weight virus-polymer complexes. We evaluate the possibility of using 
these complexes to rapidly concentrate and purify virus stocks. Also, we evaluate the 
utility of this method to improve gene transfer to different target cells with various 
pseudotyped retroviruses.  
In chapter three, we examine how aggregation of viruses into polyelectrolyte 
complexes affects the rate of binding of viruses to cells. We find that increasing the 
concentration of polymers in these complexes increases the size of the virus-polymer 
complexes and the rate of transport of viruses, while not interfering with post-binding 
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steps of transduction. Based on these findings, we examine the relationship between 
virus binding and transduction efficiency.  
In chapter four, we examine the possibility of flocculating viruses with different 
combinations of charged polymers. Also, we evaluate the advantages and 
disadvantages of using a single species of cationic polymer versus using two species of 
oppositely charged polymers to induce flocculation of viruses and to enhance 
transduction. 
In chapter five, we use polyelectrolyte complexes to purify virus stocks from 
inhibitors of transduction that are present in virus stocks. We examine the nature of the 
main inhibitor in our system, which appears to be free viral envelope protein. Also, we 
evaluate the effect of purification on the efficiency of transduction.  
In chapter six, we construct a panel of several clonal virus packaging cell lines, 
which differ only in the amount of envelope protein that they express.  We purify virus 
stocks produced by these cell lines from free envelope, and we examine how varying the 
concentration of virus-associated envelope protein affects transduction.  
In chapter seven, we summarize our major conclusions and present some 
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COMPLEXATION OF RETROVIRUSES WITH CATIONIC AND ANIONIC POLYMERS 




The combined addition of equal weight concentrations (80 µg/ml) of the cationic 
polymer Polybrene and the anionic polymer chondroitin sulfate C to retrovirus stocks 
resulted in the formation of high molecular weight retrovirus-polymer complexes that 
could be pelleted by low speed centrifugation.  The pelleted complexes contained more 
than 80% of the virus particles, but less than 0.3% of the proteins that were originally 
present in the virus stock.  Surprisingly, the viruses in the complexes remained bioactive 
and could be used to transduce cells.  The titer of the pelleted virus, when resuspended 
in cell culture medium to the starting volume, was 3-fold greater than the original virus 
stock.  The selectivity (cfu/mg protein) of the process with respect to virus activity was 
more than 1000-fold.  When the pelleted virus/polymer complex was resuspended in 
one-eighth of the original volume and used to transduce NIH 3T3 murine fibroblasts, 
gene transfer was increased 10 to 20-fold over the original unconcentrated retrovirus 
stock.   
 
2.2 Introduction 
Recombinant retroviruses are frequently used for experimental and clinical gene 
transfer because of their ability to permanently modify the genome of cells, their ability to 
transfer genes to a wide variety of primary human cell types, and the relative ease of 
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their construction and production.  Despite these advantages, recombinant retroviruses 
have had limited success in human gene therapy clinical trials, in part because they fail 
to transfer enough genes to achieve a required biological effect [1-5].   
Retrovirus infection requires the successful completion of a complex series of 
steps that begins with the transport and binding of the virus particle to the surface of the 
cell.  Binding has been thought occur through specific interactions between the envelope 
proteins that protrude from the surface of the virus particle and the receptors for the virus 
that are expressed on the surface of the target cells [6].  However, recent studies have 
shown that the initial step of virus binding does not require specific envelope-receptor 
interactions and that the efficiency of retrovirus infection appears to correlate well with 
the efficiency of an initial, receptor-independent, binding event [7, 8].  These 
observations suggest that it may be possible to substantially increase the efficiency of 
gene transfer by improving the rate at which retroviruses complete this initial, receptor-
independent, binding step.  In this context, charged polymers, which are thought to act 
on an early receptor-independent step of infection, have been shown to alter the 
efficiency of retrovirus infection [9, 10].  Cationic polymers, such as poly-l-lysine, 
Polybrene, and protamine enhance infection by as much as ten-fold, possibly by 
reducing the electrostatic repulsion between retroviruses and cells.  Likewise, anionic 
polymers such as dextran sulfate and heparin reduce the transduction efficiency of 
retroviruses and are thought to decrease binding by increasing the electrostatic 
repulsion between viruses and cells [10]. 
Polyanionic polymers that are naturally secreted by cells, such as chondroitin 
sulfate proteoglycans and glycosaminoglycans, have been shown to inhibit retrovirus 
transduction [11-13].  Interestingly, the efficiency of infection is slightly enhanced, rather 
than inhibited, when low doses of the glycosaminoglycan chondroitin sulfate C (CSC) 
are used in conjunction with equal weight concentrations of Polybrene (PB) [14].  These 
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results suggested that it might be possible to further enhance the efficiency of gene 
transfer if higher doses of these polymers were used and if the mechanism of 
enhancement was understood.  Therefore, in this study we tested the hypothesis that 
inclusion of high concentrations of CSC and PB would substantially enhance the 
efficiency of retrovirus-mediated gene transfer. 
 
2.3 Materials and methods 
Chemicals and antibodies.  Nonidet P-40, o-nitrophenyl-β-D-galactopyranoside 
(ONPG), glutaraldehyde, rhodamine B, 3-(4,5-dimethylthiazol)-2,5-diphenyl tetrazolium 
bromide (MTT), 1,5-dimethyl-1,5-diazaundecamethylene polymethobromide (Polybrene), 
o-phenylenediamine (OPD), and chondroitin sulfate C (CSC) (shark cartilage, 59 kDa) 
were purchased from Sigma Chemical Co., St Louis, MO.  5-Bromo-4-chloro-3-indolyl-β-
D-galactopyranoside (X-Gal) was purchased from Denville Scientific Inc., Metuchen, NJ.  
BLOTTO® Blocker in TBS was from Pierce, Rockford, IL.  Mouse anti-p30 antibodies 
were purified from the supernatant harvested from CRL-1912 hybridoma cell line (ATCC, 
Rockville, MD) following standard protocols [15].  The goat polyclonal anti-p30 antibody 
(78S221) was from Quality Biotech, Camden, NJ.  The horseradish peroxidase 
conjugated rabbit anti-goat immunoglobulin G polyclonal antibody was from Zymed 
Laboratories, South San Francisco, CA.  The PDGF-AB ELISA Kit was purchased from 
R&D Systems, Minneapolis, MN. 
Cell culture.  NIH 3T3 fibroblasts, the amphotropic packaging cell line  ψ-CRIP 
[16] and the ecotropic packaging cell line Cre Bag 2 (ATCC, CRL-1858) were cultured in 
Dulbecco’s modified Eagle’s medium with 10% bovine calf serum (HyClone Labs Inc., 
Logan, UT) containing 100 U/mL of penicillin and 100 µg/mL of streptomycin (Gibco 
BRL).  CHO-K1 Chinese hamster ovary cells were cultured in Ham’s F12K medium with 
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10% fetal bovine serum (HyClone Labs, Inc., Logan UT).  293T/17 human embryonic 
kidney (ATCC) and GP2-293 cells were cultured in DMEM, 10% fetal bovine serum 
(Hyclone Labs Inc.), 100 U/mL of penicillin, 100 µg/mL of streptomycin, and 110 µg/mL 
of sodium pyruvate (DMEM/FBS).   
Production of retroviruses.  To generate retrovirus stocks, virus-producing 
cells were grown to confluence in T175 tissue culture flasks, and then incubated for 24 h 
with 35 mL of DMEM/BCS.  The virus-laden tissue culture medium was harvested, filter 
sterilized (0.45-µm), then frozen (-80°C) for later use. We produced various pseudotyped 
retrovirus vectors encoding for GFP by transient transfection of GP2-293 cells that were 
plated the day before in 10-cm tissue culture dishes (6x106 cells/dish), and cultured in 10 
mL of DMEM that contained no antibiotics.  The next day, cells were transfected with the 
MSCV-GFP vector (kind gift of Catherine Verfaillie) and with FB4070ASALF (for 
amphotropic virus), FBMO-SALF (for ecotropic virus), pMD.G (for VSV-G virus), 
pIK.MCV.10A1.env.uTd (for 10A1 virus), pCIGASENV (for GALV virus) or no other 
plasmid (for bald virus). Eight micrograms of each plasmid were diluted into a total of 1.5 
mL of DMEM, then mixed with a solution of 1.5 mL of DMEM and 40 µL of Lipofectamine 
2000 reagent (Invitrogen Life Technologies, Carlsbad, CA), then added to the cells. The 
medium was replaced 6 hours later and 12 hours later with 10 mL of DMEM/FBS. 
Twenty four hours later the virus-laden cell culture supernatant was harvested, filter 
sterilized (0.45-µm) and frozen (-80°C) for later use. 
MTT assay for cell number.  To test the effect of the CSC and Polybrene (PB) 
on the growth rate, NIH 3T3 murine fibroblasts were plated in parallel 96 well plates at 
5000 cells per well, then incubated 24 h at 37°C.  The cell culture medium was then 
replaced with medium that contained from 0 µg/ml to 640 µg/ml of CSC, and 0 µg/ml to 
640 µg/ml of PB, and the cells incubated at 37°C.  Control cells were grown in the 
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presence of fresh medium that did not contain any CSC or PB.  To measure the number 
of viable cells, two days later 10 µl of an MTT stock (10 mg of MTT per ml in PBS, fitler 
sterilized) was added to each well.  After incubation of the plate at 37°C for 4 h, the cells 
containing dark blue formazan precipitate were solubilized by addition of 150 µl of 10% 
sodium dodecyl sulfate (SDS) and incubation overnight at 37°C.  The absorbance at 570 
nm was read, and nonspecific background at 650 nm subtracted. 
Transduction efficiency assay.  To test the effect of CSC and PB on 
transduction efficiency, the day before transduction five thousand cells were plated in 
100 µl of medium per well in a 96-well flat-bottomed tissue culture dish with a low-
evaporation lid (Costar Corp., Cambridge, MA).  The next day (19 to 25 h later), virus 
stocks were brought to a concentration of CSC ranging from 0 µg /ml to 20 µg/ml, 
incubated for 10 min at 37°C, then brought to 8 µg/ml PB and incubated an additional 10 
min at 37°C.  Alternatively, virus stocks were brought to a concentration of CSC ranging 
from 0 µg/ml to 200 µg/ml, incubated for 10 min at 37°C, then brought to 80 µg/ml PB 
and incubated an additional 10 min at 37°C.  The medium was removed, and the virus-
polymer mixtures added to each well (final volume, 100 µl per well).  Two days after 
transduction, the medium was removed, and the cells were washed once with 100 µl of 
phosphate-buffered saline (PBS) containing 1 mM MgCl2.  After removal of the wash 
solution, 50 µl of lysis buffer was added (PBS with 1 mM MgCl2 and 0.5% nonidet P-40) 
to each well, and the plate was incubated at 37°C.  After 30 min, 50 µl of lysis buffer with 
6 mM ONPG warmed to 37°C was added to each well, and the plate was incubated at 
37°C for another 15 min [17].  The reactions were halted by the addition of 20 µl of stop 
buffer (1 M Na2CO3) [18].  The plate was brought to room temperature, and the optical 
density at 420 nm (OD420) was measured using an absorbance plate reader (Molecular 
Devices, Menlo Park, CA); non-specific background at 650 nm was subtracted. Values 
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for replicate wells without virus were subtracted as background.  Values for each point 
are the average of at least triplicate wells.   
Virus precipitation and resuspension.  To determine the concentration of 
polymers needed to form a complex with retrovirus, stocks were brought to a range of 
concentrations of CSC (0 to 160 µg/ml) and to an equal weight concentration of PB, then 
incubated for 20 minutes at 37°C.  In later experiments, the retrovirus-polymer complex 
was formed by bringing virus stocks to 80 µg/ml of CSC and 80 µg/ml of PB.  Once the 
polymers had been added, a portion of the virus solution was removed for analysis, and 
the remainder centrifuged at 10000 g in a 1.5 mL microcentrifuge tube in an Eppendorf 
centrifuge for 5 minutes at room temperature.  The supernatant was removed for 
analysis, and the visible pellet resuspended in PBS or cell culture medium to its original 
volume or to one-eighth its original volume.  All samples were then analyzed for virus 
titer, transduction efficiency, concentration of virus proteins, and/or total protein 
concentration.  An additional eight micrograms of PB was added per ml of sample prior 
to their use in the transduction efficiency assay. 
Detection and quantitation of MoMuLV p30 capsid protein by ELISA.  To 
determine the concentration of virus capsid protein (p30) in virus stocks, we used an 
ELISA.  ELISA plates (Nunc immuno Maxisorp 96-well plates, Nalge Nunc International, 
Rochester, NY) were coated overnight at 4°C with 10 µg/mL of mouse anti-p30 antibody 
(100 µL/well) in PBS. The next day, the antibody solution was removed and blocking 
buffer (PBS, 0.05% Tween-20, 5% non-fat milk) added (200 µL/well) for 2 h at 37°C to 
block non-specific binding sites.  Samples were brought to 0.5% Triton-X to expose the 
p30 antigen, then added to the ELISA plate (100 µL/well) and incubated for 1 h at 37°C.  
Bound p30 was sandwiched by the addition of the goat polyclonal anti-p30 antibody 
diluted 1:1000 in blocking buffer, and incubated for 1 h at 37°C.  The horseradish 
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peroxidase conjugated polyclonal rabbit anti-goat immunoglobulin G was diluted 1:5000 
in blocking buffer then added to the ELISA plate (100 µL/well) for 1 hour at 37°C to 
enable detection and quantitation of the sandwiched p30 antigen. The plates were 
developed for 5 min using hydrogen peroxide (H2O2) and OPD (100 µg/well) from a 
solution of 10 mg of OPD and 10 µl H2O2 in 25 mL of substrate buffer (24 mM citric acid-
monohydrate, 51 mM Na2HPO4-7H20, pH 5.0).  8N sulfuric acid (50 µL/well) was used to 
stop the reaction and the optical density at 490 nm (OD490) measured using an 
absorbance plate reader and the non-specific background at 650nm subtracted. Values 
for replicate wells without virus were subtracted as background. Values for each point 
are the average of at least triplicate wells. 
Diluted virus titer assay.  Serial dilutions of LacZ virus stock were made in 
DMEM with 10% bovine calf serum and PB (8 µg/ml).  2 mL were used to transduce 
cells in 6 well plates (Costar Corp., Cambridge, MA) seeded at 1.5 x 105 NIH 3T3 
cells/well the previous day.  The transduced cells were incubated for two days at 37°C 
until confluent, fixed and stained for lacZ activity with XGAL, colonies of lacZ+ cells 
counted and the titer (cfu/ml) calculated as previously described [19]. 
Protein concentration.  Protein concentrations were determined with the 
Coomassie Plus-200 Protein Assay Reagent in accordance with the manufacturer’s 
instructions (Pierce, Rockford, IL).  Bovine serum albumin was used as the standard. 
Virus tropism experiments.  To determine if retrovirus-polymer mixtures were 
able to transduce cells that did not express the receptor for the retrovirus, amphotropic 
and ecotropic retrovirus-polymer complexes were formed and pelleted with 80 µg/ml of 
CSC and 80 µg/ml of PB as described above. The pellets were resuspended in cell 
culture medium that was appropriate for the target cell type, then used to transduce NIH 
3T3 murine fibroblasts, 293T/17 cells, and CHO-K1 Chinese hamster ovary cells.  
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2.4 Results 
In previous research, small but statistically significant increases in the efficiency 
of retrovirus transduction were observed when virus stocks were brought to equal weight 
concentrations of the cationic polymer Polybrene (PB) and the anionic polymer 
chondroitin sulfate C (CSC) prior to transduction [14].  These results prompted us to 
investigate whether substantial increases in retrovirus-mediated gene transfer could be 
achieved using these polymers. 
Our first experiments showed that gene transfer efficiency increased in 
proportion to the concentration of polymers, which suggested that further increases in 
the concentration of polymers might result in even higher gene transfer efficiencies.  To 
determine if high concentrations of polymers were cytotoxic, we incubated NIH 3T3 
fibroblasts with a range of concentrations of Polybrene (PB) only, chondroitin sulfate C 
(CSC) only, or a mixture of both PB and CSC for two days, then measured the final cell 
number with the MTT assay (Figure 2.1).  We found that PB, but not CSC, was cytotoxic 
at high concentrations.  However, mixtures of equal weight concentrations of PB and 
CSC were not cytotoxic, suggesting that CSC mitigates the cytotoxic effects of PB. 
Since high concentrations of PB and CSC mixtures were not cytotoxic, we decided to 
investigate if higher doses of polymers could be used, and to observe how transduction 
efficiency would vary with changes in concentration and with changes in the the ratio of 
the two polymers.  Virus stocks were brought to low doses of PB (8 µg/ml) or to high 
doses of PB (80 µg/ml), and then to range of concentrations of CSC. These stocks were 
used to transduce cells.  As a control, cells were transduced with virus that contained 
only 8 µg/ml PB. Regardless of the concentration of PB used, the transduction efficiency 
increased, reached a peak, then decreased with increasing concentrations of CSC 




















Figure 2.1 Mixtures of PB and CSC are not cytotoxic.  NIH 3T3 cells were grown in the 
presence of various concentrations of CSC ( ), PB ( ), or equal weight concentrations 
CSC and PB ( ).  After two days of growth, mitochondrial activity was determined using 






















































(80 µg/ml) and CSC were used, and less than 2-fold when low doses of PB (8 µg/ml) 
and CSC were used.  of PB (80 µg/ml) and CSC were used, and less than 2-fold when 
low doses of PB (8 µg/ml) and CSC were used.  As expected due to its cytotoxicity, gene 
transfer was negligible when high doses of PB (80 µg/ml) were used in the absence of 
CSC.  Interestingly, regardless of the absolute concentration of the polymers, the highest 
transduction efficiencies were observed when the weight concentrations of CSC and PB 
were about equal.  Thus, for the remaining studies, we used equal weight concentrations 
of CSC and PB. 
In the course of these experiments we noted the presence of granular 
precipitates on the surface of the cells that had been exposed to 80 µg/ml PB and 80 
µg/ml CSC. This suggested that PB, CSC, and perhaps viruses, had formed complexes 
that sedimented onto the cells.  To determine if retrovirus had incorporated into polymer 
complexes, we brought virus stocks to equal concentrations of CSC and PB ranging 
from 0 to 160 µg/ml each, then centrifuged the stocks at 10000g for 5 minutes.  We 
obtained a visible pellet that we resuspended to its original volume in fresh medium. We 
measured the concentration of virus capsid protein (p30) in the pellet by ELISA. Levels 
of p30 in the pellet increased with increasing concentrations of polymers until, at 80 
µg/ml of each polymer, more than 85% of p30 was found in the pellet (Figure 2.3). At 
greater than 80 µg/ml, no further increases in the amount of p30 in the pellet were 
observed.   
To determine if incorporation of viruses into polymer complexes was dependent 
on the envelope protein, we brought stocks of viruses not displaying an envelope protein 
(bald viruses) and stocks of viruses pseudotyped with the amphotropic, ecotropic, 
VSVG, 10A1 or GALV envelope protein, to 80 µg/mL of CSC and to 80 µg/mL of PB. We 




















Figure 2.2 Mixtures of CSC and PB enhance gene transfer.  NIH 3T3 cells (5000 per 
well) were plated in a 96 well dish and the next day transduced with 100 µl of medium 
containing amphotropic lacZ virus, 8 µg/ml PB ( ) or 80 µg/ml PB ( ), and a weight 
concentration of CSC ranging from 0 to 2.5-fold that of PB.  After two days the cells were 
assayed for β-galactosidase activity. Each point shows the mean ± standard deviation of 
three replicates. 
 





























































Figure 2.3 Retrovirus particles form complexes with PB and CSC. A stock of 
amphotropic LacZ virus was brought to a range of equal weight concentrations of CSC 
and of PB, incubated at 37°C, then pelleted by centrifugation. The pellet was 
resuspended to the original volume in fresh medium. The concentration of virus in the 
supernatant ( ), resuspended pellet ( ), and original stock with added PB and CSC 
prior centrifugation ( ), was determined with the p30 ELISA.  Each point shows the 
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medium.  We found that viruses were incorporated into the complexes with equal 
efficiency, regardless of which envelope protein was used to pseudotype them, and 
even when bald viruses were used (Figure 2.4). To determine if the viruses in the 
polymer complex were still active, we brought a stock of amphotropic viruses to 80 µg/ml 
CSC and 80 µg/ml PB, centrifuged and resuspended the resulting virus-polymer pellet to 
its original volume in fresh cell culture medium, and then used it to transduce NIH 3T3 
cells.  The titer of virus that had been pelleted and resuspended to its original volume, 
was three-fold higher than the titer of the original virus stock (Table 2.1).  Similar 
increases in gene transfer as measured by the transduction efficiency assay were 
observed when the pelleted and resuspended virus was applied directly to cells in 
undiluted form.  Interestingly, increases in titer were not observed in virus stocks that 
were brought to 80 µg/ml of CSC and 80 µg/ml PB but not pelleted (Table 2.1).  The titer 
of the supernatant that remained after centrifugation of the virus-polymer complex was 
variable but low (9 ± 7% of the original virus titer, n=5), as expected, indicating that most 
of the virus had been pelleted.  
To determine the selectivity of the complexation process, we measured the total 
protein concentration in the supernatant and the pellet as well as in the original virus 
stock before and after addition of the polymers (Table 2.1).  The protein concentration in 
the pellet was less than 0.3 percent of the protein concentration in the virus stock prior to 
centrifugation, whereas the protein concentration in the supernatant was 
indistinguishable from the original stock. 
Since the use of high concentrations of polymers was not cytotoxic and pelleting 
of the complexes did not inactivate the viruses, we decided to test if concentrated virus 
stocks, generated by pelleting and resuspension of the virus-polymer complex in 

















Figure 2.4 Retroviruses are incorporated into complexes regardless of the pseudotype.  
Viruses pseudotyped with the amphotropic (A), ecotropic (E), VSVG, 10A1, GALV, or no 
(BALD) envelope protein, were brought to 80 µg/mL CSC and PB, pelleted, and then 
resuspended to their original volume.  The amount of virus in the pellet was determined 
by p30 ELISA and is expressed as a percent of the virus from the original stock. Each 
point represents the mean ± standard deviation of triplicate samples. 
 
 























































Before Pelleting    6900 ± 800        0.37 ± 0.04     37,000 ± 7200             1.3 ± 0.04 
After Pelleting        20 ± 4.0        0.29 ± 0.04   110,000 ± 30,000             2.4 ± 0.30 
% Recovery     0.29 ± 0.07           78 ± 14          300 ± 100            180 ± 24 
 
aLacZ virus was brought to 80 µg/ml CSC, incubated for 10 min at 37°C, brought to 80 
µg/ml of PB, then incubated for an additional 10 min.  A portion of this virus-polymer 
suspension was saved for later analysis (Before Pelleting); the remainder was 
centrifuged at 10,000 rpm in a 1.5 ml microcentrifuge tube for 5 min at room 
temperature.  The supernatant was removed and the pelleted virus-polymer complex 
was resuspended to the original volume in PBS (After Pelleting).  The samples were 
then analyzed for total protein content, concentration of p30, virus titer and transduction 
efficiency as described in the materials and methods.  Values are means ± SD for at 
least three replicates. 
bThe titer of the virus stock used in these experiments was 37,000 ± 12,000 cfu/ml.  




centrifuged a virus stock that contained 80 µg/ml of CSC and 80 µg/ml of PB, then 
resuspended the pellet in one-eighth of the original volume with cell culture medium. We 
used the concentrated virus to transduce NIH 3T3 fibroblasts. The concentrated virus-
polymer complex transduced NIH 3T3 fibroblasts more than 10-fold more efficiently than 
the unconcentrated virus-polymer mixture, and more than 20-fold more efficiently than 
the original virus stock that contained no polymers (Figure 2.5). 
To determine if the tropism of the virus was altered by complexation with the 
polymers, we brought stocks of ecotropic and amphotropic retroviruses to 80 µg/ml of 
CSC and PB. We pelleted the stocks, resuspended the pellets in fresh culture medium, 
and used them to transduce NIH 3T3 fibroblasts, 293T/17 cells, and CHO-K1 cells.  
Amphotropic and ecotropic viruses were only able to transduce cells that expressed the 
amphotropic and ecotropic receptor, respectively, regardless of whether or not they had 
been complexed with CSC and PB (Figure 2.6).   
Taken together, our results indicated that complexation of viruses with charged 
polymers permits to efficiently and easily concentrate virus stocks within less than 30 
min (including 20 min of incubation of viruses with polymers to allow formation of the 
complexes and 5 min for pelleting of the complexes). In a effort to minimize the time 
required to conduct this procedure, we varied the incubation time of the virus stock with 
the polymers between 0 and 20 min (while maintaining the centrifugation time at 5 min) 
and the centrifugation time between 0 and 5 min (while maintaining the incubation time 
at 20 min), then quantified the recovery of p30 in the pellet. Incubation of the virus stock 
with PB and CSC for 5 minutes and centrifugation of the stock for 3 minutes resulted in 
optimal recovery of p30 (Figure 2.7). Also, a 5-min incubation followed by a 3-min 



















Figure 2.5 Retrovirus-polymer complex can transduce cells.  Amphotropic LacZ virus 
was brought to 80 µg/ml CSC and PB and the resulting virus-polymer complex pelleted, 
then resuspended, to one-eighth of the original volume. NIH 3T3 cells were transduced 
with: control starting virus with no added polymers (CNTL), the starting virus with added 
polymers prior to centrifugation (POL), the supernatant (SN), or the virus-polymer 
complex resuspended to 1/8 the original volume (PELL).  All samples were brought to a 
final concentration of 8 µg/ml of PB prior to transduction. Transduction was measured 
using the transduction efficiency assay that measures the level of β-galactosidase 
activity in the transduced cells.  Each point shows the mean ± standard deviation of 























































Figure 2.6 Virus tropism is not altered by the formation of a virus-polymer complex.  
Ecotropic (black bars) and amphotropic (white bars) lacZ viruses were brought to 80 
µg/ml CSC and PB and the resulting virus-polymer complex pelleted, then resuspended, 
to their original volume in cell culture medium that was appropriate for the intended 
target cell type.  Resuspended pellets were used to transduce human embryonic kidney 
cells (293T/17)(permissive for amphotropic), murine fibroblasts (3T3)(permissive for 
ecotropic and amphotropic), or Chinese hamster ovary cells (CHO-K1)(nonpermissive 
for ecoptropic and amphotropic). Transduction was measured using the transduction 
efficiency assay that measures the level of β-galactosidase activity in the transduced 




























































Figure 2.7 Optimization of the incubation and centrifugation times for pelleting of viruses 
with polymers. Stocks of amphotropic virus were brought to 80 µg/mL of PB and 80 
µg/mL of CSC, incubated for 0, 5, 10 or 20 min at 37°C, then centrifuged at 10000g for 5 
min. Also, virus stocks were incubated for 20 min at 37°C, then centrifuged at 10000g for 
1, 3 or 5 min. The supernatants were collected and the pellets resuspended to their 
original volume.  The concentration of p30 in the original virus stock (line above the 
bars), the supernatants (white bars) and the pellets (black bars) was measured by 
















































(data not shown). These results indicated that concentration of virus stocks is possible in 
less than 10 min. 
 
2.5 Discussion 
Addition of high and equal weight concentrations of the cationic polymer PB and 
the anionic polymer CSC resulted in the formation of visible virus-polymer complexes 
that incorporated 80% of the virus particles, but fewer than 0.3% of the proteins that 
were originally present in the virus stock.  PB and CSC mixtures were not cytotoxic even 
when concentrations as high as 640 µg/ml of each polymer were used.  When the virus-
polymer complexes were formed by the addition of 80 µg/ml of CSC and 80 µg/ml of PB, 
the efficiency of gene transfer increased by more than 3-fold.  Centrifugation of these 
complexes resulted in the formation of a visible pellet. Resuspension of the pellet to one 
eighth the original volume resulted in a 10 to 20-fold increase in gene transfer to NIH 
3T3 cells. 
The mechanism by which the oppositely charged polymers and the negatively 
charged virus form a complex is not known, but our results indicate that high 
concentrations of both polymers must be added to get significant precipitation of the 
virus.  In addition, our results demonstrate that the formation of the complexes is not the 
result of specific interactions with the virus envelope protein since non-enveloped 
viruses and various pseudotyped viruses formed complexes equally well with the 
polymers.  Also, in this study we did not examine the mechanism by which the complex 
enhances the efficiency of gene transfer of unconcentrated or concentrated virus. 
However, our results permit eliminating some possibilities: the polymers do not stimulate 
target cell growth (Figure 1) or eliminate the requirement for the retrovirus receptor 
(Figure 7).   
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We were surprised to find that the virus trapped in the high molecular weight 
complex could transduce cells and that the efficiency of gene transfer was enhanced by 
the complex.  We expected to find that the complex might reduce gene transfer by 
impeding the ability of the virus to diffuse to and bind to the virus receptor on the cell 
surface.  In addition, since both cationic and anionic polymers were used, the complex is 
probably neutrally charged and is therefore unlikely to enhance gene transfer simply by 
reducing the electrostatic repulsion between the virus and the cell, as has been 
previously observed when cationic polymers only were added to retrovirus stocks [9, 10, 
20].   
One possibility, given the selectivity with which retroviruses are incorporated into 
the complexes, is that complex formation enhances gene transfer by purifying or 
separating the viruses from an inhibitor of transduction.  Another possibility is that the 
virus-polymer complexes are large enough to sediment onto the target cells.  This would 
increase the rate at which viruses encounter target cells, thereby reducing the number of 
viruses that decay before they reach the cell by simple diffusion [21, 22].  Neither 
possibility is ruled out by our observation that pelleting and resuspension of the virus-
polymer complex increased the titer by about three-fold over virus that had formed a 
complex but had not been pelleted and resuspended.  For example, it is possible that 
the virus is tightly associated with an inhibitor that is not released by simple dilution into 
cell culture medium but which is released during the process of pelleting and 
resuspension.  Alternatively, it is possible that pelleting, which substantially increases 
the concentration of the polymers and virus (until they are resuspended) induces a 
change in the size or structure of the complex that improves gene transfer.  
Our results show that by adding CSC and PB, retrovirus can be rapidly 
concentrated and purified in a single step without destroying biological activity.  The 
selectivity (cfu/mg protein) of the process with respect to virus activity is more than 1000-
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fold.  The complexes captured 80% of the virus particles in the stock, as measured by 
p30, but they captured 300% virus stock’s gene transfer activity.  Moreover, the 
complexes only incorporated 0.3% of the protein present in the original virus stock. 
Therefore, this single processing step represents a significant step in the purification of 
retrovirus.   
Complexation of retroviruses into polymer complexes may have several 
important applications.  It can be used to rapidly concentrate retrovirus and significantly 
improve the efficiency of ex vivo gene transfer. Given its simplicity, rapidity, and low 
cost, if it can be scaled-up, it may have advantages over other large-scale processing 
approaches such as tangential flow, hollow fiber filtration, ultrafiltration and 
ultracentrifugation. [23-27].  The virus-polymer complexes can be resuspended in a 
culture medium that is optimal for the proliferation of the intended target cell type which 
may help increase gene transfer.  Moreover, the purification achieved by the formation of 
the complexes may remove inhibitors or undesirable impurities.  Such purification steps 
are important for the eventual formulation of a therapeutic retrovirus preparation that is 
suitable for injection and in vivo gene transfer applications. 
A better understanding of the mechanism by which viruses are captured into 
polymer complexes and the key properties of the polymers that are necessary for 
complex formation would permit optimizing this procedure for specific gene transfer 
applications. In the following chapters, we will examine in more detail the mechanism of 
complexation of viruses with polymers, as well as the mechanism by which virus-
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COMPLEXATION OF RETROVIRUSES WITH CHARGED POLYMERS ENHANCES 




3.1 Abstract  
We have previously found that retrovirus transduction is enhanced when an 
anionic polymer (chondroitin sulfate C) is added to virus stocks that contain an equal 
weight concentration of a cationic polymer (Polybrene).  This observation was 
unexpected given that previous work has shown that cationic polymers enhance 
transduction while anionic polymers have the opposite effect.  Using model recombinant 
retroviruses and lentiviruses that encode for the Escherichia coli lacZ gene and 
quantitative assays of virus adsorption and transduction, we examined the mechanism of 
enhancement.  We found that addition of oppositely charged polymers (Polybrene and 
chondroitin sulfate C) to virus stocks enhanced gene transfer by increasing the flux of 
active viruses to the cells.  Virus-polymer complexes formed that did not reduce the 
stability of the viruses yet were large enough to sediment, delivering the viruses to the 
cells more rapidly than by simple diffusion.  The size of the complexes, the rate of 
sedimentation, and the levels of gene transfer increased with increasing concentrations 
of polymers.  The degree to which transduction was enhanced ranged from 2 to nearly 
40-fold, and varied depending on the type of cells and viruses used.  Interestingly, we 
found that association of the viruses with the polymer complexes did not significantly 
hinder their ability to complete post-binding steps of transduction.  We concluded that 
                                            
* Modified from Journal of Gene Medicine, 2004, 6(12):1304-19 
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complexation of retroviruses with charged polymers significantly improves the efficiency 
of ex vivo gene transfer by increasing the number of active viruses that reach the cells.  
 
3.2 Introduction 
Recombinant retroviruses offer a number of advantages as gene transfer 
vectors, particularly when permanent modification of the genome is desired [1, 2].  
Nevertheless, their success in human gene therapy clinical trials has been limited, in 
part because they fail to transfer enough genes to cells to achieve the desired 
therapeutic effect [1, 3, 4].  Retrovirus transduction appears to be limited by a number of 
barriers, a significant one being the slow rate that retroviruses bind to cells [5-7].  
Retrovirus binding to cells is limited by biophysical constraints that control the rate that 
viruses are transported to the cells, and by biochemical factors that interfere with their 
adsorption once they have reached the surfaces of the cells.   
In conventional transductions, retroviruses are transported to cells by diffusion, a 
slow process compared to the rate that viruses lose their bioactivity (decay).  As a result, 
less than one-tenth of viruses used in a typical gene transfer protocol reach the surfaces 
of the cells before losing their bioactivity [5, 7, 8].  Viruses that successfully reach the 
cell surface while still active must then bind to the cell.  This initial binding event appears 
to involve interactions between extracellular matrix proteins on the surfaces of the cells 
and viruses, and is strongly influenced by the presence of charged polymers in the virus 
stocks [9-12].  Cationic polymers enhance retrovirus binding and transduction, 
presumably by reducing the electrostatic repulsion between the negatively charged 
viruses and cells [13-17].  Anionic polymers almost always inhibit retrovirus transduction, 
presumably by increasing the electrostatic repulsion between the viruses and cells [12, 
16, 18-20].  Not all anionic polymers inhibit transduction solely by increasing the 
electrostatic repulsion between the viruses and the cells.  For example, we have 
 
 48
previously shown that chondroitin sulfate proteoglycans and glycosaminoglycans inhibit 
retrovirus transduction, but only if they have a high degree of sulfation and a specific 
carbohydrate structure [21]. Others recently observed that free heparin and heparan 
sulfate glycosaminoglycans inhibit retrovirus binding and transduction by competitively 
binding to the heparan-binding domains of fibronectin molecules bound to the surfaces 
of cells or tissue culture plates [22, 23] or by binding to the surface of the virus and 
competing with cell associated glycosaminoglycans for virus binding [19]. 
While studying the effects of charged polymers on transduction, we previously 
found that the combined addition of an anionic polymer (chondroitin sulfate C; CSC) and 
a cationic polymer (Polybrene; PB) led to the formation of virus-polymer complexes that 
contained more than 80% of the virus particles, but less than 0.3% of other proteins 
(refer to Chapter 2) [24].  To concentrate and purify the virus-polymer complexes, we 
pelleted them by low speed centrifugation, resuspended them to one-eighth their original 
volume in fresh medium, and then used them to transduce cells.  Gene transfer was 
enhanced 10 to 20-fold. Interestingly, gene transfer was enhanced 3 to 4-fold even when 
the virus-polymer complexes were not concentrated or purified, but the mechanism of 
enhancement was not explored.  Given these promising results, we decided to 
investigate the mechanism by which the polymers enhance gene transfer without the 
need for concentration or purification. 
 
3.3 Materials and methods 
Chemicals and antibodies.  Chondroitin sulfate C (CSC) (shark cartilage), 
gluteraldehyde, 1,5-dimethyl-1,5-diazaundecamethylene polymethobromide (polybrene, 
PB), o-Nitrophenyl β-D-galactopyranose (ONPG) and Igepal CA-630 were from Sigma 
Chemical Co. (St. Louis, MO).  Hydrogen peroxide 30%, and Polyoxyethylene 20-
Sorbitan Monolaurate (Tween 20) were from Fisher Scientific (Fair Lawn, NJ).  Non-fat 
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dry milk (blotting grade) was from Bio-Rad Laboratories (Hercules, CA).  o-
Phenylenediamine Dihydrochloride (OPD) was from Pierce (Rockford, IL).  5-Bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (X-Gal) was from Denville Scientific, Inc. 
(Metuchen, NJ).  Mouse anti-p30 antibodies were purified from the supernatant of the 
CRL-1219 hybridoma cell line (ATCC, Rockville, MD) following standard procedures 
[25].  The goat polyclonal anti-p30 antibody (78S221) was from Quality Biotech 
(Camden, NJ).  The horseradish peroxidase conjugated rabbit anti-goat immunoglobulin 
G polyclonal antibody was from Zymed Laboratories (South San Francisco, CA).  
Cell culture.  NIH 3T3 mouse fibroblasts and the amphotropic packaging cell line 
Ψ-CRIP producing the α-SGC-LacZ virus [26], kind gifts of Jeffrey R. Morgan, and the 
ecotropic packaging cell line CRE BAG, obtained from the American Type Culture 
Collection (ATCC), were cultured in Dulbecco's modified Eagle's medium (DMEM; 
Hyclone Labs Inc., Logan, UT) with 10% bovine calf serum (Hyclone Labs Inc.), 100 
U/mL of penicillin, 100 µg/mL of streptomycin (Hyclone Labs Inc.) and 110 µg/mL of 
sodium pyruvate (Hyclone Labs Inc.) (DMEM/BCS).  TELCeB6 (TE671 cells expressing 
Mo-MLVgagpol and the retroviral vector MFGnlsLacZ [27] were kind gifts of F.L. Cosset.  
TE671 (human medulloblastoma epithelial cells), HeLa cells (human adenocarcinoma 
cells), and 293T/17 human embryonic kidney cells were obtained from the ATCC.  
These cell lines were cultured in DMEM, 10% fetal bovine serum (Hyclone Labs Inc.), 
100 U/mL of penicillin, 100 µg/mL of streptomycin, and 110 µg/mL of sodium pyruvate 
(DMEM/FBS).   
Generation of a stable amphotropic retrovirus packaging cell line.  An 
amphotropic packaging cell line (TELCeB6-A) was generated by stable transfection of 
TELCeB6 cells.  Five micrograms of the plasmid FB4070ASALF, an expression plasmid 
that encodes for the amphotropic envelope glycoprotein (a kind gift of Stephen Russell), 
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was dissolved in 400 µL of 0.25M CaCl2, mixed with 400 µL of 2X HEPES buffered 
saline (274 mM NaCl, 42 mM Hepes acid, 10 mM KCl, 1.4 mM Na2HPO4 and 12 mM 
dextrose), incubated at room temperature for 20 minutes, then added to a 50% confluent 
T75 flask of TELCeB6 cells.  Twelve hours after transfection the cells were washed with 
PBS, and then the medium replaced with fresh DMEM/FBS.  Two days later the cells 
were trypsinized, pelleted, and resuspended. Two hundred microliters of the 
resuspended cells were diluted in 10 mL of selective medium (DMEM, 10% FBS, 50 
µg/mL of phleomycin, and 7 µg/mL of blasticidin), and plated in a T75 flask.  Fourteen 
days later pooled clones of stably transfected cells were frozen for later use. 
Production of retroviruses and lentiviruses.  To generate retrovirus stocks, 
virus-producing cells were grown to confluence in T175 tissue culture flasks, and then 
incubated for 24 h with 35 mL of DMEM/BCS.  The virus-laden tissue culture medium 
was harvested, filter sterilized (0.45-µm), then frozen (-80°C) for later use.  We produced 
lentivirus vectors by transient transfection of 293T/17 cells that were plated the day 
before in 10-cm tissue culture dishes (6x106 cells/dish), and cultured in 10 mL of DMEM 
that contained heat inactivated FBS (10%) but no antibiotics.  The next day (between 18 
to 30 h later), cells were transfected with pCMV∆R8.91 (kind gift of Scott S. Case, [28]), 
pTY-EfnlacZ (NIH AIDS Research & Reference Reagent Program, Rockville, MD), and 
pMD.G (kind gift of Scott S. Case, [28]) or FB4070ASALF.  To produce GFP-labeled 
lentivirus, cells were also transfected with GFP-Vpr (a kind gift of Thomas Hope) [29]. 
Eight micrograms (six micrograms for GFP-labeled lentivirus) of each plasmid were 
diluted into a total of 1.5 mL of DMEM, then mixed with a solution of 1.5 mL of DMEM 
and 90 µL of Lipofectamine 2000 reagent (Invitrogen Life Technologies, Carlsbad, CA), 
then added to the cells. Thirty-six hours later the medium was replaced with 10 mL of 
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DMEM/FBS. Twelve hours later the virus-laden cell culture supernatant was harvested, 
filter sterilized (0.45-µm) and frozen (-80°C) for later use. 
Diluted titer assay.  Ten-fold serial dilutions of lacZ virus stock were made in 
DMEM/BCS and Polybrene (8 µg/mL).  A 1-mL amount per well was used to transduce 
3T3 cells that had been seeded (7 x 104 per well) the previous day in a 12-well plate.  
Two days after the start of the transduction, the cells were fixed and stained for β-
galactosidase activity with X-Gal [30].  Colonies of lacZ+ cells (typically in clusters of 2, 
4, or 8 blue cells) were counted with the aid of a dissecting microscope.  At appropriate 
dilutions of the virus stock, the clusters of blue cells were sufficiently spread over the 
dish such that each cluster arose from a single transduction event.     From triplicate 
wells, the number of lacZ+ CFU per milliliter was 6.1 x 104 ± 0.6 x 104 for amphotropic 
retrovirus produced from the Ψ-CRIP cell line, 1.1 x 105 ± 0.2 x 105 for ecotropic 
retrovirus produced from the CRE BAG cell line, 7.2 x 106 ± 0.6 x 106 for amphotropic 
retrovirus from the TELCeB6-A cell line, 1.0 x 105 ± 0.06 x 105 for amphotropic lentivirus 
produced by transient transfection of 293T/17 cells, and 3.1 x 104  ± 0.3 x 104 for 
vesicular stomatitis virus glycoprotein (VSVG) pseudotyped lentivirus produced by 
transient transfection of 293T/17 cells. 
Beta-galactosidase (β-gal) assay.  To test the effect of polymers on 
transduction, five thousand NIH 3T3 murine fibroblasts in 100 µL of medium were plated 
per well in a 96-well flat-bottomed tissue culture dish with a low-evaporation lid (Costar 
Corp., Cambridge, MA).  The next day (19 to 26 h later), virus stocks were brought to a 
range of equal weight concentrations of PB and CSC by adding, in immediate 
succession, appropriate volumes of aqueous stock solutions (20 mg/mL) of the polymers 
and vortexing the mixture. The concentration of PB was then raised an additional 8 
µg/mL. The medium was removed and 100 µL of the virus-polymer mixture added to 
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each well.  Two days after transduction, the medium was removed and the cells washed 
once with 100 µL of phosphate-buffered saline (PBS) containing 1mM MgCl2.  After 
removal of the wash solution, 50 µL of lysis buffer (PBS with 1mM MgCl2 and 0.5% 
Igepal) were added to each well, and the plate incubated at 37°C.  After 30 min, 50 µl of 
lysis buffer with 6 mM ONPG warmed to 37°C were added to each well, and the plate 
incubated at 37°C for 5 to 60 min until a visible yellow color was obtained.  The reactions 
were halted by the addition of 20 µL per well of stop buffer (1M Na2CO3). The optical 
density at 420 nm (OD420) was measured using an absorbance plate reader (Molecular 
Devices, Menlo Park, CA) and the non-specific background at 650 nm subtracted. 
Values for replicate wells without virus were subtracted as background. Values for each 
point are the averages of at least triplicate wells. 
Percent transduced assay.  Cells were transduced with the lacZ virus as 
described above, grown to confluence, and trypsinized; then 20 µl of the trypsinized cells 
were diluted into 1 mL of medium. Ten microliters of this dilution were plated into a 10-
cm dish. After 10 days, macroscopic colonies had grown and were fixed and stained for 
β-galactosidase activity with X-Gal as described in the diluted titer assay. Colonies were 
counterstained with a solution of 1% rhodamine B, rinsed with water and air-dried. 
Values of the percentage of lacZ+ colonies at each point are the averages of three 
independent experiments. 
Virus incubation with polymers.  Five thousand NIH 3T3 murine fibroblasts in 
100 µl of DMEM/BCS were plated in each well of a 96-well flat-bottomed tissue culture 
dish. The next day (19 to 26 h later), the cells were incubated with virus (α-SGC-LacZ) 
and PB (8 µg/mL) for 2 h and either pretreated (Pre), cotreated (Co) or post-treated 
(Post) with polymer complexes (320 µg/mL of PB and 320 µg/mL of CSC). Pretreated 
cells were incubated with medium that contained polymer complexes (320 µg/mL of PB 
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and 320  µg/mL of CSC) for 2 hours, washed three times with fresh medium (100 
µL/well), then incubated for 2 hours with virus and PB (8 µg/mL).  Cotreated cells were 
incubated with virus containing polymer complexes (320 µg/mL of PB and 320 µg/mL of 
CSC) plus an additional 8 µg/mL PB, then washed three times with fresh medium.  Post-
treated cells were incubated for 2 hours with virus and PB (8 µg/mL), washed three 
times with fresh medium, incubated for 2 hours with medium containing polymer 
complexes (320 µg/mL of PB and 320 µg/mL of CSC) and washed three times with fresh 
medium. As control, cells were incubated with virus and PB (8 µg/mL) and washed three 
times with fresh medium (None). All cells were then incubated with fresh medium (100 
µL/well) for two days at 37°C until confluent, and then tested for β-gal activity in the β-gal 
assay.   
Phase contrast and fluorescence microscopy.  To visualize virus-polymer 
complexes, amphotropic LacZ retrovirus stocks produced from the ψ-CRIP cell line 
containing equal weight concentrations of PB and CSC were added to NIH 3T3 
fibroblasts that had been plated the previous day at 70,000 cells per well in 12-well 
dishes.  Phase contrast images of the complexes were taken one day later (40x).  In 
addition, stocks of GFP-labeled amphotropic lentiviruses and fresh cell culture medium 
were brought to 640 µg/mL of PB and CSC, incubated overnight at 37°C, then observed 
under an inverted fluorescence microscope (IX-50, Olympus America, Inc., Melville, NY). 
ELISA for p30.  We used an enzyme-linked immunosorbent assay (ELISA) to 
determine the concentration of virus capsid protein (p30) in cell lysates and virus stocks.  
ELISA plates (Nunc immuno Maxisorp 96-well plates, Nalge Nunc International, 
Rochester, NY) were coated overnight at 4°C with 10 µg/mL of mouse anti-p30 antibody 
(100 µL/well) in PBS. The next day, the antibody solution was removed and blocking 
buffer (PBS, 0.05% Tween-20, 5% non-fat milk) added (200 µL/well) for 2 h at 37°C to 
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block non-specific binding sites.  Samples were brought to 0.5% Triton-X to expose the 
p30 antigen, then added to the ELISA plate (100 µL/well) and incubated for 1 h at 37°C.  
Bound p30 was sandwiched by the addition of the goat polyclonal anti-p30 antibody 
diluted 1:1000 in blocking buffer, and incubated for 1 h at 37°C.  The horseradish 
peroxidase conjugated polyclonal rabbit anti-goat immunoglobulin G was diluted 1:5000 
in blocking buffer then added to the ELISA plate (100 µL/well) for 1 hour at 37°C to 
enable detection and quantitation of the sandwiched p30 antigen. The plates were 
developed for 5 min using hydrogen peroxide (H2O2) and OPD (100 µg/well) from a 
solution of 10 mg of OPD and 10 µl H2O2 in 25 mL of substrate buffer (24 mM citric acid-
monohydrate, 51 mM Na2HPO4-7H20, pH 5.0).  8N sulfuric acid (50 µL/well) was used to 
stop the reaction and the optical density at 490 nm (OD490) measured using an 
absorbance plate reader and the non-specific background at 650nm subtracted. Values 
for replicate wells without virus were subtracted as background. Values for each point 
are the average of at least triplicate wells. 
Virus adsorption and degradation assay.  Adsorption to cells and subsequent 
degradation of amphotropic retrovirus were analyzed by ELISA.  NIH-3T3 cells were 
plated in 12-well dishes (7.0 X 104 per well) and then cultured at 37°C for 3 days until 
confluent.  The medium was removed and replaced with 0.5 mL of virus stock brought to 
a range of equal weight concentrations of PB and CSC, and then the concentration of 
PB raised by an additional 8 µg/mL.  For virus adsorption experiments, cells were 
incubated with virus for a range of times, then the supernatant and cell lysates analyzed 
for levels of p30 by ELISA.  For virus degradation experiments, plates were centrifuged 
for 30 min at 4°C at 2500 rpm (1100 g) to establish a cohort of viruses on the surfaces of 
the cells (pulse), washed three times at 4°C with 1 mL of fresh culture medium (chase), 
incubated for a range of times, then the cell lysates analyzed for levels of p30 by ELISA.  
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To quantify the levels of p30 in cell lysates, cells were washed once with fresh medium, 
incubated with 0.2 mL lysis buffer (1% Igepal, 150mM NaCl and 50mM Tris, pH 8) 
containing protease inhibitor (Complete Mini, Roche Diagnostics GmbH, Germany) on 
ice for 30 min, then centrifuged at 14000 rpm (20000 g) for 10 min at 4°C to remove 
cellular debris.  The resulting supernatant was stored at -80°C for later analysis by 
ELISA.  
Measurement of retrovirus decay.  Frozen lacZ virus in culture medium was 
thawed, brought to an equal weight concentration of PB and CSC (0 or 640 µg/mL), then 
incubated at 37°C and 10% CO2.  Samples were taken at regular intervals and frozen at 
-80°C.  At later times, the samples were thawed, brought to 8 µg/mL of PB, and then 
used to transduce NIH 3T3 cells in the β-gal assay. 
Estimation of the rates of virus binding and intracellular degradation.  To 
determine rates of virus binding and intracellular degradation for a range of polymer 
concentrations, we assumed that the rate of change in the concentration of free virus 
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where sedk  is the virus sedimentation rate. We also assumed that once virus particles 
are associated with target cells, they are degraded intracellularly at a rate that is 
proportional to the concentration of cell-associated virus particles. The rate of change in 
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where degk is the intracellular degradation rate.  Therefore, the concentration of 
undegraded virus that is associated with cells (B) as a function of time is described by 
the equation: 
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where F0 is the concentration of free virus at the start of transduction.  As one of two 
independent means to estimate the values of the degradation and sedimentation rate 
constants, we used nonlinear regression of data from Figure 3.7 to equation (3) to find 
their best fit-values. 
The rate of change in the concentration of virus that is associated with cells (B) 
but has not yet degraded during a pulse-chase experiment is described by the equation: 
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This equation is similar to equation (2), except that for a pulse-chase experiment, the 
rate of virus binding is zero because the cell culture medium (chase) does not contain 
any virus (i.e, F = 0).  As a second independent means to estimate the value of the 




Estimation of the efficiency of post-binding steps of transduction.  To 
determine the efficiency of post-binding steps of transduction, the efficiency of gene 
transfer (i.e., β-galactosidase activity) for a range of polymer concentrations was plotted 
versus the number of active viruses to reach the cells, which we reported as a fraction of 
the total number of active viruses that were present at the start of the transduction.  The 
efficiency of post-binding steps of transduction was assumed to be proportional to the 
best-fit slopes of these curves, which were determined using the method of least 
squares.  The efficiency of gene transfer was measured using the β-gal assay and the 
number of active viruses to reach the cells was determined using a simple mathematical 
model of virus sedimentation and decay (described below).   
We assumed that active viruses bind to cells at a rate that is proportional to the 
concentration of active particles in solution (V).  Therefore, the rate that active viruses 
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where sedk  is the virus sedimentation rate and C is the cumulative concentration of 
viruses to have reached the cells in an active state.  The fraction (A) of the total number 












Equation (6) was evaluated for t = 48 h, the length of a typical transduction.  To solve 
equations (5) and (6), values for sedk  and V  were needed.  As a second independent 
means to estimate the value of the sedimentation rate constant for each polymer 
concentration, we used the method of least squares to fit experimental data that 
measured the disappearance of p30 from solution (see Figure 3.8) to equation (1) where 
F is the concentration of p30 in solution as measured by ELISA.  The concentration of 
active virus in solution )(V  was assumed to vary with time due to decay and 
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where dk  is the virus decay rate.  The best-fit value for the virus decay rate )( dk , 8 
hours, was determined by using the method of least squares to fit experimental data for 
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as previously described [5]. 
Data analysis.  Data are summarized as the mean +/- the standard deviation for 
at least triplicate samples.  Statistical analysis was performed using one-way analysis of 
variance for repeated measurements of the same variable.  The Tukey multiple 
comparison test was used to conduct pairwise comparisons between means.  
Differences at P < 0.05 were considered statistically significant.  Data were fit to 




In a previous study, we found that retrovirus transduction is enhanced by the 
combined addition of equal weight concentrations (80 µg/mL) of a cationic polymer 
(Polybrene) and an anionic polymer (chondroitin sulfate C), and that cell proliferation is 
not affected by the polymers, even when they are used at high doses (640 µg/mL) (refer 
to Chapter 2) [24].  As a first step towards understanding the mechanism by which 
Polybrene (PB) and chondroitin sulfate C (CSC) enhance transduction, we measured the 
effects on transduction of changes in the concentration of the two polymers.  We brought 
stocks of a replication-defective amphotropic retrovirus that encoded for β-galactosidase 
and which was harvested from the ψ-CRIP packaging cell line (α-SGC-lacZ virus) to a 
range of concentrations of CSC (0 to 1000 µg/mL) and PB (8 to 1008 µg/mL), then used 
them to transduce NIH 3T3 murine fibroblasts.  In each experiment we used 
concentrations of PB that were 8 µg/mL higher than CSC in order to simplify 
comparisons with control experiments that used virus stocks supplemented with PB (8 
µg/mL) only.  As additional controls, we brought virus stocks to a range of concentrations 
of PB only (8 to 1008 µg/mL) or to 8 µg/mL of PB and a range of concentrations of CSC 
(0 to 1000 µg/mL), and then used them to transduce NIH 3T3 cells. The efficiency of 
gene transfer decreased substantially when high concentrations of only one polymer 
were used (Figure 3.1). In contrast, gene transfer increased with increasing 
concentrations of polymers when high concentrations of both polymers were added to 
the virus stock, reached a maximum enhancement when 320-640 µg/mL of CSC and 
328-648 µg/mL of PB were used, then decreased slightly at the highest doses of 
polymers tested (Figure 3.1, Table 3.1).  We confirmed these results using an assay in 



































Figure 3.1 Mixtures of PB and CSC enhance gene transfer. NIH 3T3 cells were plated in 
a 96-well dish (5,000 per well) and, the next day, transduced with 100 µl of amphotropic 
lacZ retrovirus (α-SGC-LacZ) produced from the ψ-CRIP cell line that contained 0 to 
1000 µg/mL CSC and a weight concentration of PB that was 8 µg/mL more than that of 
CSC ( ), 0 to 1000 µg/mL CSC and 8 µg/mL PB ( ), or 8 to 1008 µg/mL of PB only ( ).  
Two days later, the level of gene transfer was quantified using the β-gal assay.  Each 







































































Figure 3.2 Mixtures of PB and CSC increase the percentage of cells transduced. NIH 
3T3 cells were transduced with α-SGC-LacZ retrovirus that contained 0 to 1000 µg/mL 
CSC and a weight concentration of PB that was 8 µg/mL more than that of CSC. Cells 
were trypsinized, diluted, and plated onto a 10-cm dish.  After 10 days of growth, 
macroscopic colonies were fixed, stained for lacZ activity with the X-Gal substrate, and 
counterstained with rhodamine B.  Values for the percentage of lacZ+ colonies at each 
point (blue colonies/total colonies x 100) are the mean ± standard deviation of triplicate 












































Table 3.1 Mixtures of PB and CSC increase the efficiency of gene transfer in a 














Polymer Dose at 





ψ-CRIP MLV amphotropic NIH 3T3 320-640 5.5 ± 2.2 
ψ-CRIP MLV amphotropic Hela 320-640 37 ± 27 
ψ-CRIP MLV amphotropic TE671 320-640 17 ± 5.0 
CRE BAG MLV ecotropic NIH 3T3 320-640 13 ± 4.7 
TELCeB6-A MLV amphotropic HeLa 320-640 1.9 ± 0.33 
293T/17 Lentivirus amphotropic NIH 3T3 160-1000 3.0 ± 0.80 
293T/17 Lentivirus VSVG NIH 3T3 320-1000 3.2 ± 1.1 
 
a MLV: Moloney murine leukemia virus;  VSVG: vesicular stomatitis virus;  TE: 
transduction efficiency. 
b MLV was produced from stable virus producer cell lines; Lentivirus was produced by 
transient transfection of 293T/17 cells with  pCMV∆R8.91, pTY-EfnlacZ, and 
FB4070ASALF or  pMD.G. 
c Fold Enhancement of transduction was defined as the ratio of the maximum TE 
achieved when mixtures of PB and CSC were used to the TE achieved when only PB (8 




To determine if the combined addition of PB and CSC enhances the level of 
gene transfer to other cell lines or with different retroviruses, we brought stocks of α-
SGC-lacZ virus to a range of CSC and PB concentrations and used them to transduce 
HeLa and TE671 cells (Table 3.1).  We also examined the ability of the polymers to 
enhance the efficiency of transduction of four additional types of recombinant 
retroviruses:  an amphotropic retrovirus produced from TELCeB6 cells, an ecotropic 
retrovirus harvested from the CRE BAG cell line, and lentiviruses produced by transient 
transfection of 293T/17 cells and pseudotyped with either the amphotropic or the VSVG 
envelope protein.  In each case we found that the combined addition of polymers to virus 
stocks enhanced the efficiency of gene transfer, although the level of enhancement was 
somewhat variable (Table 3.1).   
As a first step towards understanding the mechanism of enhancement, we tested 
if the polymers enhanced transduction by binding to the target cells prior to virus 
adsorption.  NIH 3T3 cells were incubated for two hours with CSC (320 µg/mL) and PB 
(320 µg/mL), washed to remove unbound polymers, then exposed for two hours to α-
SGC-lacZ virus supplemented with PB (8 µg/mL).  As a control, cells that had not been 
pretreated with PB and CSC were transduced with virus that contained only PB (8 
µg/mL).  Pretreatment of cells with PB and CSC had no effect (p < 0.05) on transduction 
(Figure 3.3). To determine if polymers enhance transduction by interacting with the 
viruses, or by interacting with the cells and enhancing transduction after it begins, we 
compared the efficiency of transduction of NIH 3T3 cells incubated with α-SGC-lacZ 
virus in the presence of CSC (320 µg/mL) and PB (328 µg/mL) to the efficiency of 
transduction of cells that were incubated with virus supplemented with PB (8 µg/mL) 
only, but then incubated with both CSC (320 µg/mL) and PB (320 µg/mL) immediately 





















Figure 3.3 CSC and PB enhance transduction only when they are present at the same 
time the cells are exposed to virus.  Cells, plated the previous day at 5000 cells per well 
in a 96 well plate, were incubated with α-SGC-LacZ virus and PB (8 µg/mL) for 2 h and 
either pretreated (Pre), cotreated (Co) or post-treated (Post) with polymer complexes 
(320 µg/mL of PB and 320 µg/mL of CSC). Pretreated cells were incubated with medium 
that contained polymer complexes (320 µg/mL of PB and 320 µg/mL of CSC) for 2 
hours, washed three times with fresh medium, then incubated for 2 hours with virus and 
PB (8 µg/mL).  Cotreated cells were incubated with virus containing polymer complexes 
(320 µg/mL of PB and 320 µg/mL of CSC) plus an additional 8 µg/mL PB, then washed 
three times with fresh medium.  Post-treated cells were incubated for 2 hours with virus 
and PB (8 µg/mL), washed three times with fresh medium, incubated for 2 hours with 
medium containing polymer complexes (320 µg/mL of PB and 320 µg/mL of CSC) and 
washed three times with fresh medium. As a control, cells were incubated with virus and 
PB (8 µg/mL) and washed three times with fresh medium (None). All cells were then 
incubated with fresh medium, grown to confluence, and tested for β-gal activity.  Fold 
increases in β-gal activity with respect to None are plotted as the mean ± SD of three 
replicates.  Statistically significant differences (p < 0.05) from None are denoted with an 
asterisk. 




































enhanced only when CSC and PB were present at the same time the cells were 
exposed to the virus particles (p < 0.05).  
Shortly after transduction was initiated we observed the rapid accumulation of 
granular precipitates on the cells, the median size of which became larger as the 
concentration of polymers used increased (Figures 3.4 and 3.5).  Taken together, these 
observations prompted us to hypothesize that the addition of CSC and PB to virus 
stocks leads to the formation of virus-polymer complexes that, due to their large size, 
rapidly sediment to the bottom of the tissue culture plates, increasing the rate of virus 
adsorption to the cells.  To assess the possibility that virus particles were incorporated 
into these visible precipitates, we brought stocks of GFP-labeled lentiviruses, or fresh 
medium as a control, to 640 µg/mL of PB and CSC, incubated these solutions 
overnightat 37°C, and then visualized them by fluorescence microscopy.  Viruses were 
associated with the complexes, and, interestingly, located primarily on their outer 
surfaces (Figure 3.6).  
To examine if CSC and PB increase the rate of virus adsorption, we incubated 
confluent monolayers of NIH 3T3 cells with α-SGC-lacZ virus stocks that contained a 
range of concentrations of PB and CSC.  At various times we washed and lysed the 
cells, then quantified the levels of cell-associated virus using an ELISA for p30, the virus 
capsid protein.  Levels of cell-associated p30 increased rapidly within the first 4 hours of 
transduction, reached a plateau during the next 6 to 10 hours, then declined slightly.  For 
each time point, the levels of cell-associated p30 increased with increasing 
concentrations of polymers used (Figure 3.7).  These findings indicate that the combined 
addition of CSC and PB to virus stocks increases the rate of virus adsorption to cells, 














































Figure 3.4 Retrovirus-polymer complexes are visible on the surfaces of cells shortly after 
the start of transduction.  Retrovirus stocks (α-SGC-LacZ) were brought to 320 µg/mL of 
PB and CSC, and then incubated with NIH 3T3 cells for (a) 0, (b) 0.5, (c) 2, (d) 4, (e) 8, 
or (f) 24 h, after which the medium was removed and the cells visualized by phase 








































Figure 3.5 The size of the complexes increases with increasing concentrations of the 
polymers.  Retrovirus stocks (α-SGC-LacZ) were brought to (a) 0 (b) 320 (c) 640 or (d) 
1000 µg/mL each of PB and CSC, then incubated with NIH 3T3 cells.  Phase contrast 











































Figure 3.6 Viruses are mostly at the surface of the complexes.  (a) Stocks of GFP-
labeled lentiviruses were brought to 640 µg/mL of PB and CSC, incubated overnight at 
37°C, and then visualized by fluorescence microscopy (magnification 60x). (b)  Polymer 




































Figure 3.7 CSC and PB increase the rate of virus binding.  Retrovirus stocks (α-SGC-
LacZ) were brought to 8 µg/ml PB ( ), 80 µg/ml CSC and 88 µg/ml PB ( ), 160 µg/ml 
CSC and 168 µg/ml PB ( ), 320 µg/ml CSC and 328 µg/ml PB ( ), 640 µg/ml CSC and 
648 µg/ml PB ( ), and 1000 µg/ml CSC and 1008 µg/ml PB ( ), then added to 
confluent cultures of NIH-3T3 cells.  At various times the cells were lysed, and the 
lysates analyzed using the p30 ELISA.  Each point shows the mean ± standard deviation 














































The development of a plateau in the level of cell-associated p30 at later times 
suggests that the rate of virus association has declined or the rate of virus removal from 
the cells has increased, either by dissociation or by intracellular degradation. To 
determine what factors contributed most significantly to the development of the plateau 
in cell-associated virus, we first sought to determine whether or not the rate of virus 
adsorption declined with time during transduction. To examine if the cell culture medium 
is depleted of virus particles within the first few hours of transduction, we incubated α-
SGC-lacZ virus stocks containing PB and CSC with confluent cultures of NIH 3T3 cells, 
then quantified the levels of p30 in the medium at various times by ELISA.  We found 
that when both CSC and PB were added to virus stocks, the concentration of p30 in the 
supernatant declined rapidly during the first 12 to 15 hours, then more slowly at later 
times (Figure 3.8).  In addition, we found that the rate of decline increased with 
increasing concentrations of polymers.  When only PB (8 µg/mL) was added to virus 
stocks, the levels of p30 declined about 15% within the first 4 hours, whereas when high 
doses of CSC (1000 µg/mL) and PB (1008 µg/mL) were used, the levels of p30 declined 
more than 70%.  These findings show that, upon addition of CSC and PB, virus particles 
are rapidly depleted from the cell culture medium. 
To examine if there were any differences between the rate at which inactive 
viruses are depleted from the medium versus the rate at which active viruses are 
depleted, we heat-inactivated stocks of α-SGC-lacZ virus by incubating them at 37°C for 
24 hours, brought them to equal weight concentrations of CSC and PB (80, 160, or 640 
µg/mL of each polymer), then incubated them with confluent cultures of NIH 3T3 cells.  
In parallel, we conducted the same experiment with stocks of viruses that had not been 
heat-inactivated.  At various times we collected samples of the supernatant and 


































Figure 3.8 CSC and PB increase the rate of disappearance of p30 from solution.  
Retrovirus stocks (α-SGC-LacZ) were brought to 8 µg/ml PB ( ), 80 µg/ml CSC and 88 
µg/ml PB ( ), 160 µg/ml CSC and 168 µg/ml PB ( ), 320 µg/ml CSC and 328 µg/ml PB 
( ), 640 µg/ml CSC and 648 µg/ml PB ( ), and 1000 µg/ml CSC and 1008 µg/ml PB 
( ), then added to confluent cultures of NIH-3T3 cells.  At various times, the virus 
supernatant was collected and analyzed using the p30 ELISA. Each point shows the 

















































concentration of p30 in the supernatant declined with time and at the same rate, whether 
or not the particles were active or inactive (Figure 3.9).  Taken together, these results 
suggest that it is the rapid depletion of virus particles from the cell culture medium, and 
not the inability of inactive viruses to sediment onto the cells, that contributes to the 
development of a plateau in cell-associated levels of p30 during transduction. 
 An increase in the rate of removal of cell-associated p30 from cells, either by 
degradation of internalized viruses or by the release of bound viruses from the cell 
surface, could also contribute to the development of a plateau in the levels of cell-
associated p30.  To examine these two possibilities, we performed a pulse-chase 
experiment in which α-SGC-lacZ virus stocks were brought to a range of concentrations 
of CSC and PB, centrifuged onto NIH 3T3 cells at 4°C for 30 minutes at 1100 g (pulse), 
then removed and replaced with fresh medium (chase) that had been pre-warmed to 
37°C.  During the chase period (12 h), we monitored the cell culture medium and cell 
lysates for levels of p30.  We did not detect any p30 in the medium during the entire 
chase period (data not shown).  Levels of cell-associated p30 dropped significantly 
during the chase period at a rate that correlated with the levels of cell-associated p30.  
Levels of p30 declined most rapidly at early times when the levels of p30 were high and 
least rapidly at later times when the levels of p30 were low (Figure 3.10).  The 
development of a plateau in the levels of cell-associated p30 during transduction, 
following an initial rapid rise, can therefore be explained as the result of a decrease in 
the rate at which new p30-containing virus particles reach the cell surface due to 
depletion of viruses from the culture medium, coupled with an increase in the rate at 
which p30 is degraded due to its accumulation to higher levels within the cells over time.   
We utilized the measurements of association of p30 with target cells (Figure 3.7) and a 





















Figure 3.9 Bioactive and heat-inactivated viruses bind to the cells at the same rate. 
Retrovirus stocks were divided into two aliquots; one was heat-inactivated by incubation 
at 37°C for 24 h, then frozen, whereas the control aliquot was frozen immediately.  
Active (closed symbols) and heat-inactivated (open symbols) virus stocks were thawed, 
brought to 80 µg/ml CSC and 88 µg/ml PB (active ( ), inactive ( )), 160 µg/ml CSC and 
168 µg/ml PB (active ( ), inactive (∆)), and 640 µg/ml CSC and 648 µg/ml PB (active 
( ), inactive ( )), then added to confluent cultures of NIH 3T3 cells.  At various times, 
samples of the supernatant were taken and analyzed for virus concentration with the p30 














































































Figure 3.10 Intracellular degradation of viral proteins. Retrovirus stocks (α-SGC-LacZ) 
were brought to 8 µg/ml PB ( ), 80 µg/ml CSC and 88 µg/ml PB ( ), 160 µg/ml CSC 
and 168 µg/ml PB ( ), 320 µg/ml CSC and 328 µg/ml PB ( ), 640 µg/ml CSC and 648 
µg/ml PB ( ), and 1000 µg/ml CSC and 1008 µg/ml PB ( ), then added to confluent 
cultures of NIH-3T3 cells. After addition of the virus stocks to the cells, the tissue culture 
dishes were centrifuged (30 min, 1100g, 4°C) to establish a cohort of viruses on the 
surfaces of the cells (pulse), washed three times at 4°C with fresh medium (chase), 
incubated for a range of times, then the cells lysed and the concentration of p30 in the 
















































binding and intracellular degradation of viral proteins (Figures 3.11-3.12). We found that 
the rates of binding increased with increasing concentrations of polymers while the rates 
of degradation did not correlate with the concentration of polymers. Degradation 
occurred more rapidly when only 8 µg/mL of PB were used, but remained unchanged 
when concentrations of PB and CSC equal to, or higher than, 80 µg/mL were used. In 
order to assess the validity of relying on disappearance of p30 from the supernatant to 
measure binding, and of performing a pulse-chase experiment to measure intracellular 
degradation, we also measured these rates using separate sets of data (see the 
Materials and Methods and Figures 3.8 and 3.10). The values for the degradation and 
sedimentation rate constants were similar, regardless of which method we used to 
estimate them (Figures 3.11-3.12). 
Our results suggest that the combined addition of CSC and PB to virus stocks 
results in the formation of virus-polymer complexes that sediment, rather than passively 
diffuse, towards the surfaces of the cells, increasing their rate of delivery.  These 
increases in the rates of virus delivery to cells would be expected to increase the 
efficiency of transduction, but only if the polymers did not adversely affect virus function 
or the successful completion of post-binding steps of transduction. 
To determine if the polymers affect the rate of virus decay, stocks of α-SGC-lacZ 
virus were brought to equal weight concentrations of PB and CSC (640 µg/mL), then 
incubated for several hours in a tissue culture dish at 37°C.  As a control, virus stocks 
were incubated at 37°C in the absence of polymers.  At various times, samples of the 
virus solutions were collected, used to transduce NIH 3T3 cells, and the level of gene 
transfer quantified using the β-gal assay.  The transduction efficiency of the virus stocks 
decreased with a half-life of 7 to 8 hours in the presence or absence of polymers, 




































Figure 3.11 Retrovirus binding increases with increasing polymer concentration.  Virus 
degradation rates were estimated using a mathematical model and measurements of 
association of p30 with target cells over time (white bars) or measurements of 
degradation obtained from pulse-chase experiments (gray bars). Statistically significant 
differences (p < 0.05) from the degradation rate at 80 µg/ml are denoted with an 
asterisk. 









































































































Figure 3.12 Retrovirus degradation does not correlate with the concentrations of 
polymers. Binding rates were estimated using a mathematical model and measurements 
of the concentration of p30 associated with the target cells (white bars) or the 
concentration of p30 remaining in the supernatant (gray bars) as a function of time.   











































































Figure 3.13 Retrovirus decay rate is not affected by the presence of CSC and PB.  
Retrovirus stocks (α-SGC-LacZ) that contained 640 µg/mL PB and 640 µg/mL CSC ( ), 
or no polymers ( ), were incubated at 37°C for 0 to 24 h.  Samples were taken at 
various times, frozen, later thawed and their concentration of PB raised by 8 µg/mL, and 
then used to transduce NIH 3T3 cells in the β-gal assay.  Each point shows the mean ± 


















































To determine if association of viruses with polymer complexes impedes their 
ability to complete post-binding steps of transduction, we compared the rate that active 
viruses adsorb to cells versus the rate they transduce them.  To measure the 
transduction rate, NIH 3T3 cells were exposed to α-SGC-lacZ virus stocks that 
contained a range of concentrations of CSC (0 to 1000 µg/mL) and PB (8 to 1008 
µg/mL).  At intervals after the start of transduction, the virus was removed and replaced 
with fresh medium. Incubation continued at 37°C for two days, then the efficiency of 
gene transfer was quantified with the β-gal assay.  The level of gene transfer increased 
with exposure time to virus for all solutions tested and approached a maximum after 24 h 
(Figure 3.14).  Consistent with our previous results, the level of gene transfer increased 
with increasing concentrations of polymers, reached a maximum when 640 µg/mL of  
CSC and 648 µg/mL of PB were used, then decreased slightly when higher doses of 
polymers were used.  Interestingly, the use of high doses of polymers seemed to 
accelerate the rate of transduction at early times (Figure 3.15).  Half-maximal levels of 
transduction were reached within 2 to 3 hours when high doses (≥ 320 µg/mL) of 
polymers were used but only after about 6 to 7 hours when low doses (0 to 160 µg/mL) 
of polymers were used. 
To estimate the rate that active viruses adsorb to cells in the presence of 
polymers, we used a simple mathematical model (see Materials and Methods).  We 
assumed that the rate that active virus particles adsorbed to cells was proportional to the 
rate that they were depleted by sedimentation from the cell culture medium.  We 
modeled virus decay using first order reaction kinetics with a half-life of 8 hours.  We 
then plotted the level of gene transfer (i.e., β-galactosidase activity) for a range of 
polymer concentrations versus the number of active particles that adsorbed to the cells, 




















Figure 3.14 CSC and PB increase the rate of transduction.  Retrovirus stocks (α-SGC-
LacZ) were brought to 8 µg/ml PB ( ), 80 µg/ml CSC and 88 µg/ml PB ( ), 160 µg/ml 
CSC and 168 µg/ml PB ( ), 320 µg/ml CSC and 328 µg/ml PB ( ), 640 µg/ml CSC and 
648 µg/ml PB ( ), and 1000 µg/ml CSC and 1008 µg/ml PB ( ), and then added to 
confluent cultures of NIH-3T3 cells.  At various times, the virus was removed and 
replaced with fresh medium, and incubation continued at 37°C.  Two days after the start 
of transduction, the level of gene transfer was quantified using the β-gal assay.  Each 






































































Figure 3.15 Time versus percent maximal infection for each of the polymer doses. Data 















































the start of transduction.  We found that the level of gene transfer was linearly 
proportional (0.86 ≤  r2 ≤ 0.99) to the number of active particles delivered per cell (Figure 
3.16, Table 3.2).  The slopes of these linear correlations are a measure of the probability 
that an active virus, once it has reached the cell surface, will successfully complete post-
binding steps of infection and transduce the cell.  No statistically significant differences in 
the slopes of the lines were observed (p < 0.05), which indicates that an active virus that 
is associated with a polymer complex has the same probability of successfully 
transducing a cell once it has reached the cell surface as an active virus that is not 
associated with a polymer complex.   
Other methods have been developed that increase the efficiency of gene transfer 
by increasing the rate that viruses are delivered to cells.  For example, centrifugation of  
virus stocks onto cells (i.e., spinoculation) increases the efficiency of gene transfer.  We 
wondered if gene transfer could be further improved if spinoculation were used, in 
combination with the formation of virus-polymer complexes, to transduce cells.  Stocks 
of α-SGC-lacZ virus were brought to a range of concentrations of CSC and PB, added to 
cells, and then centrifuged (2000g) for 90 min. As a control, parallel cultures of cells 
were incubated with virus-polymer complexes but were not centrifuged.  Virus was either 
left on the cells until they reached confluence, or removed and replaced with fresh 
medium 90 minutes after the start of transduction.  The highest levels of gene transfer 
were achieved when virus-polymer complexes, formed using 320 µg/mL of PB and CSC, 
were incubated with cells for 48 hours without centrifugation (Figure 3.17), or when 
virus-polymer complexes, formed using 80 µg/mL of PB and CSC, were centrifuged onto 
the cells for 90 minutes, then immediately removed and replaced with fresh medium 
(Figure 3.18).  Interestingly, when spinoculation was used, gene transfer declined if the 


































Figure 3.16 Complexation of virus with polymers does not affect the efficiency with 
which they complete post-binding steps of transduction.  Retrovirus stocks (α-SGC-
LacZ) were brought to 8 µg/ml PB ( , ·······), 80 µg/ml CSC and 88 µg/ml PB ( ,  ·  
),  160 µg/ml CSC and 168 µg/ml PB ( ,   ),  320 µg/ml CSC and 328 µg/ml PB ( , 
− − − ), and 640 µg/ml CSC and 648 µg/ml PB ( ,  ), and then added to cultures of 
NIH-3T3 cells.  At various times, the supernatant was removed and frozen for later 
analysis, then replaced with fresh medium and incubation continued at 37°C.  Two days 
after the start of transduction, the level of gene transfer was quantified using the β-gal 
assay.  Samples of supernatant were thawed and analyzed for virus concentration using 
the p30 ELISA.  The fraction of the total number of active viruses that were present at 
the start of transduction that reached the cells was estimated using a mathematical 
model of virus sedimentation and decay (see Materials and Methods).  The level of gene 
transfer was plotted versus the fraction of active viruses delivered to the cells.  Each 
point shows the mean ± standard deviation of three replicates.  Lines, determined by the 
method of least squares, are the best-fit slopes of the data, which are proportional to the 






















FRACTION OF VIRUSES TO REACH 



















Table 3.2 Polymers do not affect the efficiency of post-binding steps of transduction 
 
 




Best-fit slopea  




0 / 8 1.00 ± 0.00 0.99 
80 / 88 1.30 ± 0.31 0.93  
160 / 168 1.22 ± 0.53 0.86  
320 / 328 1.19 ± 0.65 0.95  
640 / 648 1.18 ± 0.46 0.94  
1000 / 1008 0.93 ± 0.42 0.92 
 
a Best-fit slopes were assumed to be proportional to the efficiency 








































Figure 3.17 When the virus is left on the cells until they reach confluence, the highest 
transduction is achieved without spinoculation. Retrovirus stocks (α-SGC-LacZ) were 
brought to 0 to 320 mg/mL CSC and a weight concentration of PB that was 8 mg/mL 
more than that of CSC, added to cultures of NIH 3T3 fibroblasts, then the cells 
centrifuged ( ) for 90 min at 2000g, or not centrifuged ( ). The virus-laden supernatant 
was not replaced for the duration of the experiment.  Cells were incubated for 2 days 
until confluent, and then the efficiency of gene transfer quantified using the β-gal assay.  
Results were reported as fold-enhancement with respect to the level of gene transfer 
achieved using the conventional transduction method in which virus and PB (8 µg/mL) 



























































































Figure 3.18 When the virus stock is removed from the cells shortly after the start of 
transduction, mixtures of CSC and PB increase the efficiency of gene transfer by 
spinoculation.  Retrovirus stocks (α-SGC-LacZ) were brought to 0 to 320 mg/mL CSC 
and a weight concentration of PB that was 8 mg/mL more than that of CSC, added to 
cultures of NIH 3T3 fibroblasts, then the cells centrifuged ( ) for 90 min at 2000g, or not 
centrifuged ( ). The virus-laden supernatant was replaced with fresh medium 90 
minutes after the start of transduction (immediately after centrifugation). Cells were 
incubated for 2 days until confluent, and then the efficiency of gene transfer quantified 
using the β-gal assay.  Results were reported as fold-enhancement with respect to the 
level of gene transfer achieved using the conventional transduction method in which 

















   
   
   
   


























   
   
   
   















on the cells for the duration of the experiment.  These results show that high levels of 
gene transfer can be realized through the use of virus-polymer complexes without the 
use of spinoculation, but that spinoculation can reduce the amount of polymers that need 
to be used, and the length of time cells need to be exposed to virus. 
 
3.5 Discussion 
Charged polymers are known to significantly affect retrovirus transduction.  In 
general, it appears that cationic polymers enhance transduction by increasing virus 
binding whereas anionic polymers inhibit transduction by decreasing virus binding [14, 
22].  Although the mechanism by which charged polymers affect virus binding has not 
been thoroughly investigated, it is generally thought that cationic polymers reduce the  
electrostatic repulsion between the negatively charged viruses and cells, and that 
anionic polymers have the opposite effect.  In addition, some anionic polymers (e.g., 
heparin and heparan sulfate) appear to act by binding to the heparan-binding domain of 
fibronectin, a region of fibronectin to which retroviruses bind [22], or to domains on the 
virus that would otherwise bind to cell-associated glycosaminoglycans [19].  We were 
surprised then to find that retrovirus transduction is more efficient when both anionic and 
cationic polymers are added to virus stocks than when only cationic polymers are used.  
Since our observation seemed to conflict with the current model of charged polymer – 
virus interactions, we decided to determine the mechanism by which transduction was 
enhanced. 
Using quantitative assays of retrovirus transduction and binding, we found that 
the addition of oppositely charged polymers (PB and CSC) to virus stocks enhanced 
gene transfer by increasing the flux of active viruses to the cells.  Virus-polymer 
complexes formed that did not reduce the stability of the viruses, yet were large enough 
to sediment, delivering the viruses to the cells more rapidly than by simple diffusion.  As 
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the concentration of the polymers increased, the size of the complexes increased, 
leading to an increase in the rate of sedimentation. This was expected because the 
velocity with which particles sediment (vsed) increases with the square of their radius (R) 
and is a function of the difference between the density of the particle and the density of 
the medium ( )ρρ −s , gravitational constant (g), and the viscosity of the medium (η) [31, 
32]: 
 
   ( ) ηρρ 92 2 gRv ssed −=     (10) 
 
Viruses that were associated with these larger complexes sedimented faster, were more 
likely to bind to cells before they lost their bioactivity, and led to higher levels of gene 
transfer. 
When high concentrations of only one polymer were used, visible complexes 
were not formed and gene transfer was not enhanced, but decreased to undetectable 
levels. This decrease is consistent with previous data showing that high concentrations 
of PB in the absence of an anionic polymer are cytotoxic (refer to Chapter 2) [24], and 
that high concentrations of CSC in the presence of low concentrations of PB inhibit gene 
transfer [21]. 
We tested the ability of the polymers to enhance transduction using a number of 
different cell types and viruses.  Transduction was enhanced in all of our experiments 
but to a degree that varied depending on the type of cells and viruses used.  For 
example, transduction was enhanced the most with cells that were difficult to transduce 
using the conventional protocol in which only one polymer, Polybrene, was used.  This is 
probably because the rate of virus binding when both polymers were used was a 
function only of the sedimentation rates of the virus-polymer complexes that formed and 
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was therefore the same regardless of the cell type that was transduced.  In contrast, the 
rate of virus binding when only Polybrene was used may have been a function of the 
properties of the cells that were transduced, such as how avidly Polybrene was able to 
bind to them. This rate may have been lower in cell types that were relatively refractory 
to Polybrene-mediated transduction, such as HeLa cells, than in cell types that were 
more susceptible to Polybrene-mediated transduction, such as NIH-3T3 cells. 
The properties of the virus stocks also appeared to influence the degree to which 
the complexes enhanced transduction.  Transduction of HeLa cells was enhanced more 
than 30-fold when viruses produced by murine fibroblasts (Ψ-CRIP) were used, but only 
2–fold when viruses produced by TELCeB6-A cells were used.  Similarly, transduction of 
NIH 3T3 cells was enhanced nearly 8-fold when amphotropic retroviruses were used, 
but only 3-fold when amphotropic lentiviruses were used.  Lentivirus transduction may 
have been enhanced to a lesser extent than retrovirus transduction because lentiviruses 
lose their activity more slowly than do retroviruses (data not shown).  In addition, virus 
stocks produced by TELCeB6-A cells contained high levels of inhibitory activity which 
may explain why polymer-complexation enhanced their efficiency of gene transfer to a 
lesser extent than when other virus stocks were used that contained significantly less 
inhibitory activity (refer to Chapter 5). 
We wondered if viruses that were associated with complexes were hindered in 
their ability to transduce cells once they bound to the cell surface.  Using a simple 
mathematical model and experimental measurements of the rates of virus sedimentation 
and decay, we estimated, as a function of polymer concentration, the rate that active 
virus particles reached the surfaces of the cells and the efficiency with which they 
completed post-binding steps of transduction.  Surprisingly, we found that association of 
the viruses with complexes did not significantly hinder their ability to complete post-
binding steps of transduction.  Perhaps the viruses do not remain associated with the 
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complexes once they reach the cells, either because the complexes are degraded by 
cellular enzymes, or because the complexes are in a continuous state of disaggregation 
and reaggregation that provides the viruses with transient opportunities to escape from 
the complexes. Also, given that most of the viruses appear to be located on the outer 
surface of the complexes, it is possible that the complexes do not block their access to 
their cellular receptors.  
The formation and sedimentation of virus-polymer complexes is most likely a 
form of flocculation, the destabilization of a suspension of colloids by the addition of a 
chemical agent known as a flocculant [33].  Charged polymers have been used as 
flocculants in a number of industrial settings including in the processing of minerals and 
pulp, in the purification of proteins and wastewater, and as a method to control the 
surface properties and behavior of biopharmaceuticals [34].  Highly charged, relatively 
low molecular weight polymers such as those used in this study typically induce 
flocculation by binding to oppositely charged sites on the surfaces of the colloids, 
forming an “electrostatic patch” that then binds to oppositely charged patches on 
adjacent particles [33].  In principle, virus-polymer complexes can be formed using a 
single type of cationic polymer.  For example, Zhang et al formed lentivirus-poly-L-lysine 
complexes as a means to more efficiently concentrate lentiviruses by centrifugation [35].  
We have previously found, however, that if two oppositely charged polymers (e.g., CSC 
and PB) are used to form the complexes, it is possible to achieve high levels of gene 
transfer by applying the virus-polymer complexes directly to the cells, without the need 
for centrifugation [24].  We suspect that the negatively charged polymer (CSC) helps to 
protect the cells from what would otherwise be a cytotoxic dose of the cationic polymer 
(PB). Regardless of the precise mechanism by which charged polymers induce viruses 
to flocculate and sediment onto cells, our studies show that the transport of retroviruses 
to cells is a major rate-limiting step of transduction.  This observation is consistent with a 
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number of previous studies, including one that showed that virus binding is diffusion 
limited and occurs on a much longer time scale than does virus decay when 
conventional transduction protocols are used [7].   
The formation of retrovirus-polymer complexes may have a number of important 
applications.  Similar to other methods that rapidly deliver retroviruses to cells, they can 
be used to significantly improve the efficiency of ex vivo gene transfer [36-39]. Virus-
polymer complexes are not cytotoxic, are straightforward and inexpensive to form, can 
be formed with retroviruses and lentiviruses regardless of the type of viral envelope 
protein they are pseudotyped with, and can be used to rapidly transduce cells without 
the need for specialized equipment such as centrifuges, flow-through tissue culture 
devices, or magnetic beads and magnets.  As shown in our previous study, retrovirus-
polymer complexes can also be used to concentrate and purify retrovirus stocks, 
resulting in substantial enhancement of transduction [24]. This concentration method is a 
promising alternative to other methods that are time-consuming and can only 
accommodate small volumes, such as ultracentrifugation. In addition, our method 
permits resuspending viruses in culture medium that is optimal for the proliferation of the 
intended target cell type and may therefore further increase gene transfer.  Recently, we 
have successfully enhanced gene transfer to murine bone marrow progenitor cells by 
concentrating stocks of ecotropic retrovirus using PB and CSC. We found that a 10-fold 
concentration resulted in a 4-fold enhancement of transduction (personal 
communication, Spencer, HT, Emory University, 2004). 
In summary, we have shown that the combined addition of oppositely charged 
polymers to retrovirus stocks leads to the formation of virus-polymer complexes that can 
be used to overcome some of the major rate-limiting steps of retroviral-mediated gene 
transfer. Virus-polymer complexes sediment, increasing the number of active viruses 
that are delivered to the cells, and are easily concentrated and purified by low speed 
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centrifugation and resuspension in fresh medium.   Future studies are needed to 
determine the properties of the viruses and polymers that are necessary for complex 
formation, and the mechanism by which viruses are able to transduce cells as part of a 
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 FLOCCULATION OF RETROVIRUSES WITH VARIOUS COMBINATIONS OF 
OPPOSITELY CHARGED POLYMERS OR WITH A SINGLE SPECIES OF CATIONIC 




We have shown in Chapters 2 and 3 that the combined addition of high and 
equal weight concentrations (80 to 1000 µg/mL) of the cationic polymer Polybrene (PB) 
and the anionic polymer chondroitin sulfate C (CSC) to stocks of retroviruses results in 
the formation of high molecular weight complexes. These complexes selectively 
incorporate virus particles and enhance the efficiency of transduction by increasing the 
rate of binding of viruses to cells. In addition, these complexes can be rapidly pelleted by 
centrifugation in a table top centrifuge. Resuspension of the pellet to smaller volumes 
further enhances gene transfer. While flocculation of viruses with combinations of PB 
and CSC appears to be an effective means for enhancing transduction, the possibility of 
inducing flocculation with other polymers has not been investigated. In this study we 
used five cationic polymers and seven anionic polymers to assess the efficiency of dual 
flocculation of viruses with oppositely charged polymers and its effect on transduction.  
Viruses aggregated into complexes regardless of the combination we tried, and 
enhanced gene transfer between 2.5 and 5.5-fold. In each case, gene transfer was 
maximal when the number of positive charges and the number of negative charges 
added to the stock was about equal.  
While investigating the possibility of dual flocculation with various polymers, we 
found that it is possible to concentrate viruses by flocculation with a single species of 
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cationic polymer. Viruses concentrated after single flocculation significantly enhanced 
gene transfer, but to a lesser extent than viruses concentrated after dual flocculation.  
The difference in enhancement of transduction between these two concentration 
methods was due to the fact that viruses concentrated after dual flocculation remained 
as part of polymer complexes and were rapidly transported to the cells. In contrast, 
viruses concentrated after single flocculation appeared to disaggregate from the 
complexes and were transported mainly by diffusion. We concluded that concentration 
by single flocculation may be a useful alternative method for concentrating and purifying 
virus for applications in which high concentrations of polymers are undesirable or when it 
is not necessary for viruses to rapidly sediment onto the target cells. 
 
4.2 Introduction 
The presence of charged polymers in stocks of retroviruses can significantly alter 
the efficiency of transduction. Cationic polymers have been shown to enhance gene 
transfer and are commonly added to stocks of retroviruses during transduction [1-3]. 
While the mechanism of enhancement is not fully understood, some studies indicate that 
these polymers increase the rate of binding of virus particles to target cells [4, 5]. Most 
likely, positively charged polymers reduce the electrostatic repulsion between the 
negatively charged surfaces of viruses and cells [6]. Alternatively, they may induce 
aggregation of viruses into complexes, which are more susceptible to sedimentation 
than free virus particles [6]. In spite of their potential for enhancing retrovirus 
transduction, the use of these polymers has been limited to low concentrations (2 to 20 
µg/ml in most cases), because they are cytotoxic at higher doses [1-3] . 
Anionic polymers, on the other hand, have been shown to almost always inhibit 
retrovirus transduction [7]. The mechanism of inhibition is not well understood, but these 
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polymers appear to decrease the rate of binding of viruses to cells [8-11], probably by  
increasing the electrostatic repulsion between viruses and cells. Some of the anionic 
polymers present in virus stocks are a byproduct of the virus production system. They 
are secreted by packaging cells in the form of glycosaminoglycans and proteoglycans [7, 
11]. However, not all these polymers inhibit transduction. For example, chondroitin 
sulfate proteoglycans and glycosaminoglycans appear to inhibit gene transfer only if they 
have a high degree of sulfation and a specific carbohydrate structure [11]. In addition to 
increasing repulsion between viruses and cells, glycosaminoglycans that do inhibit 
transduction appear to prevent non-specific binding of viruses to cells.  This binding step 
can be mediated by interactions between the surface of the virus and 
glycosaminoglycans expressed on the surface of the cells [9]. Alternatively, binding may 
result from interactions between glycosaminoglycans on the surface of the viruses and 
heparan-binding domains of fibronectin molecules bound to the surfaces of cells or 
tissue culture plates  [12]. Thus, free glycosaminoglycans are likely to compete with cell-
associated glycosaminoglycans for virus binding or with virus-associated 
glycosaminoglycans for binding to the cells through fibronectin [9, 12]. Regardless of the 
mechanism of inhibition, removal of anionic polymers from virus stocks has been shown 
to improve transduction [13].  
Interestingly, we found that addition of high concentrations of the 
glycosaminoglycan chondroitin sulfate C (CSC) to a retrovirus stock can substantially 
increase gene transfer when added in conjunction with a high and equal weight 
concentration of the cationic polymer Polybrene (PB) [14, 15]. Addition of PB and CSC 
to stocks of retroviruses results in the formation of retrovirus-polymer complexes that 
incorporate more than 80% of the viruses and less than 0.3% of the proteins originally 
present in the stock [14]. These complexes do not reduce the stability of the viruses, yet 
are large enough to sediment, delivering the viruses to the cells more rapidly than by 
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simple diffusion.  Moreover, the complexes are not cytotoxic even though they contain 
high concentrations of cationic polymer. Rather, increasing doses of PB and CSC 
correlate with increasing levels of gene transfer (refer to Chapter 3) [15].  
Viruses within polymer complexes not only benefit from an accelerated binding to 
cells, but they can also be rapidly and easily concentrated and purified. Centrifugation of 
the complexes for 5 min at 10000g, followed by resuspension of the pellet in a reduced 
volume of fresh cell culture medium has resulted in substantial enhancement of 
transduction (refer to Chapter 2) [14].   
While association of virus particles with polyelectrolyte complexes of PB and 
CSC appears to be an effective means for enhancing the efficiency or retroviral-
mediated gene transfer, the possibility of forming virus-polymer complexes with other 
charged polymers with the aim of improving transduction has not been investigated. The 
formation of complexes in the presence of PB and CSC is most likely a form of 
flocculation, the destabilization of a suspension of colloids by the addition of a chemical 
agent known as a flocculant [16].  Charged polymers have been used as flocculants in a 
number of industrial settings including in the processing of minerals and pulp, in the 
purification of proteins and wastewater, and as a method to control the surface 
properties and behavior of biopharmaceuticals [17-24].  Highly charged, relatively low 
molecular weight polymers such as those used in this study typically induce flocculation 
by binding to oppositely charged sites on the surfaces of the colloids, forming an 
“electrostatic patch” that then binds to oppositely charged patches on adjacent particles 
[16]. In principle, and in analogy with other viruses, retrovirus-polymer complexes can be 
formed using a single species of cationic polymer (single flocculation) [25-27].  For 
example, Zhang et al formed lentivirus-poly-L-lysine complexes as a means to more 
efficiently concentrate lentiviruses by centrifugation [28]. In our system, flocculation with 
two oppositely charged polymers (dual flocculation), permits achieving high levels of 
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gene transfer by applying the virus-polymer complexes directly to the cells [15].  This 
suggests that the negatively charged polymer CSC protects the cells from what would 
otherwise be a cytotoxic dose of the cationic polymer PB. 
In the present study, we examined the possibility of inducing flocculation of 
viruses and enhancing gene transfer using different combinations of oppositely charged 
polymers. To examine this possibility, we hypothesized that virus flocculation was driven 
by interactions with a cationic polymer, and that an anionic polymer was required during 
transduction to neutralize the toxicity of the cationic polymer. 
 
4.3 Materials and methods 
Chemicals and antibodies.  Chondroitin sulfate A sodium salt from bovine 
trachea (CSA), chondroitin sulfate B sodium salt (CSB), chondroitin 6-sulfate sodium salt 
from shark cartilage (CSC), dextran sulfate sodium salt Leuconostoc spp. (DS), Heparin 
sodium salt from porcine intestinal mucosa (HEP), de-N-sulfated heparin sodium salt 
(desHEP), hyaluronic acid potassium salt from human umbilical cord (HA), 
 hexadimethrine bromide (Polybrene, PB), Poly-L-lysine hydrobromide (PLL), protamine 
sulfate salt Salmon (PS), gluteraldehyde, , o-Nitrophenyl β-D-galactopyranose (ONPG) 
and Igepal CA-630 were from Sigma Chemical Co. (St. Louis, MO).  Hydrogen peroxide 
30%, and Polyoxyethylene 20-Sorbitan Monolaurate (Tween 20) were from Fisher 
Scientific (Fair Lawn, NJ).  Non-fat dry milk (blotting grade) was from Bio-Rad 
Laboratories (Hercules, CA).  o-Phenylenediamine Dihydrochloride (OPD) was from 
Pierce (Rockford, IL).  5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) was 
from Denville Scientific, Inc. (Metuchen, NJ).  Mouse anti-p30 antibodies were purified 
from the supernatant of the CRL-1219 hybridoma cell line (ATCC, Rockville, MD) 
following standard procedures [29].  The goat polyclonal anti-p30 antibody (78S221) was 
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from Quality Biotech (Camden, NJ).  The horseradish peroxidase conjugated rabbit anti-
goat immunoglobulin G polyclonal antibody was from Zymed Laboratories (South San 
Francisco, CA).  
Cell culture.  NIH 3T3 mouse fibroblasts and the amphotropic packaging cell line 
Ψ-CRIP producing the α-SGC-LacZ virus [30], were cultured in Dulbecco's modified 
Eagle's medium (DMEM; Hyclone Labs Inc., Logan, UT) with 10% bovine calf serum 
(Hyclone Labs Inc.), 100 U/mL of penicillin, 100 µg/mL of streptomycin (Hyclone Labs 
Inc.) and 110 µg/mL of sodium pyruvate (Hyclone Labs Inc.) (DMEM/BCS). 
Production of retroviruses.  To generate retrovirus stocks, virus-producing 
cells were grown to confluence in T175 tissue culture flasks, and then incubated for 24 h 
with 35 mL of DMEM/BCS.  The virus-laden tissue culture medium was harvested, filter 
sterilized (0.45-µm), then frozen (-80°C) for later use.   
ELISA for p30.  We used an enzyme-linked immunosorbent assay (ELISA) to 
determine the concentration of virus capsid protein (p30).  ELISA plates (Nunc immuno 
Maxisorp 96-well plates, Nalge Nunc International, Rochester, NY) were coated 
overnight at 4°C with 10 µg/mL of mouse anti-p30 antibody (100 µL/well) in PBS. The 
next day, the antibody solution was removed and blocking buffer (PBS, 0.05% Tween-
20, 5% non-fat milk) added (200 µL/well) for 2 h at 37°C to block non-specific binding 
sites.  Samples were brought to 0.5% Triton-X to expose the p30 antigen, then added to 
the ELISA plate (100 µL/well) and incubated for 1 h at 37°C.  Bound p30 was 
sandwiched by the addition of the goat polyclonal anti-p30 antibody diluted 1:1000 in 
blocking buffer, and incubated for 1 h at 37°C.  The horseradish peroxidase conjugated 
polyclonal rabbit anti-goat immunoglobulin G was diluted 1:5000 in blocking buffer then 
added to the ELISA plate (100 µL/well) for 1 hour at 37°C to enable detection and 
quantitation of the sandwiched p30 antigen. The plates were developed for 5 min using 
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hydrogen peroxide (H2O2) and OPD (100 µg/well) from a solution of 10 mg of OPD and 
10 µl H2O2 in 25 mL of substrate buffer (24 mM citric acid-monohydrate, 51 mM 
Na2HPO4-7H20, pH 5.0).  8N sulfuric acid (50 µL/well) was used to stop the reaction and 
the optical density at 490 nm (OD490) measured using an absorbance plate reader and 
the non-specific background at 650nm subtracted. Values for replicate wells without 
virus were subtracted as background. Values for each point are the average of at least 
triplicate wells. 
Virus flocculation, precipitation and resuspension. We compared two 
methods to flocculate virus particles: single flocculation and dual flocculation.   For single 
flocculation, virus stocks were brought to various concentrations of PB and incubated at 
37°C for 20 min to allow aggregation of viruses and molecules of PB. The aggregates 
were concentrated in an invisible pellet by centrifugation for 5 min at 10000g. The 
supernatant was decanted and the pellet resuspended in fresh medium by pipetting up 
and down. For dual flocculation, virus stocks were brought to various concentrations of a 
cationic polymer and to various concentrations of an anionic polymer (refer to Table 4.1 
for a list of cationic and anionic polymers), then incubated at 37°C for 20 min to allow 
aggregation of polymers and viruses into visible polyelectrolyte complexes. The 
complexes were pelleted by centrifugation for 5 min at 10000g. The supernatant was 
decanted and the pellet resuspended in fresh medium by pipetting up and down. 
Cell viability assay. Ten microliters per well of MTT solution (100 mg of MTT in 
1 mL of PBS) were added per well to cells in a 96-well plate. The plate was incubated for 
4 hours at 37°C, then 150 µL of 10% SDS were added per well and the plate incubated 
overnight. The optical density at 570 nm was measured using an absorbance plate 
reader and the non-specific background at 650nm subtracted. Values for replicate wells 
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without cells were subtracted as background. Values for each point are the average of 
triplicate wells. 
β-galactosidase (β-gal) assay.  To test the effect of polymers on transduction, 
five thousand NIH 3T3 murine fibroblasts in 100 µL of medium were plated per well in a 
96-well flat-bottomed tissue culture dish with a low-evaporation lid (Costar Corp., 
Cambridge, MA).  The next day (19 to 26 h later), the medium was removed and 100 µL 
of the virus stocks were added to each well.  Two days after transduction, the medium 
was removed and the cells washed once with 100 µL of phosphate-buffered saline 
(PBS) containing 1mM MgCl2.  After removal of the wash solution, 50 µL of lysis buffer 
(PBS with 1mM MgCl2 and 0.5% Igepal) were added to each well, and the plate 
incubated at 37°C.  After 30 min, 50 µl of lysis buffer with 6 mM ONPG warmed to 37°C 
were added to each well, and the plate incubated at 37°C for 5 to 15 min until a visible 
yellow color was obtained.  The reactions were halted by the addition of 20 µL per well of 
stop buffer (1M Na2CO3). The optical density at 420 nm (OD420) was measured using an 
absorbance plate reader (Molecular Devices, Menlo Park, CA) and the non-specific 
background at 650 nm subtracted. Values for replicate wells without virus were 
subtracted as background. Values for each point are the averages of at least triplicate 
wells. 
Ratio and concentration of polymers that maximize the efficiency of 
transduction. Virus stocks were brought to low (80 µg/mL) or high (640 µg/mL) 
concentrations of PB and to various concentrations to one of the anionic polymers listed 
in Table 4.1. Alternatively, virus stocks were brought to low (80 µg/mL) or high (640 
µg/mL) concentrations of CSC and to various concentrations to one of the cationic 
polymers listed in Table 4.1. These stocks were added to NIH 3T3 fibroblasts that were 
plated the previous day at 5000 cells per well in a 96-well dish. Two days later, the 
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efficiency of transduction was quantified using the β-galactosidase assay. In each case, 
the ratio of anionic to cationic polymer that resulted in maximal transduction was 
determined (Table 4.2). To examine the concentration of polymers that maximized the 
gene transfer, various concentrations of the cationic polymer and the anionic polymer 
were added to virus stocks at the ratio previously determined. These stocks were used 
to transduce NIH 3T3 cells and the efficiency of gene transfer was quantified two days 
later. In each case, transduction increased with increasing concentrations of the 
polymers, reached a plateau level and eventually decreased with increasing 
concentrations of polymers. The concentrations of polymers that led to the highest 
transduction efficiencies were reported in Table 4.2. 
Ratio of positive to negative charges added to the virus stock. Based on the 
chemical structure of each polymer, the molecular weight of the monomer (MW) and the 
number of positive charges (P) or negative charges (N) per monomer at neutral pH were 
determined. The total number of positive charges (TP) or negative charges (TN) 




NavmPTP ∗∗=  
 
MW
NavmNTN ∗∗=  
 
where Nav is the Avogadro’s number. The ratio of positive charges to negative charges 
added to the stock was determined by dividing TP by TN.  
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4.4 Results 
Flocculation of viruses with a single charged polymer 
To investigate the possibility that viruses aggregate with polyelectrolyte 
complexes by interacting primarily with a positively charged group, we examined if 
aggregation of viruses was possible when only a cationic or anionic polymer was added 
to the stock.  For that purpose, we used the criterion that while free viruses are subject 
to diffusion limitations, viruses within aggregates sediment, thereby reaching the target 
cells faster than free viruses (refer to Chapter 3) [15]. We brought stocks of retroviruses 
to 320 µg/mL of PB, 320 µg/mL of CSC, a combination of 320 µg/mL of PB and 320 
µg/mL of CSC, or, as a control, 8 µg/mL of PB. We added these stocks to layers of NIH 
3T3 cells and, at various times, measured the concentration of viral capsid protein (p30) 
remaining in solution. When 320 µg/mL of CSC were used, the rate of disappearance of 
viruses from solution was similar to that in the control. However, when 320 µg/mL of PB 
were used, the rate of disappearance of viruses from solution was higher than that of the 
control, but lower than that in the presence of both polymers (Figure 4.1). This 
suggested that PB, but not CSC, could induce flocculation of retroviruses. 
To directly evaluate the possibility that viruses flocculate in the presence of PB, 
we brought virus stocks to various concentrations of PB. We incubated the stocks for 20 
min to allow aggregation of viruses, then centrifuged the stocks and decanted the 
supernatants. We did not observe pellets at the bottom of each tube, but we assumed 
the pellets were invisible and resuspended them to the original volume in fresh medium. 
As a control, we also pelleted virus stocks in the presence of 80 µg/mL of PB and 80 
µg/mL of CSC, and, as expected, obtained a visible pellet (refer to Chapter 2). To 
examine if aggregates of virus particles were precipitated, we measured the 




















Figure 4.1 High concentrations of PB, but not CSC, increase the rate of binding of 
viruses to cells. Virus stocks were brought to 320 µg/mL of PB ( ), 320 µg/mL of CSC 
( ), to a combination of 320 µg/mL of PB and 320 µg/mL of CSC ( ), or to 8 µg/mL of 
PB ( ), then added to NIH 3T3 fibroblasts. At various times, the supernatant was 
collected and the concentration of virus capsid protein (p30) remaining in the 
supernatant was quantified by ELISA. Each point represents the mean ± the standard 


















































 presence of only PB, the percentage of viral proteins in the pellet increased with 
increasing concentrations of the polymer (Figure 4.2). When 320 µg/mL of PB were 
used, the recovery of viruses was similar to that obtained with 80 µg/mL of both PB and 
CSC. These results indicated that PB could, in fact, flocculate viruses. 
Given that the pellets obtained after flocculation with only PB were not visible, we 
suspected that only a small fraction of the PB added to the stock was incorporated into 
the complexes. To study this possibility, we took into account our previous finding that 
high concentrations of PB are toxic to target cells (refer to Chapter2) [14]. Therefore, we 
hypothesized that upon centrifugation of the aggregates, the pellet would only 
concentrate a small fraction of PB and not be toxic. To test this hypothesis, we brought 
virus stocks to various concentrations of PB. After a 20-min incubation, we pelleted the 
stocks, collected the supernatants and resuspended the pellets to their original volume 
in fresh medium. As a control, we also pelleted virus stocks containing 80 µg/mL of PB 
and 80 µg/mL of CSC. We added the virus stocks, the supernatants and the 
resuspended pellets to layers of cells and, two days later, measured cell viability. The 
supernatants containing free PB were as toxic as the original stocks, while the pellets 
were not toxic (Figure 4.3). This supported our hypothesis that only a small fraction of 
PB aggregated with virus particles.  
Taken together, our results indicated that viruses could flocculate by interacting 
with a positively charged polymer, but not with a negatively charged polymer. This 
suggested that viruses adsorb mainly to positively charged patches of polyelectrolyte 






















Figure 4.2 PB induces aggregation of virus particles. Virus stocks were brought to 
various concentrations of PB, incubated at 37°C for 20 min and centrifuged at 10000g 
for 5 min. The supernatant was decanted and the pellet resuspended to the original 
volume in fresh medium. As a control, virus stocks were brought to 80 µg/mL of PB and 
80 µg/mL of CSC, then pelleted in a similar manner.  The concentration of p30 in virus 
stocks ( ), the decanted supernatants ( ), the resuspended pellets ( ) and the control 
pellet ( ) were quantified by ELISA. (Note that the control pellet does not contain 
varying concentrations of PB). Each point represents the mean ± the standard deviation 



































































Figure 4.3 Aggregates of viruses and PB are not toxic. Virus stocks were brought to 
various concentrations of PB, incubated at 37°C for 20 min and centrifuged at 10000g 
for 5 min. The supernatant was decanted and the pellet resuspended to the original 
volume in fresh medium. As a control, virus stocks were brought to 80 µg/mL of PB and 
80 µg/mL of CSC, then pelleted in a similar manner.  The virus stocks ( ), the decanted 
supernatants ( ), the resuspended pellets ( ) and the control pellet ( ) were added to 
NIH 3T3 cells and two days later, cell viability was measured. (Note that the control 
pellet does not contain varying concentrations of PB). Each point represents the mean ± 





































Dual flocculation of viruses with oppositely charged polymers 
We have previously shown that while high doses of PB are cytotoxic, 
combinations of equal weight concentrations of PB and CSC are not (refer to Chapter 2) 
[14]. Based on this finding, we hypothesized that CSC, the anionic polymer, mitigated 
the toxicity of PB, the cationic polymer by neutralizing the excess of positive charge. To 
test this hypothesis, we first assessed the extent to which anionic polymers other than 
CSC could mitigate the toxicity of PB. We incubated cells for two days with virus stocks 
containing 640 µg/mL of PB and a range of concentrations of one of the anionic 
polymers listed in Table 4.1: chondroitin sulfate A (CSA), chondroitin sulfate (CSB), 
CSC, heparin (HEP), de-N-sulfated heparin (desHEP), dextran sulfate (DS) or hyaluronic 
acid (HA). In all the cases, high concentrations of the anionic polymer mitigated the toxic 
effect of PB (Figures 4.4 - 4.5). We also examined the possibility that CSC could mitigate 
the toxicity of other cationic polymers. We incubated cells with virus stocks containing 
640 µg/mL of CSC and various concentrations of one of the cationic polymers listed in 
Table 4.1: PB, poly-l-lysine of low molecular weight (PLL (low)), poly-l-lysine of medium 
molecular weight (PLL (med)) or poly-l-lysine of high molecular weight (PLL (high)). As 
expected, an excess of any cationic polymer decreased cell viability (Figure 4.6). These 
results suggested that the anionic polymer reduced the toxicity of the cationic polymer by 
neutralizing the excess of positive charge in the medium.  
Based on these findings and the observation that viruses interacted mainly with 
PB, we hypothesized that viruses would aggregate with complexes formed by PB and 
any of the anionic polymers listed in Table 4.1, and that viruses in these complexes 
would transduce cells more efficiently than free viruses. To test this hypothesis, we 
transduced cells with virus stocks containing 640 µg/mL of PB and a range of 


















Polybrene PB Cationic amino 5-10 Linear 
Protamine sulfate PS Cationic amino 5 Linear 
Poly-L-lysine (low MW) PLL (low) Cationic amino 4-15 Linear 
Poly-L-lysine (medium MW) PLL (med) Cationic amino 30-70 Linear 
Poly-L-lysine (high MW) PLL (high) Cationic amino >300 Linear 
Chondroitin sulfate A CSA Anionic sulfate, carboxyl 20-30 Linear 
Chondroitin sulfate B CSB Anionic sulfate, carboxyl 13 Linear 
Chondroitin sulfate C CSC Anionic sulfate, carboxyl 60 Linear 
Heparin HEP Anionic sulfate, carboxyl 16-17 Linear 
De-N-sulfated heparin desHEP Anionic sulfate, carboxyl 17-18 Linear, de-N-sulfated
Dextran sulfate DS Anionic sulfate 500 Branched 
Hyaluronic acid HA Anionic carboxyl 750 Linear 



































Figure 4.4 Anionic polymers mitigate the toxicity of cationic polymers. Virus stocks were 
brought to 640 µg/mL of PB and to various concentrations of CSA ( ), CSB ( ) or CSC 
( ), then added to NIH 3T3 cells. Two days later cell viability was quantified. Each point 






















































Figure 4.5 Anionic polymers mitigate the toxicity of cationic polymers (continue). Virus 
stocks were brought to 640 µg/mL of PB and to various concentrations of DS ( ), HEP 
( ), desHEP ( ) or HA ( ), then added to NIH 3T3 cells. Two days later, cell viability 

























































Figure 4.6 Anionic polymers mitigate the toxicity of cationic polymers (continue). Virus 
stocks were brought to 640 µg/mL of CSC and to various concentrations of PB ( ), PLL 
(low) ( ), PLL (med) ( ) or PLL (high) ( ), then added to NIH 3T3 cells. Two days 
later, cell viability was quantified. Each point represents the mean ± the standard 




































 transfer increased with increasing concentrations of the anionic polymer, reached a 
maximum and then decreased with increasing concentrations of the anionic polymer 
(Figures 4.7-4.8). This indicated that aggregation of viruses within polyelectrolyte 
complexes was possible in the presence of anionic polymers with different 
characteristics. However, it was not clear if PB was required for aggregation of viruses or 
if it could be replaced by a different cationic polymer. To address this point, we 
transduced cells with virus stocks containing 640 µg/mL of CSC and a range of 
concentrations of each of the cationic polymers listed in Table 4.1. We found that in each 
case transduction was enhanced (Figure 4.9).  
These results indicated that varying the molecular weight, charge density, 
charged groups or geometry of the polymers did not prevent viruses from aggregating 
into complexes and efficiently transducing cells (for a more detailed analysis of the 
trends observed, refer to the discussion section). To further examine if varying the 
structure of the polymers affected transduction, we determined the weight ratio of 
oppositely charged polymers that resulted in maximal gene transfer (Table 4.2). While 
maintaining this ratio, we varied the concentrations of the polymers and assessed their 
effect on transduction. In Table 4.2 we report the concentrations that achieved maximal 
transduction, as well as the fold enhancement in gene transfer with respect to 
transduction with virus stocks containing 8 µg/mL of PB. The fold-increase in gene 
transfer varied between 2.5 and 5.5 depending on the combination of polymers used. 
We also estimated the ratio of positive to negative charges that were added to the 
medium in order to achieve maximal transduction. This ratio was close to 1:1 and varied 
between 0.78 and 1.53 depending on the combination of polymers used (Table 4.2). In 




















Figure 4.7 Combinations of PB and different anionic polymers enhance transduction. 
Virus stocks were brought to 640 µg/mL of PB and to various concentrations of CSA ( ), 
CSB ( ) or CSC ( ), then used to transduce NIH 3T3 cells. Each point represents the 




































































Figure 4.8 Combinations of PB and different anionic polymers enhance transduction 
(continue). Virus stocks were brought to 640 µg/mL of PB and to various concentrations 
of DS ( ), HEP ( ), desHEP ( ) or HA ( ), then used to transduce NIH 3T3 cells. 




































































Figure 4.9 Combinations of CSC and different cationic polymers enhance transduction. 
Virus stocks were brought to 640 µg/mL of CSC and to various concentrations of PB ( ), 
PLL (low) ( ), PLL (med) ( ), PLL (high) ( ) or PS ( ), then used to transduce NIH 








































































Fold increase relative to
8 µg/mL of PBc 
 
PB DS 4 : 3 1 : 1.24 160:120 - 320:240 5.48 ± 1.58 
PB HEP 4 : 3 1 : 0.87 160:120 - 640:480 4.10 ± 1.03 
PB desHEP 2 : 3 1 : 1.53 160:240 - 640:960 4.18 ± 0.24 
PB HA 1 : 1 1 : 0.45 80:80 - 160:160 2.99 ± 0.41 
PB CSA 1 : 1 1 : 0.78 320:320 - 640:640 3.49  ± 0.78 
PB CSB 1 : 1 1 : 0.78 320:320 3.52 ± 0.48 
PB CSC 1 : 1 1 : 0.78 320:320 4.00 ± 0.13 
PLL (low) CSC 1 : 1 1: 0.87 200:200 - 320:320 4.88 ± 0.88 
PLL (med) CSC 1 : 1 1: 0.87 160:160 3.94 ± 0.74 
PLL (high) CSC 1 : 1 1: 0.87 40:40 -160:160 2.71 ± 0.49 
PS CSC 1 : 1 N/A 320:320 - 640:640 2.45 ± 0.65 
a: Optimum ratio based on weight concentration 
b: Corresponding to the optimum weight ratio of cationic polymer to anionic polymer. Estimated based on the number of 
charged groups and molecular weight of the monomers in each polymer. 
c: Results obtained from three independent experiments 
N/A: not available. Only the composition of a major component of PS was available. 
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Based on our finding that viruses interacted with the cationic polymer and not 
with the anionic polymer, we considered the possibility that this slight excess of positive 
charge was neutralized by negative charges on the surface of virus particles. To further 
explore this possibility, we hypothesized that an excess of negative charge in the 
medium would prevent viruses from incorporating into complexes. To test this 
hypothesis, we brought virus stocks to 80 µg/mL of PB and to a range of concentrations 
of CSC, and then incubated the stocks for 20 min. We centrifuged each stock and 
obtained visible pellets when 80 to 960 µg/mL of CSC were used, suggesting that 
polyelectrolyte complexes were formed even when CSC was in large excess. To 
determine the extent to which viruses aggregated within these complexes, we measured 
the concentration of p30 in the original stocks, the supernatants and the pellets. About 
70% of p30 was recovered in the pellet when the concentration of CSC was 80 µg/mL, 
that is, when the two polymers were added at the optimum ratio 1:1. However, when 
concentrations of CSC equal to or higher than 160 µg/mL were used, most of the viral 
proteins remained in the supernatant (Figure 4.10), indicating that viruses did not 
aggregate with polyelectrolyte complexes. This result suggested that viruses competed 
with the anionic polymer for binding to the cationic polymer, and that an excess of 
cationic polymer was required to secure incorporation of viruses into polyelectrolyte 
complexes. 
In previous studies we observed that viruses were located primarily on the outer 
surfaces of the complexes (refer to Chapter 3)[15]. This observation raised the possibility 
that the oppositely charged polymers were forming cores and that viruses were binding 
to the surface of these cores. However, the results from single flocculation indicated that 
viruses could bind to free cationic polymer and thus raised the possibility that flocculation 























Figure 4.10 An excess of negative charge prevents incorporation of viruses into 
complexes. Virus stocks were brought to 80 µg/mL of PB and to various concentrations 
of CSC, incubated for 20 min at 37°C, then centrifuged for 5 min at 10000g. The 
supernatants were decanted and the pellets resuspended to the original volume in fresh 
medium. The concentration of p30 in the original solutions ( ), the supernatants ( ), 
and the resuspended pellets ( ) was quantified by ELISA. Each point represents the 

















































the cationic polymer would bind to the negatively charged surface of the viruses and 
render this surface positively charged. Then, the anionic polymer would form bridges 
among virus particles. It has been shown that the order of addition of polymers 
determines the efficiency of patching and bridging [32, 33]. In our system, a more 
efficient patching and bridging was expected if the cationic polymer was added prior to 
the anionic polymer. To determine if this was the case, we brought a virus stock to 80 
µg/mL of PB, incubated it for 10 min at 37°C, then brought it to 80 µg/mL of CSC and 
incubated it for another 10 min at 37°C. As a control, we brought the stock to 80 µg/mL 
of CSC, incubated it for 10 min at 37°C, then brought it to 80 µg/mL of PB and incubated 
it for another 10 min at 37°C. As an additional control, we brought the stock to 80 µg/mL 
of PB and to 80 µg/mL CSC by adding the polymers in immediate succession, and then 
incubated it for 20 min at 37°C. We centrifuged the stocks for 5 min at 10000g, decanted 
the supernatants and resuspended the pellets to their original volume in fresh medium. 
We found that 70 to 80% of the virus capsid protein (p30) was recovered in the pellet 
regardless of the order of addition of the polymers to the virus stock (Figure 4.11). 
Moreover, the recovery of p30 was slightly lower when PB was added before CSC than 
when CSC was added before PB or when the polymers were added in immediate 
succession. These results suggested that flocculation of viruses did not occur through a 
patching and bridging mechanism. Probably, PB and CSC were aggregating into 
complexes and viruses were binding to preformed complexes of PB and CSC (refer to 


















Figure 4.11 The order of addition of the polymers does not affect the efficiency of 
flocculation. Virus stocks were brought to 80 µg/mL of PB, incubated at 37 °C for 10 min, 
then brought to 80 µg/mL of CSC and incubated at 37 °C for 10 min (PB FIRST). 
Alternatively, virus stocks were brought to 80 µg/mL of CSC, incubated at 37 °C for 10 
min, then brought to 80 µg/mL of PB and incubated at 37 °C for 10 min (CSC FIRST). As 
a control, virus stocks were brought to 80 µg/m of PB and to 80 µg/mL of CSC by 
addition of the polymers in immediate succession, then incubated at 37 °C for 20 min 
(CNTL). The stocks were centrifuged for 5 min at 10000g, the supernatants decanted 
and the pellets resuspended to the original volume in fresh medium. The concentration 
of p30 in the original stocks (black bars), the supernatants (gray bars) and the pellets 
(white bars) was measured by ELISA. Each point represents the mean ± the standard 
deviation of three samples. 


































































Single flocculation vs. dual flocculation for enhancing gene transfer 
We have previously used dual flocculation of viruses with the purpose of 
enhancing gene transfer by rapidly transporting viruses to the surface of the cells (refer 
to Chapter 3) [15] and by concentrating virus stocks (refer to Chapter 2) [14].  
We have shown that viruses within complexes of oppositely charged polymers 
are rapidly transported to the surface of the cells, and that this rapid transport correlates 
with increases in the efficiency of transduction. Our results from Figure 4.1 indicated that 
single flocculation of viruses with PB also increased the rate of binding of viruses to 
cells, and therefore raised the possibility that single flocculation could enhance gene 
transfer. However, we have also observed that high doses of PB are cytotoxic (Figure 
4.3), and therefore not suitable for transduction. Given that in previous experiments we 
assessed the toxicity of PB after a two-day transduction, we considered the possibility 
that PB could be used for short-term transductions. To address this possibility, we 
incubated cells for various periods of time with virus stocks containing 320 µg/mL of PB. 
As controls, we also incubated cells with virus stocks containing 320 µg/mL of CSC, a 
combination of 320 µg/mL of PB and 320 µg/mL of CSC, or 8 µg/mL of PB. We found 
that exposure to CSC, to a combination of PB and CSC or to 8 µg/mL of PB did not 
decrease cell viability. In contrast, exposure to high concentrations of PB reduced cell 
viability by 10% after 8 hours, by 66% after 14 hours and to undetectable levels after 30 
hours (Figure 4.12). In parallel, we quantified the efficiency of gene transfer by 
measuring the β-galactosidase activity inside the cells. In the presence of only CSC, 
transduction was below the sensitivity of the assay.  In the presence of 320 µg/mL of PB, 
transduction increased at early times, but remained lower than transduction in the 
presence of both PB and CSC, and decreased to undetectable levels after 10 hrs of 



















Figure 4.12 High concentrations of PB, but not CSC, are toxic to target cells. Virus 
stocks were brought to 320 µg/mL of PB ( ), 320 µg/mL of CSC ( ), to a combination of 
320 µg/mL of PB and 320 µg/mL of CSC ( ), or to 8 µg/mL of PB ( ), then added to 
NIH 3T3 fibroblasts. At various times, the conditioned medium was replaced with fresh 
medium. Two days later, cell viability was quantified. Each point represents the mean ± 





































higher than that in the presence of 8 µg/mL of PB (Figure 4.13). These results indicated 
that single flocculation could only be used in transductions for less than 8 hours and that, 
even within this time frame, transduction with two oppositely charged polymers was 
more efficient.  
We have also used dual flocculation to concentrate virus stocks (refer to Chapter 
2) [14]. Briefly, we induce flocculation of viruses in the presence of oppositely charged 
polymers, centrifuge the stock and concentrate the complexes into a pellet. We decant 
the supernatant, resuspend the pellet to a smaller volume and use it to transduce cells. 
Our findings from Figures 4.2 and 4.3 indicated that flocculation with a single species of 
cationic polymer permited concentrating virus aggregates into a pellet and that the pellet 
was not cytotoxic. This suggested that single flocculation of viruses could be used for 
concentration of virus stocks prior to transduction. To evaluate this possibility, we 
brought virus stocks to 320 µg/mL of PB, or as a control to a combination of 80 µg/mL of 
PB and 80 µg/mL of CSC. We pelleted the stocks and resuspended the pellets in fresh 
medium to the original volume or to one fourth the original volume. We transduced cells 
with these resuspended pellets or, as a control, with virus stocks containing 8 µg/mL of 
PB. Resuspension of the pellet to the original volume did not enhance gene transfer with 
respect to the control when single flocculation was used, but enhanced gene transfer by 
4.5-fold when double flocculation was used (Figure 4.14). Upon a four-fold concentration 
of the stock, single flocculation led to a 2.4-fold increase in transduction, while dual 
flocculation led to a 13-fold increase in transduction.  
These differences in transduction were likely due to differences in the rate that 
viruses bound to cells. Viruses concentrated after single flocculation were probably 
transported to the cells in a similar manner as free viruses, while viruses concentrated 




















Figure 4.13 High concentrations of PB enhance gene transfer in short-term 
transductions. Virus stocks were brought to 320 µg/mL of PB ( ), 320 µg/mL of CSC 
( ), to a combination of 320 µg/mL of PB and 320 µg/mL of CSC ( ), or to 8 µg/mL of 
PB ( ), then added to NIH 3T3 fibroblasts. At various times, the conditioned medium 
was replaced with fresh medium. Two days later, the efficiency of transduction was 




















































Figure 4.14 Viruses concentrated after dual flocculation achieve higher efficiencies of 
transduction than viruses concentrated after single flocculation. Virus stocks were 
brought to 320 µg/mL of PB (gray bars) or to a combination of 80 µg/mL of PB and 80 
µg/mL of CSC (white bars), incubated at 37°C for 20 min, then centrifuged for 5 min at 
10000g. The supernatants were decanted and the pellets resuspended in fresh medium 
to the original volume (1X) or to one fourth the original volume (4X). NIH 3T3 cells were 
transduced with the resuspended pellets, or a control, with virus stocks containing only 8 





































assess this possibility, we measured the kinetics of virus binding. We added the pellets 
that had been resuspended to the original volume to layers of cells. After various 
intervals, we collected the supernatant and replaced it with fresh medium. We measured 
the concentration of p30 remaining in the supernatant over time, as well as the kinetics 
of gene transfer. The rates of binding and transduction with viruses concentrated after 
single flocculation were similar to those from the original virus stock containing 8 µg/mL 
of PB (Figures 4.15 - 4.16). On the contrary, the rates of binding and transduction with 
viruses concentrated after double flocculation were higher than those from the original 
virus stock containing 8 µg/mL of PB.  
 
4.5 Discussion 
We have previously shown that the combined addition of the cationic polymer PB 
and the anionic polymer CSC to stocks of retroviruses results in flocculation of virus 
particles and in substantial enhancement of transduction. In this study we showed that it 
is possible to induce flocculation of viruses and enhance gene transfer using other 
combinations of oppositely charged polymers. During dual flocculation, viruses appear to 
bind primarily to the cationic polymer, as flocculation with a single species of cationic 
polymer, but not with single species of anionic polymer, was possible. The anionic 
polymer appears to also bind to the cationic polymer, mitigate the cytotoxicity due to the 
excess of positive charge in the medium, and give rise to complexes bigger than those 
obtained upon single flocculation.  
Based on these findings, we examined the possibility that the cationic polymer 
could form patches on the surface of virus particles, while the anionic polymer could 
form bridges to connect the positively charged patches. This mechanism of patching and 




















Figure 4.15 Viruses concentrated after single flocculation with PB bind to the cells at the 
same rate as viruses in the original stock. Virus stocks were brought to 320 µg/mL of PB 
(single flocculation) or to a combination of 80 µg/mL of PB and 80 µg/mL of CSC (dual 
flocculation), incubated at 37°C for 20 min, then centrifuged for 5 min at 10000g. The 
supernatants were decanted and the pellets resuspended to the original volume in fresh 
medium. The resuspended pellet obtained after single flocculation ( ), the resuspended 
pellet obtained after dual flocculation ( ) or the original stock containing 8 µg/mL of PB 
( ) were added to NIH 3T3 cells. At various times, the supernatant was collected and 
the concentration of virus capsid protein (p30) remaining in the supernatant was 





















































































Figure 4.16 Viruses concentrated after single flocculation with PB transduce at the same 
rate as viruses in the original stock. Virus stocks were brought to 320 µg/mL of PB 
(single flocculation) or to a combination of 80 µg/mL of PB and 80 µg/mL of CSC (dual 
flocculation), incubated at 37°C for 20 min, then centrifuged for 5 min at 10000g. The 
supernatants were decanted and the pellets resuspended to the original volume in fresh 
medium. The resuspended pellet obtained after single flocculation ( ), the resuspended 
pellet obtained after dual flocculation ( ) or the original stock containing 8 µg/mL of PB 
( ) were used to transduce NIH 3T3 cells. At various times after the start of 
transduction, the conditioned medium was replaced with fresh medium. Two days later, 
the efficiency of transduction was quantified. Transduction was normalized with the 
concentration of p30 in each virus stock. Each point represents the mean ± the standard 
























































particles and alumina particles [32-34] and for flocculation of Escherichia coli and B. 
thuringiensis var. israelensis cellular suspensions [35]. However, flocculation by this 
mechanism is more efficient when the polymer that forms the patches is mixed with the 
colloidal particles prior to addition of the oppositely charged polymer [32, 33]. In our 
study, addition of the cationic polymer prior to addition of the anionic polymer did not 
improve the efficiency of virus aggregation with respect to simultaneous addition of both 
polymers. Moreover, patching and bridging would most likely result in incorporation of 
viruses in the interior of the complexes, which is not consistent with our previous 
observations. Upon double flocculation, viruses within complexes of PB and CSC are 
located primarily on their outer surfaces of the complexes (refer to Chapter 3)[15].  
Based on these findings, we propose that flocculation of viruses with oppositely 
charged polymers occurs as a two step process. First, oppositely charged polymers 
aggregate into polyelectrolyte cores, then the viruses bind to the surface of these cores.  
In this model, the oppositely charged polymers aggregate through electrostatic 
interactions, thereby neutralizing most of their charges and giving rise to hydrophobic 
structures. Molecules of the positively charged polymer, which is added in excess, are 
exposed at the surface of these structures and act as anchor for virus particles (Figure 
4.17).  
The first step of this model is consistent with a model proposed by Schatz et al. 
to characterize the aggregation of the polyanion dextran sulfate with the polycation 
chitosan [36, 37]. They showed that addition of dextran sulfate to a solution of chitosan 
results in the formation of spherical particles, which are likely composed by a neutral 
core surrounded by a shell of uncomplexed chitosan. The second step of this model can 
be described as aggregation of viruses into preformed complexes. Preformed complexes 
of oppositely charged polymers have proven efficient at flocculating clay and silica 

















Figure 4.17 Model for dual flocculation of viruses with oppositely charged polymers. The 
anionic and the cationic polymer aggregate and form a hydrophobic core. The excess of 
cationic polymer bind to the surface of this core and form positively charged patches. 





































































 [32, 38-40]. In our system, we did not preform polyelectrolyte complexes, but mixed the 
oppositely charged polymers and the viruses in a single step. It is possible that the 
cationic polymer is more readily attracted to the anionic polymer than to virus particles, 
such that aggregation of viruses can only occur once polyelectrolyte complexes are 
formed. Alternatively, the anionic polymer might be in vast excess to the virus particles, 
such that most of the cationic polymer will bind to the anionic polymer and only the 
leftover cationic polymer will bind to the viruses. 
Also, it is to be expected that viruses, due to their charged surface, would 
preferentially bind to the hydrophilic outer surface of the complexes and not to the 
hydrophobic core. Consistent with this idea, Cathrin et al. have shown that while 
hybrophobic bacteria are found in the interior of sludge flocs, hydrophilic bacteria are 
found at the surface of these flocs [41]. 
Previous studies of dual flocculation have shown that varying the characteristics 
of the polymers can have a major impact on the efficiency of flocculation of colloidal 
particles [31, 32, 38-40]. In this study, we did not directly evaluate the efficiency of 
flocculation by measuring the concentration of virus particles within the polyelectrolyte 
complexes. Rather, we evaluated the extent to which flocculation with charged polymers 
enhanced gene transfer by rapidly transporting viruses to the surface of the cells. 
Regardless of the combination of cationic polymer and anionic polymer we added to the 
virus stocks, gene transfer was significantly enhanced and the range of enhancement 
varied between 2.5 and 5.5-fold with respect to a standard transduction in the presence 
of 8 µg/mL of PB. We concluded that varying the nature of the charged groups, the 
charge density, the molecular weight or the geometry of the polymers, did not prevent 
viruses from incorporating into complexes. However, enhancement of gene transfer 
appeared to benefit from the use of lower molecular weight cationic polymers. In our 
study, the efficiency of transduction increased with decreasing molecular weight of PLL 
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in complexes of PLL and CSC. Interestingly, increasing the molecular weight of PLL also 
decreased the ability of CSC to mitigate the cytotoxicity in the medium. Additionally, we 
noted that the high molecular weight anionic polymer HA was less efficient than other, 
lower molecular weight, anionic polymers at mitigating the toxicity of PB and at 
enhancing gene transfer. These findings suggest that low molecular weight polymers are 
more likely to aggregate into polyelectrolyte complexes and favor flocculation of viruses. 
Nevertheless, it is possible that factors other than molecular weight affected flocculation. 
For example, HA was the only non-sulfated anionic polymer we tested and it is possible 
that sulfate groups favor aggregation of viruses. In order to identify the precise factors 
that assist flocculation, we need to conduct a more direct and exhaustive analysis of the 
physicochemical characteristics of the complexes. 
Regardless of the specific characteristics of the polymers we used, in almost all 
the cases we achieved maximal gene transfer when the positive charges added to the 
medium were in slight excess of the negative charges. This finding is consistent with our 
flocculation model (Figure 4.17). However, it is not clear why an excess of negative 
charge was necessary for two of the polymer combinations, namely PB with DS and PB 
with desHEP. It is possible that DS, due to its branched conformation and its high 
molecular weight, imposed electrosteric hindrances on the complexes and did not 
efficiently aggregate with other polymer chains into compact structures. In the case of 
desHEP, it is possible that a high degree of acetylation resulted in higher hydrophobicity 
of the polymer, which impeded its efficient complexation with CSC by charge-charge 
interactions. 
While conducting this study, we found that single flocculation of viruses with 
concentrations of PB as high as 320 µg/mL induced aggregation of more than 70% of 
the viruses. However, only a small fraction of PB interacted with virus particles, while the 
rest remained free in solution and was highly cytotoxic. We were able to purify the virus 
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aggregates from free PB by pelleting the complexes, removing the supernatant and 
resuspending the pellet in fresh medium. Interestingly, after resuspension, viruses were 
transported and transduced at similar rates as free virus particles, suggesting that they 
had disaggregated from the complexes. These viruses were still bioactive and enhanced 
gene transfer when resuspended to one fourth the original volume. These findings 
indicate that single flocculation is an efficient method for concentrating virus stocks and 
improving transduction. Nevertheless, concentration after dual flocculation achieved 
levels of gene transfer 4 to 5-fold higher than concentration after single flocculation. This 
higher increase in transduction was likely due to the fact that viruses within complexes of 
PB and CSC do not disaggregate upon resuspension of the pellet in fresh medium. They 
reach the surface of target cells much faster than free viruses, thereby increasing the 
rate of transduction (refer to Chapter 3) [15]. 
Taken together, our results suggest that concentration of viruses after double 
flocculation has the advantage of increasing the rate of binding of viruses to cells. On the 
other hand, concentration of viruses after single flocculation has the advantage of 
concentrating only trace doses of polymer, and is therefore desirable for applications 
where an excess of polymers is undesirable or for which higher rates of virus adsorption 
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COMPLEXATION WITH CHONDROITIN SULFATE C AND POLYBRENE RAPIDLY 
PURIFIES RETROVIRUS FROM INHIBITORS OF TRANSDUCTION AND 




Using amphotropic retrovirus stocks produced by TELCeB6-A cells that encode 
the Escherichia coli lacZ gene, we found that complexation with chondroitin sulfate C 
(CSC) and Polybrene (PB) is an effective means to purify retrovirus.  Virus stocks 
contained high levels of inhibitory activity that blocked amphotropic, but not ecotropic, 
retrovirus transduction.  When virus stocks were brought to 80 µg/mL each of CSC and 
PB, complexes of CSC and PB formed that incorporated more than 70% of the virus 
particles but less than 0.4% of all other proteins and no detectable inhibitory activity.  
Purified virus transduced NIH 3T3 murine fibroblasts 21 to 186-fold more efficiently than 
virus that was not purified.  In addition, virus purification significantly altered the dose 
response of transduction.  When virus that had not been purified was used to transduce 
cells, the relationship between transduction and virus concentration was highly non-
linear.  In contrast, when purified virus was used, transduction increased monotonically 
and was linearly proportional to virus concentration, except when high doses of virus 
were used.  Interestingly, when high doses of virus were used gene transfer reached a 
maximum plateau level, most likely because particle-associated amphotropic envelope 
proteins had saturated the cellular receptors for the virus.  Our findings illustrate that 
retrovirus purification increases the maximum number of genes that can be transferred, 
reduces the amount of virus required to achieve a given level of gene transfer, and 
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reduces uncertainties about the relationship between the amount of virus used and the 
number of genes transferred.      
 
5.2 Introduction 
Recombinant retroviruses are frequently used to genetically modify cells, 
primarily because they permanently and faithfully integrate their genetic material into the 
chromosomal DNA of target cells [1].  Unfortunately, the use of retroviruses in the clinic 
has met with limited success, in part because retroviruses often transfer too few genes 
to cells to achieve the desired therapeutic effect [2].  In addition, it has proven difficult to 
achieve predictable and reproducible levels of gene transfer with retroviruses [3].  
Predictable and reproducible levels of gene transfer are important in order to maximize 
the benefits of retrovirus transduction while minimizing the likelihood of any adverse side 
effects, including insertional mutagenesis [3, 4].  We and others have found that one 
cause of low and variable levels of gene transfer is the presence of inhibitors of 
transduction in virus stocks [5-9].  A number of substances that inhibit transduction have 
been identified, including negatively charged molecules such as proteoglycans and 
glycosaminoglycans [5, 6], as well as retrovirus envelope proteins that are not 
associated with the virus particles (i.e., free envelope proteins) [5, 6, 9, 10].  Little is 
known about the mechanism of inhibition, or what controls whether or not inhibitors are 
present in virus stocks, or to what extent these inhibitors block transduction when they 
are present.  As a result, the presence of inhibitory activity in virus stocks makes it 
difficult to predict and control the outcome of retrovirus transduction protocols.   
Traditionally, predictions of the outcome of transduction protocols have been 
based on the results of virus titer assays.  Virus titer assays provide an estimate of the 
concentration of active virus in virus stocks.  To determine titer, virus stocks are diluted 
several thousand-fold and then used to transduce cells [11-13].  The titer, expressed as 
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the number of colony forming units per milliliter (CFU/mL), is the number of colonies of 
transduced cells multiplied by the dilution factor and divided by the volume of virus that 
was applied to the cells.  Values for titer are frequently incorporated into the calculation 
of the multiplicity of infection (MOI), the expected number of gene transfer events per 
cell in a transduction protocol.  Unfortunately, recent studies have demonstrated that 
virus titer and MOI are not reliable predictors of the transduction process [14, 15].  This 
is due in part to the fact that virus titers are measured using virus stocks that have been 
diluted several thousand-fold in fresh medium and therefore contain virtually no inhibitory 
activity.  Under these conditions the number of genes transferred is proportional to the 
concentration of active virus.  In contrast, when high doses of virus are applied to cells, 
as is done in human gene transfer protocols, the relationship between the concentration 
of active virus and the number of genes transferred is non-linear and complex, due in 
part to the presence of high levels of inhibitory activity [9, 14]. 
As a result, there is significant motivation for developing methods for purifying 
retroviruses from inhibitors of transduction.  One of the most commonly used methods 
for purifying retroviruses is to pellet them by ultracentrifugation, after which they are 
resuspended in fresh cell culture medium that does not contain any inhibitors.  
Unfortunately, retroviruses are often inactivated by this procedure, presumably because 
shear forces cause the retrovirus envelope proteins to separate from the virus particles, 
giving rise to virus particles that are no longer fusogenic.  The problem of inactivation of 
retroviruses by ultracentrifugation was solved to some extent with the development of 
retroviruses pseudotyped with the vesicular stomatitis virus G protein (VSV-G), which 
are not inactivated by ultracentrifugation [16].  Unfortunately, the cytotoxicity of the VSV-
G protein has complicated attempts to construct stable virus producer cell lines and 
limits the amount of virus that can be applied to the target cells [17-19].  VSV-G 
pseudotyped retroviruses have other shortcomings as well, including the fact that they 
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are pantropic [16] and are therefore less suitable than most other retrovirus pseudotypes 
for use in applications that require targeted gene delivery.  In addition, despite their 
exceptionally wide tropism, VSV-G pseudotyped retroviruses are not able to efficiently 
transduce some important cell types, including polarized epithelial cells of the lung [20].  
Virus purification strategies are needed that will work with all types of retrovirus 
pseudotypes, not just with retroviruses that can be concentrated by ultracentrifugation.  
Numerous alternatives to ultracentrifugation as a means to purify retrovirus have been 
developed, including low-speed centrifugation, size-exclusion membrane filtration, 
affinity chromatography, and complexation with calcium phosphate, cationic polymers or 
paramagnetic beads [11, 12, 16, 21-33].  Although each of these approaches are 
capable of concentrating retrovirus stocks and improving gene transfer, they do not 
increase the number of genes transferred to the same extent that the virus stocks are 
concentrated, which suggests that these virus processing methods co-concentrate 
inhibitors [7, 34] or directly reduce the ability of the viruses to transduce cells.  In 
addition, many of these methods are labor and time intensive and difficult to scale up. 
Improved methods for processing retrovirus stocks are needed that are rapid, 
inexpensive, scalable, universally applicable to any type of retrovirus, and which do not 
co-concentrate inhibitors or otherwise reduce the ability of the viruses to transduce cells.  
Recently, we developed a rapid method to concentrate retrovirus stocks [13, 35] that 
consists of adding high concentrations of the oppositely charged polymers Polybrene 
(PB) and chondroitin sulfate C (CSC) to retrovirus stocks prior to transduction. Polymers 
and viruses flocculate and form high molecular weight complexes which can be rapidly 
pelleted by centrifugation in a table top centrifuge. Resuspension of the pellet to smaller 
volumes substantially increases the efficiency of gene transfer to numerous cell lines, as 
well as to primary human fibroblasts [13, 35, 36] and murine hematopoietic progenitor 
cells (personal communication, Spencer, HT, Emory University, 2005).  In addition, we 
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observed that retroviruses, but few other proteins, were selectively incorporated into the 
polymer complexes (refer to Chapter 2) [13].  Given the selectivity of retrovirus 
incorporation, we hypothesized that complexation of retroviruses with PB and CSC could 
be used to purify them from inhibitors of transduction, increase the maximum level of 
gene transfer, and linearize the dose response curve, thereby simplifying attempts to 
obtain reproducible and predictable levels of transduction.  To test this hypothesis, we 
formed retrovirus-polymer complexes in virus stocks produced by TELCeB6-A 
packaging cells that contained high levels of inhibitory activity, isolated the virus-polymer 
complexes, and examined the effect of this separation process on the dose response of 
gene transfer.   
 
5.3 Materials and methods 
Chemicals and antibodies.  Chondroitin sulfate C (CSC) (shark cartilage), 
gluteraldehyde, 1,5-dimethyl-1,5-diazaundecamethylene polymethobromide (polybrene, 
PB), o-Nitrophenyl β-D-galactopyranose (ONPG), 3-(4.5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) and Igepal CA-630 were from Sigma Chemical Co. 
(St. Louis, MO).  Hydrogen peroxide 30%, bovine serum albumin fraction V (BSA) and 
Polyoxyethylene 20-Sorbitan Monolaurate (Tween 20) were from Fisher Scientific (Fair 
Lawn, NJ).  Non-fat dry milk (blotting grade) was from Bio-Rad Laboratories (Hercules, 
CA).  o-Phenylenediamine Dihydrochloride (OPD) was from Pierce (Rockford, IL).  5-
Bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) was from Denville Scientific, 
Inc. (Metuchen, NJ).  Mouse anti-p30 and mouse anti-gp70 antibodies were purified from 
the supernatant of the CRL-1219 (ATCC, Rockville, MD) and the 83A25 [37] hybridoma 
cell lines respectively, following standard procedures [38].  The goat polyclonal anti-p30 
antibody (78S221) and the goat polyclonal anti-gp70 (79S834) were from Quality 
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Biotech (Camden, NJ).  The horseradish peroxidase conjugated rabbit anti-goat 
immunoglobulin G polyclonal antibody was from Zymed Laboratories (South San 
Francisco, CA).  
Cell culture.  NIH 3T3 mouse fibroblasts and the amphotropic packaging cell line 
Ψ-CRIP producing the α-SGC-LacZ virus [39] were cultured in Dulbecco's modified 
Eagle's medium (DMEM; Hyclone Labs Inc., Logan, UT) with 10% bovine calf serum 
(Hyclone Labs Inc.), 100 U/mL of penicillin, and 100 µg/mL of streptomycin (Hyclone 
Labs Inc.) (DMEM/BCS).  TELCeB6 (TE671 cells expressing Mo-MLVgagpol and the 
retroviral vector MFGnlsLacZ [40]) and HeLa cells (human adenocarcinoma cells, from 
the ATCC), were cultured in DMEM, 10% fetal bovine serum (Hyclone Labs Inc.), 100 
U/mL of penicillin, and 100 µg/mL of streptomycin (DMEM/FBS).  RIE cells (rat intestinal 
epithelial cells), a kind gift from Donald H. Rubin, were cultured in DMEM, 10% fetal 
bovine serum (Hyclone Labs Inc.), 100 U/mL of penicillin, 100 µg/mL of streptomycin, 
and 2mM of L-glutamine (DMEM/FBS/L-GLUT). 
Generation of a stable amphotropic retrovirus packaging cell line.  An 
amphotropic packaging cell line (TELCeB6-A) was generated by stable transfection of 
TELCeB6 cells.  Five micrograms of the plasmid FB4070ASALF, an expression plasmid 
that encodes for the amphotropic envelope glycoprotein (a kind gift of Stephen Russell), 
was dissolved in 400 µL of 0.25M CaCl2, mixed with 400 µL of 2X HEPES buffered 
saline (274 mM NaCl, 42 mM Hepes acid, 10 mM KCl, 1.4 mM Na2HPO4 and 12 mM 
dextrose), incubated at room temperature for 20 minutes, then added to a 50% confluent 
T75 flask of TELCeB6 cells.  Twelve hours after transfection the cells were washed with 
PBS, and then the medium replaced with fresh DMEM/FBS.  Two days later the cells 
were trypsinized, pelleted, and resuspended.  Two hundred microliters of the 
resuspended cells were diluted in 10 mL of selective medium (DMEM, 10% FBS, 50 
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µg/mL of phleomycin, and 7 µg/mL of blasticidin), and plated in a T75 flask.  Fourteen 
days later pooled clones of stably transfected cells were frozen for later use. 
Retrovirus production.  To generate retrovirus stocks, virus-producing cells 
were grown to confluence in T175 tissue culture flasks, and then incubated for 24 h with 
35 mL of cell culture medium.  The virus-laden tissue culture medium was harvested, 
filter sterilized (0.45-µm), then frozen (-80°C) for later use.   
Diluted titer assay.  Ten-fold serial dilutions of lacZ virus stock were made in 
DMEM/BCS and Polybrene (8 µg/mL).  A 1-mL amount per well was used to transduce 
3T3 cells that had been seeded (7 x 104 per well) the previous day in a 12-well plate.  
Two days after the start of the transduction, the cells were fixed and stained for β-
galactosidase activity with X-Gal [41].  Colonies of lacZ+ cells (typically in clusters of 2, 4, 
or 8 blue cells) were counted with the aid of a dissecting microscope.  At appropriate 
dilutions of the virus stock, the clusters of blue cells were sufficiently spread over the 
dish such that each cluster arose from a single transduction event. From triplicate wells, 
the number of lacZ+ CFU per milliliter was determined. The stock produced by ψ-CRIP 
had a titer of 6.20x104 ± 0.86x104 CFU/mL and the stock produced by TELCeB6-A had a 
titer of 7.12x107 ± 0.60x107.    
Beta-galactosidase (β-gal) transduction assay.  Five thousand NIH 3T3 
murine fibroblasts in 100 µL of medium were plated per well in a 96-well flat-bottomed 
tissue culture dish with a low-evaporation lid (Costar Corp., Cambridge, MA)[42].  The 
next day (19 to 26 h later), the medium was removed and 100 µL of the virus-containing 
solutions was added to each well.  Two days after transduction, the medium was 
removed and the cells washed once with 100 µL of phosphate-buffered saline (PBS) 
containing 1mM MgCl2.  After removal of the wash solution, 50 µL of lysis buffer (PBS 
with 1mM MgCl2 and 0.5% Igepal) were added to each well, and the plate incubated at 
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37°C.  After 30 min, 50 µl of lysis buffer with 6 mM ONPG was warmed to 37°C and then 
added to each well, and the plate incubated at 37°C for 5 to 60 min until a visible yellow 
color was obtained.  The reactions were halted by the addition of 20 µL per well of stop 
buffer (1M Na2CO3). The optical density at 420 nm (OD420) was measured using an 
absorbance plate reader (Molecular Devices, Menlo Park, CA) and the non-specific 
background at 650 nm subtracted. Values for replicate wells without virus were 
subtracted as background. Values for each point are the averages of at least triplicate 
wells. 
Production of medium that contains free amphotropic envelope protein.  
TE671 cells, plated the previous day in a 10-cm dish (5 x 106 cells), were transfected 
with an expression plasmid (16 µg) for the amphotropic envelope glycoprotein 
(FB4070ASALF) using Lipofectamine 2000 (40 µL).  Eight hours later the medium was 
replaced with fresh medium.  Thirty-six hours after the start of the transfection the 
conditioned medium, which contained soluble envelope proteins shed from the surfaces 
of the transfected cells, was harvested, filtered (0.45µm) to remove cellular debris, and 
frozen (-80 °C) for later use. 
Retrovirus purification.  We compared three methods for purifying retrovirus:  
polymer complexation, ultracentrifugation, and low speed centrifugation.  To purify 
retrovirus by polymer complexation, virus stock (0.4 to 1.5 mL per microcentrifuge tube) 
was brought to equal weight concentrations (80 µg/mL) of PB and CSC by adding, in 
immediate succession, appropriate volumes of aqueous stock solutions (20 mg/mL) of 
the polymers. The mixture was vortexed briefly, incubated for 20 min at 37°C, and then 
centrifuged to pellet the virus-polymer complexes (10000g, 5 min).  The supernatant was 
removed and the pellet was resuspended to its original volume in fresh cell culture 
medium.  To purify retrovirus by ultracentrifugation, virus stock (9 mL) was layered over 
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2 mL of 20% sucrose and then centrifuged for 90 min at 40000 rpm (200000g) at 4°C.  
Eight milliliters of the supernatant were collected (virus-free conditioned medium, 
VFCM), after which the rest of the supernatant was decanted and discarded, and the 
pellet was resuspended to its original volume in fresh medium.  To purify retrovirus by 
low speed centrifugation, virus stock (0.4 to 1.5 mL per microcentrifuge tube) was 
centrifuged for 16 hrs at 6000g, 4°C. The supernatant was decanted and the pellet 
resuspended to its original volume in fresh medium. 
ELISA for p30 and gp70.  We used an enzyme-linked immunosorbent assay 
(ELISA) to determine the concentration of virus capsid protein (p30) and viral envelope 
glycoprotein (gp70).  ELISA plates (Nunc immuno Maxisorp 96-well plates, Nalge Nunc 
International, Rochester, NY) were coated overnight at 4°C with 10 µg/mL of mouse anti-
p30 antibody or mouse anti-gp70 antibody (100 µL/well) in PBS. The next day, the 
antibody solution was removed and blocking buffer (PBS, 0.05% Tween-20, 5% non-fat 
milk) added (200 µL/well) for 2 h at 37°C to block non-specific binding sites.  Samples 
were brought to 0.5% Triton-X to expose the p30 antigen, and then added to the ELISA 
plate (100 µL/well) and incubated for 1 h at 37°C.  Bound p30 and gp70 were 
sandwiched by the addition of the goat polyclonal anti-p30 antibody diluted 1:1000 in 
blocking buffer or the goat polyclonal anti-gp70 diluted 1:300 in blocking buffer, and 
incubated for 1 h at 37°C.  The horseradish peroxidase conjugated polyclonal rabbit anti-
goat immunoglobulin G was diluted 1:5000 in blocking buffer and then added to the 
ELISA plate (100 µL/well) for 1 hour at 37°C to enable detection and quantitation of the 
sandwiched p30 antigen. The plates were developed using hydrogen peroxide (H2O2) 
and OPD (100 µg/well) from a solution of 10 mg of OPD and 10 µl H2O2 in 25 mL of 
substrate buffer (24 mM citric acid-monohydrate, 51 mM Na2HPO4-7H20, pH 5.0).  8N 
sulfuric acid (50 µL/well) was used to stop the reaction and the optical density at 490 nm 
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(OD490) was measured using an absorbance plate reader and the non-specific 
background at 650nm subtracted. Values for replicate wells without virus were 
subtracted as background. Values for each point are the average of at least triplicate 
wells. 
Protein assays.  To visualize proteins in virus stocks, samples were boiled in 
Laemmli buffer and 5% β-mercaptoethanol (33.3 µL) for 5 min at 100°C, separated by 
size by SDS-PAGE (4-20% Tris-Glycine gel; Gradipore, Australia), and then silver-
stained using GelCode SilverSNAP Stain (Pierce, Rockford, IL).  Protein concentrations 
were determined with the Comassie Plus-200 Protein Assay Reagent (Pierce, Rockford, 
IL) using bovine serum albumin as the standard.  
Percent transduced assay. Cells were transduced in 96-well dishes as 
described above, grown to confluence, and trypsinized.  Twenty to one hundred 
microliters of the trypsinized cells were brought to 1 mL in cell culture medium.  Ten 
microliters of this solution was plated into a 10-cm dish. After 10 days, when 
macroscopic colonies had grown, the plates were washed once with PBS and fixed and 
stained for β-galactosidase as previously described [42]. The colonies were then 
counterstained with 1% rhodamine B, rinsed with water and air dried. Values for the 
percentage of lacZ+ colonies at each point (blue colonies/total colonies x 100) are the 
averages of triplicate wells of the 96-well dish. 
Determination of transgene copy number by real-time PCR.  To compare the 
number of transgenes integrated per cell, clonally derived macroscopic colonies were 
obtained as described in the percent transduced assay. Individual colonies were 
isolated, expanded in 10-cm plates, and then their genomic DNA extracted using the 
DNeasy Tissue Kit (Qiagen, Valencia, CA).  Real-time PCR was performed with an ABI 
PRISM 7700 sequence detector (Applied Biosystems) in a final volume of 30 µL.  The 
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PCR mix contained SYBR Green PCR Master Mix (Applied Biosystems, Foster City, 
CA), DNA (0.01 µg), and forward and reverse primers each brought to a final 
concentration of 30 µM.  LacZ-specific primers were designed with Primer Express 
software (version 1.5) (Applied Biosystems). The sequences were as follows:  forward 
primer 5’-TTCGCTACCTGGAGAGACGC-3’, and reverse primer 5’-
ATTTAGCGAAACCGCCAAGA-3’.  The cycling conditions were 2 min at 50°C, 10 min at 
95°C, and then 40 cycles of 95°C for 15 s and 60°C for 1 min.  The relative number of 
integrated transgenes per cell was determined using serial dilutions of lacZ amplicons 
ranging in concentration from 5x10-7 to 5 nM.  Copy numbers were normalized to 18S 
DNA which was amplified under identical conditions using the forward primer 5’-
CGCCGCTAGAGGTGAAATTC-3’ and the reverse primer 5’-
TTGGCAAATGCTTTCGCTC-3’.  Values were reported as the number of copies per cell 
relative to the clone with the lowest number of integrated transgenes.  Values are the 
averages of triplicate PCR tubes. 
Data Analysis.  Data are summarized as mean ± SD.  Statistical analysis was 
performed using a one-way analysis of variance for repeated measurements of the same 
variable.  The Tukey multiple comparison test was used to conduct pairwise 




We have previously shown that the addition to virus stocks of Polybrene (PB), a 
cationic polymer, and chondroitin sulfate C (CSC), an anionic polymer, leads to the rapid 
formation of polyelectrolyte complexes that selectively incorporate retrovirus particles but 
few other proteins (refer to Chapter 2) [13].  Given the selectivity of this process, we 
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decided to test if polymer complexation could be used to purify virus stocks from 
inhibitors of transduction.  We used stocks of lacZ amphotropic retrovirus produced by 
TELCeB6-A packaging cells because they appeared to contain high levels of inhibitory 
activity as evidenced by the highly non-linear relationship between the amount of virus 
used to transduce cells and the level of gene transfer.  For example, when these viruses 
were used to transduce NIH 3T3 cells in a microplate assay the dose response curve 
had two components, a portion in which gene transfer increased in proportion to the 
dose of virus used (0 to 20 µL per well), and a portion in which gene transfer decreased 
with increasing doses of virus (above 20 µL per well) (Figure 5.1).  To determine if the 
virus stocks contained inhibitory activity, we pelleted the virus particles from the stocks 
by ultracentrifugation, decanted the virus-free conditioned medium (VFCM) from the 
pelleted viruses, and tested its ability to inhibit transduction.  We mixed 20 µL of 
amphotropic lacZ virus with a range of volumes of VFCM (0 to 80 µL), adjusted the final 
volume to 100 µL with fresh medium, and then used the solution to transduce NIH 3T3 
cells.  Transduction was inhibited in a dose-dependent manner by increasing 
concentrations of VFCM (Figure 5.2) which confirmed that the virus stocks contained 
inhibitors of transduction.   
To determine if the inhibitory activity was specific for amphotropic retroviruses, 
we transduced NIH 3T3 cells with 80 µL of VFCM or fresh medium, and 20 µL of one of 
the following virus stocks: amphotropic virus produced by TELCeB6-A packaging cells, 
amphotropic virus produced by ψ-CRIP packaging cells, or ecotropic virus produced by 
CRE-BAG packaging cells.  VFCM inhibited transduction by 7-fold or more when 
amphotropic virus was used, but had no significant effect on transduction when ecotropic 
virus was used (Figure 5.3). These results suggest that the inhibitory activity is specific 



































Figure 5.1 Retrovirus produced by TELCeB6-A cells contains substances that inhibit 
retrovirus transduction. NIH 3T3 cells were plated in a 96-well dish (5,000 cells per well) 
and the next day transduced with 100 µL of medium than contained various volumes of 
amphotropic lacZ retrovirus produced from the TELCeB6-A cell line, 8 µg/mL PB and 
fresh medium.  Two days later the amount of β-galactosidase (β-gal) activity in lysates of 
the cells, which is proportional to the level of gene transfer, was quantified using the β-
gal transduction assay. Each point represents the mean ± standard deviation of triplicate 





































































Figure 5.2 The conditioned medium produced TELCeB6-A cells contains substances 
that inhibit retrovirus transduction.  NIH 3T3 cells were plated in a 96-well dish (5,000 
cells per well) and the next day transduced with 100 µL of medium that contained 
various volumes of virus-free medium conditioned by TELCeB6-A cells (VFCM), 20 µL of 
amphotropic lacZ virus stock produced by TELCeB6-A cells, 8 µg/mL of PB, and fresh 
medium.  Two days later the wells were assayed for β-gal activity.  Each point 





































are not associated with virus particles but which competitively bind to cell surface 
amphotropic receptors, thereby inhibiting amphotropic retrovirus transduction. 
Given that in a previous study we had shown that PB-CSC polymer complexes 
efficiently incorporate intact virus particles, we reasoned that polymer complexation 
might be useful for purifying intact virus particles from inhibitory free envelope proteins if 
the free envelope proteins were incorporated into the complexes less efficiently than 
intact viruses.  To determine the extent to which free envelope proteins are incorporated 
into PB-CSC complexes, we generated medium that contained free amphotropic 
envelope proteins by transiently transfecting TE671 cells, the parent cell line of 
TELCeB6-A packaging cells, with an expression plasmid for the amphotropic envelope 
protein.  Cell culture medium that was conditioned by these cells and which contained 
free amphotropic envelope proteins, was brought to equal weight concentrations of PB 
(80 µg/mL) and CSC (80 µg/mL), incubated for 20 minutes at 37°C to allow the charged 
polymers to form polyelectrolyte complexes, and then centrifuged (10000g) for 5 minutes 
to pellet the complexes.  We decanted the supernatant from the pelleted complexes, 
resuspended the complexes to their original volume in fresh cell culture medium, and 
then quantified by ELISA the amount of free envelope protein in the supernatant and 
resuspended pellets.  The concentration of free envelope protein in the original 
conditioned medium and in the supernatant was not signficantly different (p < 0.05) 
(Figure 5.4).  Similar results were obtained with VFCM that contained free envelope 
proteins (data not shown).  These results show that, unlike intact virus particles, free 
retrovirus envelope proteins are not efficiently incorporated into PB-CSC polymer 
complexes. 
To examine the extent to which PB-CSC complexes incorporate other proteins, 
we repeated the polymer complexation and resuspension procedure with amphotropic 

































Figure 5.3 The conditioned medium produced TELCeB6-A cells contains substances 
that inhibit amphotropic, but not ecotropic, retrovirus transduction. NIH 3T3 cells were 
plated in a 96-well dish (5,000 cells per well) and the next day transduced with 100 µL of 
medium that contained 80 µL of VFCM (black bars) or fresh medium (white bars), 8 
µg/mL of PB, and 20 µL of either amphotropic lacZ virus produced from TELCeB6-A 
cells, amphotropic lacZ virus produced from ψ-CRIP cells, or ecotropic lacZ retrovirus 
produced from CRE BAG cells.  Two days later the wells were assayed for β-gal activity.  
Each point represents the mean ± standard deviation of triplicate samples.  Statistically 
significant differences (p ≤ 0.05) from virus stocks that were diluted in fresh medium are 
denoted with an asterisk. 
 
















































































Figure 5.4 Complexes of CSC and PB do not incorporate amphotropic envelope protein. 
Conditioned medium that contained free amphotropic envelope protein, generated by 
incubation of fresh cell culture medium for 28 h with confluent cultures of TE671 cells 
transiently transfected with an expression plasmid for the amphotropic envelope protein 
(FB4070ASALF), were brought to 80 µg/mL of CSC and 80 µg/mL PB, incubated 20 min 
at 37°C to allow complexes of CSC and PB to form, and then centrifuged to pellet the 
complexes.  The pellet was resuspended in fresh medium to its original volume.  The 
concentration of amphotropic envelope protein in the conditioned medium (CM), 
supernatant (SN), and resuspended pellet (PELLET) was determined with an ELISA for 
gp70 (OD490).  Each point shows the mean ± standard deviation of three replicates.  













































 separated them by size by polyacrylamide gel electrophoresis, and then visualized the 
proteins in the gel by silver staining.  As controls, we also analyzed samples of neat 
virus stock, and virus stock that contained PB and CSC but which had not been 
centrifuged.  The supernatant contained large quantities of numerous proteins and was 
indistinguishable from the virus stocks that had not been centrifuged (Figure 5.5, lanes 
1-3).  In contrast, only small quantities of high molecular weight proteins (> 250 kDa) 
were detected in the resuspended pellets (Figure 5.5, lane 4), even when added at 
concentrations 10-fold higher than that of the other solutions (Figure 5.5, lane 5).  We 
also quantified the percentage of total protein and viral capsid protein (p30) that was 
incorporated into the complexes.  We found that the complexes captured 72% of the 
virus particles, but only 0.36% of the total protein that was initially present in the virus 
stock.  
These data show that PB-CSC complexes capture very few non virus-associated 
proteins.  Nevertheless, it remained a possibility that the high molecular weight proteins 
associated with the complexes inhibit transduction, or that the complexes contain 
inhibitors of transduction that were not detected by our assays.  To address this 
possibility, we directly quantified the level of inhibitory activity that was present in the 
complexes.  We formed polymer complexes in VFCM, pelleted the complexes by 
centrifugation, and decanted the VFCM supernatant.  In parallel, we performed the same 
procedure with fresh medium.  We then resuspended both sets of complexes to their 
original volume in the supernatant that was decanted from the complexes formed in 
VFCM, or in the supernatant that was decanted from the complexes formed in fresh 
medium.  To measure their inhibitory activity, we mixed 80 µL of these solutions with 20 
µL of amphotropic lacZ virus and used them to transduce NIH 3T3 cells.  We found that 


































Figure 5.5 Complexes of CSC and PB do not incorporate most proteins. LacZ 
amphotropic virus stock produced by TELCeB6-A cells was brought to 80 µg/mL CSC 
and 80 µg/mL PB, incubated for 20 min at 37°C, and then the complexes pelleted by 
centrifugation and resuspended to their original volume in PBS.  The proteins in 1.7 µL 
of virus stock (lane 1), virus stock brought to 80 µg/mL each of PB and CSC (lane 2), 
supernatant (lane 3), and resuspended pellet (land 4), and 17 µL of resuspended pellet 
(lane 5) were separated by size under reducing conditions by SDS-PAGE (4-20% tris-
glycine) and then visualized by silver-staining.  The mobilities of molecular mass 
markers are indicated on the left. 







transfer. This shows that PB-CSC complexes do not incorporate detectable levels of 
inhibitory activity (Figure 5.6).   
These results suggest that polymer complexation could be useful for purifying 
retroviruses from inhibitors of transduction.  To test this we formed polymer complexes in 
amphotropic virus stocks produced by TELCeB6-A and Ψ-CRIP cells, pelleted them by 
centrifugation, decanted the supernatant, resuspended the complexes to their original 
volume in fresh cell culture medium, or as a control in the decanted supernatant, and 
used them to transduce NIH 3T3 cells.  We compared the levels of transduction 
achieved by these processed virus stocks to the levels of transduction achieved by virus 
stocks that were not processed with the polymer complexes (Figure 5.7).  The level of 
enhancement ranged from 21 to 186-fold depending on which virus harvest was used, 
presumably because the level of inhibitory activity within the virus stocks varied from 
harvest to harvest (Figure 5.8).  In contrast, complexation and resuspension in fresh 
medium of viruses produced by Ψ-CRIP cells did not enhance transduction (Figure 5.7), 
most likely because Ψ-CRIP virus stocks contain much lower levels of inhibitory activity 
[6].   
To determine if this virus processing strategy could be used to increase gene 
transfer to other cell types, we formed polymer complexes with amphotropic virus stocks 
produced by TELCeB6-A cells, pelleted the virus-polymer complexes, resuspended 
them to their original volume in fresh medium, and used them to transduce rat intestinal 
epithelial (RIE), human adenocarcinoma (HeLa), and NIH 3T3 cells.  In parallel, we 
transduced cells with virus-polymer complexes that were not pelleted or resuspended in 
fresh medium.  We found that virus stocks that had been pelleted and resuspended in 
fresh medium transduced these cell lines 6 to 19-fold more efficiently than virus stocks 



































Figure 5.6 Complexes of CSC and PB do not incorporate substances that inhibit 
amphotropic retrovirus transduction. VFCM, which contains substances that inhibit 
amphotropic retrovirus transduction, was brought to 80 µg/mL of CSC and 80 µg/mL PB, 
incubated 20 min at 37°C to allow complexes of CSC and PB to form, and then 
centrifuged to pellet the complexes.  In parallel we conducted the same procedure with 
fresh medium (FM). The pellets from VFCM and FM were resuspended to their original 
volumes in supernatant that was decanted from the complexes formed in VFCM or in the 
supernatant that was decanted from the complexes formed in FM.  Twenty microliters of 
LacZ amphotropic virus stock produced by TELCeB6-A cells was brought to 100 µL with 
each of the resuspended pellets and to 8 µg/mL of PB, and then used to transduce NIH 
3T3 cells. Two days later the cells were assayed for β-gal activity.  Each point 
represents the mean ± standard deviation of triplicate samples.  Statistically significant 
differences (p ≤ 0.05) from the complexes formed in FM and resuspended in the 









































































Figure 5.7 Complexation of retrovirus with CSC and PB purifies them from inhibitors and 
substantially increases the efficiency of retrovirus transduction.   LacZ amphotropic virus 
stocks produced by TELCeB6-A and ψ-CRIP cells were brought to 80 µg/mL CSC and 
80 µg/mL PB, incubated for 20 min at 37°C, and then centrifuged to pellet the virus-
polymer complexes.  The supernatant was decanted and the pelleted complexes were 
resuspended to their original volume in fresh medium (white bars) or in the supernatant 
(black bars), brought to 8 µg/mL of PB, and used to transduce NIH 3T3 cells plated the 
previous day in a 96-well dish (5,000 cells per well).  Two days later the wells were 
assayed for β-gal activity.  Each point represents the mean ± standard deviation of 
triplicate samples.  Statistically significant differences (p ≤ 0.05) from complexes that 























































































Figure 5.8 The level of enhancement in gene transfer varies depending on the virus 
harvest. Ten different harvests of LacZ amphotropic virus stock produced by TELCeB6-
A cells were brought to 80 µg/mL CSC and 80 µg/mL PB, incubated for 20 min at 37°C, 
and then centrifuged to pellet the virus-polymer complexes.  The supernatant was 
decanted and the pelleted complexes were resuspended to their original volume in fresh 
medium, brought to 8 µg/mL of PB, and used to transduce NIH 3T3 cells plated the 
previous day in a 96-well dish (5,000 cells per well).  Two days later the wells were 
assayed for β-gal activity.  Each point represents the mean ± standard deviation of 
triplicate samples.   



















































Next we wanted to determine the relationship between the level of gene transfer 
and the concentration of polymer-purified retrovirus used to transduce cells.  We brought 
a range of volumes of polymer-purified virus (10 to 100 µL) to 100 µL with fresh medium 
and then used the solutions to transduce NIH 3T3 cells.  When low doses of virus (10 to 
20 µL per well) were used a linear relationship between virus dose and gene transfer 
was observed, whereas when higher doses (above 20 µL) of virus were used 
transduction reached a plateau and remained virtually constant (Figure 5.10).  A similar 
trend was observed when we measured the percentage of cells that had been 
transduced (Figure 5.11). 
We wondered if the plateau in beta-galactosidase activity was because the 
transduced cells contained the same number of integrated transgenes and therefore 
represented a maximum in the level of gene transfer that could be attained, or if the cells 
differed in the number of integrated transgenes but were unable, above a certain 
threshold number of integrated transgenes, to synthesize more beta-galactosidase.  To 
distinguish between these two possibilities, we examined the relationship between virus 
concentration and the number of integrated transgenes per cell.  We transduced NIH-
3T3 cells with a range of concentrations of polymer-purified virus, isolated and expanded 
three or more clonal cell lines from each of these mixed populations of transduced cells, 
and then used real-time PCR to quantify the relative number of integrated transgenes 
per cell in each clonal cell line.  We found that the number of integrated transgenes 
reached a maximum when 40 µL per well or more of purified virus was used to 
transduce cells (Figure 5.12). 
We wondered if the plateau in transduction levels was due to the presence of 
residual inhibitory activity, an excess of polymers, or if the cells were becoming 

































Figure 5.9 Complexation of retrovirus with CSC and PB increases the efficiency of 
increase gene transfer to other cell types. LacZ amphotropic virus stock produced by 
TELCeB6-A cells was brought to 80 µg/mL CSC and 80 µg/mL PB, incubated for 20 min 
at 37°C, and then centrifuged to pellet the virus-polymer complexes.  The supernatant 
was decanted and the pelleted complexes were resuspended to their original volume in 
fresh medium (white bars) or in the supernatant (black bars), brought to 8 µg/mL of PB, 
and used to transduce NIH 3T3, rat intestinal epithelial (RIE), and HeLa (HELA) cells 
plated the previous day in a 96-well dish (5,000 cells per well).  Two days later the wells 
were assayed for β-gal activity.  Values are fold-increases in gene transfer with respect 
to transduction with neat virus stocks containing 8 µg/mL of PB.  Each point represents 
the mean ± standard deviation of triplicate samples.  Statistically significant differences 
(p ≤ 0.05) from complexes that were resuspended in supernatant are denoted with an 
asterisk.   





















































































Figure 5.10 Dose-response curves for neat and purified amphotropic lacZ retrovirus 
produced by TELCeB6-A cells. LacZ amphotropic virus stock produced by TELCeB6-A 
cells was brought to 80 µg/mL CSC and 80 µg/mL PB, incubated for 20 min at 37°C, 
centrifuged to pellet the virus-polymer complexes, after which the pelleted complexes 
were resuspended to their original volume in fresh medium.  A range of volumes (0 to 
100 µL) of the original virus stock ( ) or the resuspended complexes ( ) were brought 
to 100 µL with fresh medium and to 8 µg/mL PB, and then used to transduce NIH 3T3 
plated the previous day in a 96-well dish (5,000 cells per well).  Two days later the wells 
were assayed for β-gal activity.  Each point represents the mean ± standard deviation of 
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Figure 5.11 Percentage transduction with purified amphotropic lacZ retrovirus produced 
by TELCeB6-A cells. LacZ amphotropic virus stock produced by TELCeB6-A cells was 
brought to 80 µg/mL CSC and 80 µg/mL PB, incubated for 20 min at 37°C, centrifuged to 
pellet the virus-polymer complexes, after which the pelleted complexes were 
resuspended to their original volume in fresh medium.  A range of volumes (0 to 100 µL) 
of the resuspended complexes were brought to 100 µL with fresh medium and to 8 
µg/mL PB, and then used to transduce NIH 3T3 plated the previous day in a 96-well dish 
(5,000 cells per well).  Two days later the cells were trypsinized, diluted, and plated onto 
a 10-cm dish.  After 10 days of growth, macroscopic colonies were fixed, stained, and 
the percentage of lacZ+ colonies calculated.  Each point represents the mean ± standard 































































Figure 5.12 The number of integrated transgenes reaches a maximum when high doses 
of purified retrovirus are used to transduce NIH 3T3 cells.  LacZ amphotropic virus stock 
produced by TELCeB6-A cells was brought to 80 µg/mL CSC and 80 µg/mL PB, 
incubated for 20 min at 37°C, centrifuged to pellet the virus-polymer complexes, and 
then the pelleted complexes were resuspended to their original volume in fresh medium.  
A range of volumes (5 to 100 µL) of the resuspended complexes were brought to 100 µL 
with fresh medium and to 8 µg/mL PB, and then used to transduce NIH 3T3 plated the 
previous day in a 96-well dish (5,000 cells per well). Two days after transduction, cells 
from each well were trypsinized, diluted in fresh medium and plated at clonal density in 
10-cm plates. Ten days later, three or four individual colonies from each plate were 
selected and expanded (different colonies from the same plate are denoted by the 
number in parenthesis). The genomic DNA of individual colonies was extracted and the 
relative number of integrated transgenes quantified by Real Time PCR.  Values are the 
number of integrated transgenes as a percentage of the maximum number detected.  


























































 while keeping the composition of the medium in which the viruses were suspended the 
same, we could distinguish between saturation of the cells with virus and other possible 
causes of the maximum in transduction.  Therefore, we diluted amphotropic virus stocks 
produced by TELCeB6-A cells five-fold with VFCM or fresh medium, formed polymer 
complexes within them, pelleted the complexes by centrifugation, resuspended the pellet 
to its original volume in fresh medium and used them to transduce NIH-3T3 cells.  The 
dose response curves were linear and virtually identical, regardless of whether the virus 
was originally diluted in fresh medium or conditioned medium (Figure 5.13).  These 
results suggest that the plateau in transduction is not due to the presence of inhibitors or 
to an excess of charged polymers in the purified virus stocks, and may be due to 
saturation of the cells with virus. 
Finally, we compared transduction by retrovirus purified by polymer complexation 
to transduction by retrovirus purified by ultracentrifugation and low speed centrifugation. 
To purify virus stocks by ultracentrifugation, we centrifuged them for 90 min at 200000g 
over a sucrose cushion, and then resuspended the pelleted viruses to their original 
volume in fresh medium. To purify virus stocks by low speed centrifugation, we 
centrifuged virus stocks for 16 hours at 6000g, and then resuspended the pelleted 
viruses to their original volume in fresh medium.  Interestingly, transduction by polymer-
purified virus was 2-fold more efficient than virus purified by ultracentrifugation and 4-fold 
more efficient than virus purified by low speed overnight centrifugation (Table 5.1).  
These differences in transduction did not appear to be due to differences in virus 
recovery since the amount of virus recovered by the three purification methods varied by 




































Figure 5.13 Transduction by virus purified by complexation with polymers is not limited 
by the polymers or by the presence of residual inhibitory activity.  Twenty microliters of 
LacZ amphotropic virus stock produced by TELCeB6-A cells was mixed with 80 µL of 
fresh medium ( ) or virus-free conditioned medium ( ), brought to 80 µg/mL of CSC 
and 80 µg/mL PB and incubated 20 min at 37°C to allow complexes of virus, CSC, and 
PB to form. The complexes were pelleted by centrifugation, and then resuspended to 
their original volume in fresh medium.  A range of volumes (10 to 100 µL) of the 
resuspended virus-polymer complexes were brought to 100 µL with fresh medium and to 
8 µg/mL Polybrene, and then used to transduce NIH 3T3 plated the previous day in a 
96-well dish (5,000 cells per well).  Two days later the wells were assayed for β-gal 
activity.  Each point represents the mean ± standard deviation of triplicate wells of the 
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Table 5.1 Purification of retrovirus by ultracentrifugation, low-speed centrifugation, and 
complexation with CSC and PBa 
 





Ultracentrifugation 83 ± 19 62 ± 21 26 ± 4.0* 
Low-speed centrifugation 91 ± 22 59 ± 15 12 ± 1.9* 
Polymer complexation 83 ± 16 81 ± 20 50 ± 7.8 
 
aLacZ virus produced by TELCeB6-A cells was purified by three different methods:  
centrifugation for 90 min at 200000g over a sucrose cushion (ultracentrifugation), 
centrifugation for 16 hours at 6000g (low-speed centrifugation), or by complexation with 
80 µg/mL each of PB and CSC followed by centrifugation for 5 min at 10000g (polymer 
complexation).  Centrifuged virus was resuspended to its original volume in fresh 
medium and then analyzed for concentration of p30, virus titer, and transduction 
efficiency as described in the Materials and Methods.   
b% recovery was defined as the ratio, multiplied by 100, of the p30 concentration (or 
virus titer) of virus that had been centrifuged and resuspended to its original volume to 
the p30 concentration (or virus titer) of neat virus stocks.  Values are the means ± SD for 
at least three replicates. 
c Fold-enhancement of transduction was defined as the ratio of the beta-galactosidase 
activity in the lysates of cells transduced with purified virus to the beta-galactosidase 
activity in the lysates of cells transduced with neat virus stocks.  Values are the means ± 
SD for at least three replicates. 
*Statistically significant differences (p ≤ 0.05) from virus stocks that were purified by 
polymer-complexation were denoted with an asterisk. 
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5.5 Discussion  
We have previously shown that retroviruses can be rapidly concentrated by 
complexation with the anionic polymer chondroitin sulfate C (CSC) and the cationic 
polymer Polybrene (PB) (refer to Chapter 2) [13].  Given the selectivity with which 
retroviruses are incorporated into complexes of these polymers, we hypothesized that 
virus-polymer complexation could be used to purify viruses from inhibitors of 
transduction. To test this hypothesis, we formed virus-polymer complexes in 
amphotropic retrovirus stocks produced by TELCeB6-A cells, pelleted the complexes to 
separate them from the conditioned medium, and then examined the effect of this 
separation process on the level of transduction.  We found that polymer complexation 
was an effective means to purify retrovirus.  More than 70% of the virus particles, but 
less than 0.4% of all other proteins, were incorporated into the complexes and the 
complexes contained no detectable inhibitory activity.  Viruses that were purified by 
complexation and resuspension in fresh medium transduced cells an average of 80-fold 
more efficiently than viruses that were not purified. In addition to substantially enhancing 
the level of gene transfer, virus purification also significantly altered the dose response 
of transduction.  When virus that had not been purified was used, the relationship 
between transduction and virus concentration was highly non-linear.  In contrast, when 
purified virus was used, transduction increased monotonically and was linearly 
proportional to virus concentration, except when high doses of virus were used.  Our 
results show the benefits of purifying retrovirus prior to using them to transduce cells: 
virus purification increases the maximum number of genes that can be transferred, 
reduces the amount of virus required to achieve a given level of gene transfer, and 
reduces uncertainties about the relationship between the amount of virus used and the 
number of genes transferred.    
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 Given that the purified virus contained no detectable levels of inhibitory activity, 
we were surprised to find that gene transfer reached a maximum plateau level when 
high doses of purified virus were used.  The plateau in gene transfer was eliminated 
when we diluted the virus five-fold while keeping the composition of the medium 
constant, which suggested that the plateau was not due to the presence of residual 
inhibitory activity or an excess of polymers.  Rather, we speculate that the cells were 
saturated with virus.  We estimate, based on the virus titer and a previously described 
mathematical model that accounts for several key parameters that govern retrovirus 
adsorption [15], that the virus stocks contained about 109 virus particles/mL.  One 
hundred microliters of this virus, complexed with polymers, were used to transduce 
about 20,000 cells per well in a 96-well dish.  From a previous study, we estimate that 
about 80% of these virus-polymer complexes reached the surface of the tissue culture 
plate within the first 8 hours of transduction (refer to Chapter 3) [35].  Since the cells 
occupied about 10% of the surface area of the tissue culture dish, we estimate that 
about 400 virus particles were delivered per cell.  Assuming that retroviruses each 
contain about 200-400 envelope proteins [43, 44], we estimate that about 105 envelope 
proteins were delivered per cell.  Interestingly, NIH 3T3 cells express about 105 
amphotropic receptors per cell [45].  Since retroviruses must bind to multiple receptors at 
the same time in order to transduce a cell [46, 47], it is likely that only a fraction of the 
receptors would need to be blocked or otherwise inactivated in order to render a cell 
resistant to infection.  These approximate calculations suggest that it is possible the 
plateau we observed in the dose response curve of polymer purified virus was due to 
saturation of the cellular receptors.  More experimental studies are needed to directly 
test this hypothesis.   
We did not isolate the inhibitory activity but our data suggests that it is free 
amphotropic envelope protein (i.e., envelope proteins that are not associated with a virus 
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particle) since amphotropic, but not ecotropic, retrovirus transduction was blocked.  
Several previous studies have shown that free envelope proteins are present in 
retrovirus stocks and inhibit transduction [9, 10, 45, 48, 49], but the magnitude of 
inhibition in our system was unusually high.  Neat virus stocks transferred 10-fold fewer 
genes than the same virus stock that was diluted 10-fold in fresh medium.  Slingsby et al 
previously reported similar levels of inhibition due to the presence of amphotropic 
envelope protein in virus stocks produced by FLYA13 packaging cells [9].  In contrast to 
our findings, however, they found only low levels of inhibitory activity in virus produced 
by TEFLYA packaging cells, cells that are derived from the same parental cell line 
(TE671 cells) that was used to construct the packaging cell lines we used for our 
experiments (i.e., TELCeB6-A cells).  Most likely, the level of free envelope protein that 
is present in virus stocks can vary widely between individual packaging cell lines even 
when they are derived from the same parental cell line.  Indeed, we have recently 
constructed several clonal amphotropic retrovirus packaging cell lines from TELCeB6 
cells and found that virus stocks with similar titers (within 2-fold of each other) can vary 
by 10-fold or more in their levels of soluble envelope protein (data not shown, refer to 
Chapter 6).   
We find it interesting that only recently, with the advent of high titer (>107 
CFU/mL) virus stocks, have investigators begun to observe this magnitude of inhibition.  
Although we can only speculate, we wonder if high titer virus stocks are more likely than 
low titer stocks to contain large numbers of inhibitory free envelope proteins.  Since the 
expression cassettes for the genes that encode the structural proteins needed to form a 
virus particle are not linked to the expression cassette for the envelope proteins, it is not 
immediately clear why packaging cell lines that generate more virus particles would 
necessarily generate more soluble envelope proteins.  Perhaps the process of selecting 
and isolating clonal cell lines that produce high titer virus stocks leads to the de facto 
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selection of cell lines that express high levels of envelope protein.  Bachrach et al 
showed that virus titers increase in proportion to the amount of envelope protein that is 
incorporated into the virus particles, at least up to a minimum threshold level, and the 
amount of envelope protein incorporated into virus particles is in turn proportional to the 
level of envelope expression within the cell [46].  Therefore, a packaging cell line that 
produces large numbers of virus particles would presumably also have to produce a 
proportionally higher level of envelope virus protein in order to generate a high titer virus 
stock.  It is also possible that soluble envelope proteins are shed from the virus particles 
themselves, rather than from the cells that produce the virus.  Whether or not envelope 
proteins are shed from mature retrovirus particles, and to what extent, is somewhat 
controversial.  Early studies suggested that the shedding of envelope proteins was a 
common phenomenon of retroviruses and lentiviruses [50-52], but more recent 
quantitative studies of the protein content of retroviruses and lentiviruses have 
demonstrated that envelope proteins are more stably associated with virus particles than 
previously thought and that lentiviruses shed few, if any, envelope proteins [53, 54].  
Even if significant amounts of envelope proteins are shed from retrovirus particles, a 
very high concentration of virus would likely be required to generate a sufficient number 
of soluble envelope proteins to inhibit transduction.  Battini et al showed that about 0.5 to 
1 nM of a purified fragment of the amphotropic envelope protein was sufficient to 
significantly inhibit transduction [45].  McKeating et al found that similar concentrations of 
recombinant gp120 significantly inhibited HIV-1 infection [50].  If we assume, based on 
recent studies with HIV and SIV, that retroviruses shed about half of their envelope 
proteins as they age, then a virus stock would need to contain 2x109 particles/mL or 
more in order to realistically generate enough free envelope protein to significantly inhibit 
transduction [51,55]. 
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Although more work is needed to fully understand the origin of free envelope 
proteins, it is clear that their presence in retrovirus stocks is a significant barrier to 
achieving efficient, predictable, and reproducible levels of gene transfer.  In this study we 
showed that polymer complexation is an effective means to purify retrovirus from free 
envelope protein.  An important benefit of using polymer complexation to purify virus is 
that retroviruses are incorporated into the complexes regardless of which envelope 
protein they are pseudotyped with [13], and even when they are not pseudotyped with 
any envelope protein (refer to Chapter 2).  As a result, unlike some other purification 
methods, viruses do not need to be pseudotyped with a specific envelope protein, such 
as VSV-G or an envelope protein into which special sequences have been inserted, in 
order to purify them [33, 56]. 
The mechanism by which retroviruses are selectively incorporated into 
complexes of PB and CSC is not known.  Most likely it is a form of flocculation, the 
destabilization of a suspension of colloids by the addition of a chemical agent known as 
a flocculant [57].  Charged polymers are commonly used as flocculating agents in the 
treatment of wastewater, to purify proteins, and to control the surface properties of 
biopharmaceuticals [58-63].  Consistent with our results, several studies have observed 
that polymer flocs bind large particles and proteins more readily than smaller ones [60-
62, 64-66].  The selective incorporation of large particles into polymer flocs appears to 
be a consequence of the kinetics of polymer adsorption.  The rate of polymer adsorption, 
which is the result of particle-polymer collisions that occur due to Brownian motion or 
agitation of the suspension, increases with particle size.  Since polymer adsorption is 
effectively irreversible, adsorbed polymers do not later redistribute to particles of smaller 
sizes.  As a result, the number of polymer molecules adsorbed per particle increases 
with the size of the particles, which causes the larger particles to be preferentially 
flocculated [67]. 
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These studies suggest that retroviruses are selectively incorporated into 
complexes of PB and CSC because of their large size.  If this is the case, then it is likely 
that polymer complexation can be used to purify retroviruses from many other types of 
substances, in addition to free envelope proteins.  For example, polymer complexation 
may prove useful for purifying retroviruses from substances that inhibit transduction that 
are not envelope proteins, such as TGF-beta or other unidentified inhibitors of 
transduction such as those secreted by Chinese hamster ovary cells [68, 69].  Polymer 
complexation may also prove useful for purifying retroviruses from molecules in virus 
stocks that do not inhibit transduction but nevertheless reduce the chances of success in 
a gene therapy protocol.  For example, cells that produce retroviruses that encode a 
cytotoxic protein, such as fas ligand [70], may express and secrete into the virus stock 
the cytotoxic protein or its derivative, which makes it necessary to purify the virus from 
these substances before it is used to transduce cells.  Virus stocks can also contain 
molecules, such as those found in stocks produced by HT1080 cells, that prevent 
hematopoietic stem cells from engrafting or induce them to differentiate in an 
uncontrolled manner [31, 71].  Further experiments are needed in order to determine the 
extent to which polymer complexation can be used to purify retroviruses from these and 
other substances that contaminate retrovirus stocks. 
We compared the effectiveness of retrovirus purification by complexation with 
polymers to retrovirus purification by ultracentrifugation and overnight low speed 
centrifugation.  Interestingly, we found that retrovirus purified by complexation with 
polymers transduced cells 2 to 4-fold more efficiently than retrovirus purified by these 
other methods.  Most likely this is because the polymer-purified retroviruses were still 
associated with polymer complexes when they were applied to the cells, and therefore 
were transported more rapidly to the surfaces of the cells (refer to Chapter 3) [35].  It is 
also possible that ultracentrifugation and low speed centrifugation only partially purify 
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retroviruses from inhibitors, in which case additional processing steps, such as 
chromatography or sucrose banding after centrifugation, may be required before using 
them to transduce cells [22, 25].  
In summary, we have shown that retroviruses can be rapidly purified from 
inhibitors of transduction by complexation with CSC and PB.  Purification of retrovirus by 
polymer complexation has a number of advantages:  1) retroviruses can be purified in 
larger volumes and much more rapidly than by ultracentrifugation or overnight low speed 
centrifugation, 2) retroviruses do not need to be pseudotyped with a specific envelope 
protein in order to be purified, and 3) retroviruses purified by polymer complexation 
transduce cells more efficiently than retrovirus purified by ultracentrifugation or overnight 
low speed centrifugation.  Purification steps such as these are important for the 
formulation of retrovirus preparations that are suitable for use in human gene therapy 
protocols.  Purified virus transfers more genes, can be used in smaller quantities to 
achieve the desired level of gene transfer, and most likely will improve the safety of 
these procedures by improving the reproducibility and predictability of their outcomes. 
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RELATIONSHIP BETWEEN GENE TRANSFER AND NUMBER OF ENVELOPE 
PROTEINS INCORPORATED PER RETROVIRUS PARTICLE WHEN HIGH DOSES 




The efficiency of retroviral mediated gene transfer is in part determined by the 
interaction between viral envelope glycoproteins and their cognate cellular receptors. 
While increasing the concentration of cell receptors usually results in enhancement of 
transduction, it is not clear how varying the concentration of virus envelope protein 
(gp70) affects gene transfer. Measurements of titer with diluted virus stocks have shown 
that increasing the concentration of gp70 increases the efficiency and the rate of 
transduction. However, titer accounts for transduction of a single cell with a single 
isolated virus.  These conditions do not mimic a typical gene transfer protocol, where 
undiluted stocks are used. This observation prompted us to analyze how varying the 
number of envelope proteins per virus affects transduction with undiluted virus stocks. 
The results from previous research are conflicting and suggest that gene transfer does 
not directly correlate with the concentration of gp70. In this study, we tested the 
hypothesis that an excess of virus-associated envelope glycoprotein limits the efficiency 
of transduction. To test this hypothesis, we constructed a panel of several clonal 
amphotropic murine leukemia virus packaging cell lines, each of which was derived from 
the same parental cell line and differed only in the amount of envelope protein they 
expressed. We purified the stocks produced by these cell lines from free envelope 
protein and analyzed the effect of virus-associated envelope on transduction. Stocks 
with low or high number of envelope proteins per virus achieved almost 100% 
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transduction. However, stocks containing low concentrations of virus-associated 
envelope achieved the highest efficiencies of transduction, most likely by allowing 
multiple integrations of the transgene per target cell. High concentrations of virus-
associated amphotropic envelope inhibited transduction in a receptor dependent 
manner. Taken together, our results suggested that while optimum gene transfer is 
achieved when the number of envelope proteins per virus is low, viruses displaying high 
concentrations of the envelope can mediate efficient transduction, while limiting the 
number of gene copies delivered per target cell.  
 
6.2 Introduction 
Recombinant retroviruses are commonly used as gene delivery vectors, mainly 
because they are able to stably integrate their genes into the genome of the target cells 
[1, 2]. Unfortunately, the efficiency of gene transfer using this vector is often too low to 
achieve an intended therapeutic effect. In addition, the level of transduction with 
retroviruses has proven difficult to predict and control. Predictable and reproducible 
levels of gene transfer are important in order to maximize the benefits of retrovirus 
transduction while minimizing the likelihood of any adverse side effects. In order to 
develop therapies that are effective, safe and reproducible, we require a better 
understanding of major rate-limiting steps of transduction. 
One of the earliest and critical steps of transduction is the specific interaction 
between the envelope glycoproteins of the virus and their cognate receptors on the 
surface of the target cells. This interaction mediates fusion and entry of the viral core into 
the cytoplasm of the cell. Also, it is a major determinant of the tropism of the virus (the 
range of cells that a virus can or cannot transduce). In order to target specific cells in 
gene therapy protocols, the wild type envelope of a virus has been frequently replaced 
with one from another virus to form a pseudotyped virus (a virus composed of proteins 
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from more than one virus) [3, 4]. Pseudotyping has also been exploited as a means to 
enhance the efficiency of gene transfer [5, 6], by targeting receptors that are expressed 
at high concentrations. In fact, varying the extent of receptor-envelope interactions can 
affect the overall efficiency of transduction. A better understanding of how gene transfer 
responds to changes in the absolute and relative concentrations of cellular receptors and 
viral envelope proteins can therefore be used to improve the reproducibility and 
predictability of gene transfer.  
High expression of receptors for a particular envelope appears to increase the 
likelihood of gene transfer [7-13]. In some cases, transduction has been enhanced by 
inducing overexpression of receptors through manipulation of the cell culture medium. 
For example, the amphotropic receptor (Pit-2) and the gibbon ape leukemia virus 
receptor (Pit-1) are upregulated by incubation of the cells in phosphate depleted medium 
or in the presence of phorbol 12-myristate 13-acetate (PMA) [10, 14-16]. In 
hematopoietic stem cells, these receptors can be upregulated by incubation of the cells 
with cytokines [12, 13, 17]. Alternatively, a receptor can be overexpressed by 
transfecting cells with the gene encoding for it [13, 16]. Slight upregulation of receptors 
that are normally expressed at low levels has been shown to translate in major increases 
in gene transfer [13]. 
The efficiency of envelope-receptor interactions not only depends on the number 
of cell receptors, but can also be altered by varying the number of envelope 
glycoproteins per virus particle [18]. The level of incorporation of envelope proteins on 
the surface of a virus depends on the level of expression of these proteins by packaging 
cells [18, 19] and on the recognition of the envelope by the viral core during assembly of 
the virion [20-22]. During transduction, envelopes from a single virus form oligomers and 
act cooperatively to achieve efficient fusion [22-24]. Although the exact mechanism is 
not clear, it has been proposed that the rate of fusion depends on how tightly the virus 
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binds to the cell, which is turn determined by the number of interactions between 
envelope proteins from a virus and cell receptors [18, 25]. As a result, higher 
concentrations of virus-associated envelope proteins have been shown to correlate with 
higher rates of transduction. In agreement with this idea, it has been possible to enhance 
gene transfer by  increasing the fluidity of the cellular plasma membrane [25, 26]. A 
more fluid membrane appears to favor rapid mobilization of receptors to the site of virus 
binding, thereby providing multiple binding sites for multiple envelope proteins of a virus.  
Although the rate of a transduction event increases with increasing 
concentrations of envelope proteins, low concentrations, above a certain threshold, have 
proven sufficient to achieve optimal titers [18]. Titers are measured using very diluted 
virus stocks [18]. When using undiluted or less diluted virus stocks, the results from 
various studies are inconsistent. In some cases, increasing the concentration of viral 
envelope has been shown to enhance the efficiency of gene transfer [20, 21]. This 
enhancement using the simian immunodeficiency virus envelope was only possible 
when receptors were expressed at high levels. At low levels of receptors, increasing the 
concentration of viral envelope did not have any effect on transduction [21]. In contrast, 
Slingsby et al. showed an inverse correlation between the concentration of amphotropic 
envelope proteins and the efficiency of transduction [19]. They proposed that there is an 
optimum level of expression of envelope proteins that maximizes transduction. This 
optimum level can be in part dictated by the concentration of free envelope. Free 
envelope can be shed from packaging cells and from viruses, and act as a competitive 
inhibitor of transduction by binding to cellular receptors [7-9, 24, 27, 28]. In addition, 
envelope proteins can associate with defective virus particles lacking the viral vector, 
and also compete with functional viruses for cell receptors [19]. 
Overall, the results from titer and from transduction using undiluted stocks are 
somewhat contradictory and difficult to compare. Titer has often been used to predict the 
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efficiency of transduction with undiluted virus stocks. However, to measure titer, virus 
stocks are diluted several thousand fold in fresh medium, such that each cell is likely to 
encounter at most one virus particle throughout the transduction experiment and the 
composition of the medium is optimum for the intended target cell. On the contrary, 
undiluted virus stocks are typically used in human gene therapy protocols, such that an 
individual cell may encounter many viruses within a short period of time. Transduction 
with undiluted virus stocks can be influenced by the composition of the medium, which 
can vary from harvest to harvest of the same virus. For example, some stocks contain 
higher concentrations of free envelope inhibitor than others. These differences can be 
eliminated by purifying viruses from the conditioned medium and suspending them in 
fresh cell culture medium (refer to Chapter 5). However, there is a possibility that when 
multiple viruses bind simultaneously to a single cell, the susceptibility of the cell to 
transduction is regulated by factors inherent to the viruses themselves, for example by 
the number of envelope proteins per virus. Given that in a typical gene transfer protocol 
virus stocks are not diluted but can be purified and concentrated, there is significant 
motivation to investigate how varying characteristics of the virus particles affect 
transduction. In this context, we hypothesized that increasing the concentration of virus-
associated envelope proteins above a certain threshold hinders transduction.  
 
6.3 Materials and methods 
Chemicals and antibodies.  Chondroitin sulfate C (CSC) (shark cartilage), 
gluteraldehyde, 1,5-dimethyl-1,5-diazaundecamethylene polymethobromide (polybrene, 
PB) and o-Nitrophenyl β-D-galactopyranose (ONPG) were from Sigma Chemical Co. (St. 
Louis, MO). o-Phenylenediamine Dihydrochloride (OPD) was from Pierce (Rockford, IL).  
5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) was from Denville Scientific, 
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Inc. (Metuchen, NJ).  Mouse anti-p30 and mouse anti-gp70 antibodies were purified from 
the supernatant of the CRL-1219 (ATCC, Rockville, MD) and the 83A25 [29] hybridoma 
cell lines respectively, following standard procedures [30].  The goat polyclonal anti-p30 
antibody (78S221) and the goat polyclonal anti-gp70 (79S834) were from Quality 
Biotech (Camden, NJ).  The horseradish peroxidase conjugated rabbit anti-goat 
immunoglobulin G polyclonal antibody was from Zymed Laboratories (South San 
Francisco, CA).  
Cell culture.  NIH 3T3 mouse fibroblasts were cultured in Dulbecco's modified 
Eagle's medium (DMEM; Hyclone Labs Inc., Logan, UT) with 10% bovine calf serum 
(Hyclone Labs Inc., Logan, UT), 100 U/mL of penicillin and 100 µg/mL of streptomycin 
(Hyclone Labs Inc.) (DMEM/BCS).  TE671 (human medulloblastoma epithelial cells), 
TELCeB6 (TE671 cells expressing Mo-MLVgagpol and the retroviral vector MFGnlsLacZ 
[31]), and HeLa cells (human adenocarcinoma cells), obtained from the ATCC, were 
cultured in DMEM, 10% fetal bovine serum (Hyclone Labs Inc.), 100 U/mL of penicillin 
and 100 µg/mL of streptomycin (DMEM/FBS). GP2-293 packaging cells (HEK 293 
expressing Mo-MLVgagpol, BD Biosciences, Franklin Lakes, NJ) were cultured in 
DMEM/FBS, in collagen coated Biocoat culture plates (BD Biosciences).   
Generation of stable amphotropic retrovirus packaging cell lines.  An 
amphotropic packaging cell line (TELCeB6-A) was generated by stable transfection of 
TELCeB6 cells.  Five micrograms of the plasmid FB4070ASALF, an expression plasmid 
that encodes for the amphotropic envelope glycoprotein (a kind gift of Stephen Russell), 
was dissolved in 400 µL of 0.25M CaCl2, mixed with 400 µL of 2X HEPES buffered 
saline (274 mM NaCl, 42 mM Hepes acid, 10 mM KCl, 1.4 mM Na2HPO4 and 12 mM 
dextrose), incubated at room temperature for 20 minutes, then added to a 50% confluent 
T75 flask of TELCeB6 cells.  Twelve hours after transfection the cells were washed with 
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PBS, and then the medium replaced with fresh DMEM/FBS.  Two days later the cells 
were trypsinized, pelleted, and resuspended. Two hundred microliters of the 
resuspended cells were diluted in 10 mL of selective medium (DMEM, 10% FBS, 50 
µg/mL of phleomycin, and 7 µg/mL of blasticidin), plated in a T75 flask, and the selective 
medium was replaced every 2-3 days. Fourteen days later pooled clones were collected 
and plated at clonal density. Ten days later, individual clones were selected, expanded 
and frozen (-80°C) for later use. 
Production of retroviruses.  To generate retrovirus stocks from stable 
packaging cells, virus-producing cells were grown to confluence in T175 tissue culture 
flasks, then incubated for 24 h with 35 mL of cell culture medium.  The virus-laden tissue 
culture medium was harvested, filter sterilized (0.45-µm), then frozen (-80°C) for later 
use.  We produced amphotropic and ecotropic retrovirus vectors encoding for GFP by 
transient transfection of GP2-293 cells that were plated the day before in 10-cm tissue 
culture dishes (6x106 cells/dish), and cultured in 10 mL of DMEM that contained no 
antibiotics. The next day (between 18 to 30 h later), cells were transfected with 
FB4070ASALF (for amphotropic virus) or FBMO-SALF (for ecotropic virus) and the 
MSCV-GFP vector (kind gift of Catherine Verfaillie). Eight micrograms of each plasmid 
were diluted into a total of 1.5 mL of DMEM, then mixed with a solution of 1.5 mL of 
DMEM and 40 µL of Lipofectamine 2000 reagent (Invitrogen Life Technologies, 
Carlsbad, CA), then added to the cells. The medium was replaced 6 hours later and 18 
hours later with 10 mL of DMEM/FBS. Twenty four hours later the virus-laden cell culture 
supernatant was harvested, filter sterilized (0.45-µm) and frozen (-80°C) for later use. 
ELISA for p30 and gp70.  We used an enzyme-linked immunosorbent assay 
(ELISA) to determine the concentration of virus capsid protein (p30) and the viral 
envelope glycoprotein (gp70).  ELISA plates (Nunc immuno Maxisorp 96-well plates, 
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Nalge Nunc International, Rochester, NY) were coated overnight at 4°C with 10 µg/mL of 
mouse anti-p30 antibody or mouse anti-gp70 antibody (100 µL/well) in PBS. The next 
day, the antibody solution was removed and blocking buffer (PBS, 0.05% Tween-20, 5% 
non-fat milk) added (200 µL/well) for 2 h at 37°C to block non-specific binding sites.  
Samples were brought to 0.5% Triton-X to expose the p30 antigen, then added to the 
ELISA plate (100 µL/well) and incubated for 1 h at 37°C.  Bound p30 and gp70 were 
sandwiched by the addition of the goat polyclonal anti-p30 antibody diluted 1:1000 in 
blocking buffer or the goat polyclonal anti-gp70 diluted 1:300 in blocking buffer, and 
incubated for 1 h at 37°C.  The horseradish peroxidase conjugated polyclonal rabbit anti-
goat immunoglobulin G was diluted 1:5000 in blocking buffer then added to the ELISA 
plate (100 µL/well) for 1 hour at 37°C to enable detection and quantitation of the 
sandwiched p30 antigen. The plates were developed using hydrogen peroxide (H2O2) 
and OPD (100 µg/well) from a solution of 10 mg of OPD and 10 µl H2O2 in 25 mL of 
substrate buffer (24 mM citric acid-monohydrate, 51 mM Na2HPO4-7H20, pH 5.0).  8N 
sulfuric acid (50 µL/well) was used to stop the reaction and the optical density at 490 nm 
(OD490) measured using an absorbance plate reader and the non-specific background at 
650nm subtracted. Values for replicate wells without virus were subtracted as 
background. Values for each point are the average of at least triplicate wells. 
Diluted titer assay. Ten-fold serial dilutions of lacZ virus stock were made in 
DMEM/BCS and Polybrene (8 µg/mL).  A 1-mL amount per well was used to transduce 
3T3 cells that had been seeded (7 x 104 per well) the previous day in a 12-well plate.  
Two days after the start of the transduction, the cells were fixed and stained for β-
galactosidase activity with X-Gal [32].  Colonies of lacZ+ cells (typically in clusters of 2, 
4, or 8 blue cells) were counted with the aid of a dissecting microscope.  At appropriate 
dilutions of the virus stock, the clusters of blue cells were sufficiently spread over the 
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dish such that each cluster arose from a single transduction event.  From triplicate wells, 
the number of lacZ+ CFU per milliliter was determined.  
Transduction assay.  Five thousand NIH 3T3 murine fibroblasts in 100 µL of 
medium were plated per well in a 96-well flat-bottomed tissue culture dish with a low-
evaporation lid (Costar Corp., Cambridge, MA).  The next day (19 to 26 h later), the 
medium was removed and 100 µL of the virus-containing solutions added to each well.  
Two days after transduction, the medium was removed and the cells washed once with 
100 µL of phosphate-buffered saline (PBS) containing 1mM MgCl2.  After removal of the 
wash solution, 50 µL of lysis buffer (PBS with 1mM MgCl2 and 0.5% Igepal) were added 
to each well, and the plate incubated at 37°C.  After 30 min, 50 µl of lysis buffer with 6 
mM ONPG warmed to 37°C were added to each well, and the plate incubated at 37°C 
for 5 to 60 min until a visible yellow color was obtained. The reactions were halted by the 
addition of 20 µL per well of stop buffer (1M Na2CO3). The optical density at 420 nm 
(OD420) was measured using an absorbance plate reader (Molecular Devices, Menlo 
Park, CA) and the non-specific background at 650 nm subtracted. Values for replicate 
wells without virus were subtracted as background. Values for each point are the 
averages of at least triplicate wells. 
Purification of virus stocks.   
Purification by complexation with polymers. Stocks were purified as previously 
described [33].  Briefly, stocks were brought to equal weight concentrations (80 µg/mL) 
of PB and CSC by adding, in immediate succession, appropriate volumes of aqueous 
stock solutions (20 mg/mL) of the polymers and vortexing the mixture. The mixture was 
incubated for 20 min at 37°C, then centrifuged at 10000 rpm for 5 min. The supernatant 
was aspirated and the pellet was resuspended to the original volume in fresh cell culture 
medium. 
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Purification by low speed centrifugation. Virus stocks were centrifuged for 16 hrs 
at 6000g, 4°C. The supernatant was decanted and the pellet resuspended to the original 
volume in fresh cell culture medium. 
Percent transduced assay. Cells were transduced in 96-well dishes as 
described above, grown to confluence, and trypsinized. Twenty to one hundred 
microliters of the trypsinized cells were diluted into 1 mL of medium. Ten microliters of 
this dilution was plated into a 10-cm dish. After 10 days, when macroscopic colonies had 
grown, the plates were stained for β-galactosidase as described in the titer assay. The 
colonies were then counterstained with 1% rhodamine B, rinsed with water and air dried. 
Values for the percentage of lacZ+ colonies at each point (blue colonies/total colonies x 
100) are the averages of triplicate wells of the 96-well dish. 
Fluorescence microscopy.  NIH 3T3 cells were transduced as previously 
described with viruses carrying the GFP gene. Two days later, fluorescent images of the 
cells were taken using an inverted fluorescence microscope (IX-50, Olympus America, 
Inc., Melville, NY). The percentage of GFP+ cells was measured using the image 
analysis software MetaMorph Offline (Version 6.1 r0). 
Rate of binding of viruses to cells. NIH-3T3 cells were plated in 96-well dishes 
(5000 cells per well). The next day the medium was removed and replaced with 100 µL 
per well of virus purified by pelleting with polymers. At various times, the supernatant 
was collected. The concentration of p30 remaining in the supernatant was measured by 
ELISA. The rate of disappearance of p30 from solution has been shown to correlate with 
the rate of binding of p30 to cells (refer to Chapter 3)[34]. 
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6.4 Results 
To study how varying the concentration of viral envelope glycoprotein (gp70) 
affects the efficiency of retroviral-mediated gene transfer, we constructed a panel of 
several clonal amphotropic murine leukemia virus packaging cell lines, each of which 
were derived from the same parental cell line (TELCeB6 cells).  These packaging cell 
lines (TELCeB6-A) differed only in the amount of envelope protein they expressed. We 
measured the concentrations of virus capsid protein (p30) and viral envelope protein 
(gp70) in virus stocks produced by each clonal packaging cell line and chose stocks with 
different concentrations of gp70 per p30 for further analysis.  
To determine the extent to which varying the concentration of gp70 affected the 
bioactivity of individual virus particles, we measured the titer of the stocks by transducing 
NIH 3T3 fibroblasts with stocks that had been diluted several thousand fold.  We found 
that titer, and therefore the bioactivity of viruses, increased with increasing 
concentrations of gp70 and eventually reached a plateau (Figure 6.1).  
The results from titer represent the efficiency of transduction with a very low 
concentration of viruses and in a medium that is optimum for the target cells. In order to 
assess how varying the concentration of gp70 affects transduction in a typical gene 
transfer setting, we transduced NIH 3T3 cells with undiluted stocks produced from 
TELCeB6-A clones. Transduction was maximal at concentrations of gp70 corresponding 
to titers of 1.4 x 107 CFU/mL, and decreased to very low levels at concentrations of gp70 
that achieved titers of 3.4 x 107 CFU/mL (Figure 6.2). These results showed that 
indicated that an excess of gp70 in the stocks hinders gene transfer.  
The concentration of gp70 in virus stocks corresponds to the sum of virus-
associated gp70 and free gp70.  The inhibitory effect of free gp70 is negligible when 
measuring titer, where the stock is diluted several thousand-fold prior to transduction. 




















Figure 6.1 Titer increases with increasing concentrations of gp70 and reaches a 
plateau. Virus stocks produced from various clones from TELCeB6-A were diluted 
several thousand fold in fresh medium, then brought to 8 µg/mL of PB and used to 
transduced NIH 3T3 fibroblasts. The titer was normalized with the concentration of p30 























































Figure 6.2 Transduction with undiluted virus stocks is maximal at low concentrations of 
gp70. Undiluted virus stocks were brought to 8 µg/mL of PB, then used to transduce NIH 
3T3 fibroblasts. The efficiency of gene transfer was normalized with the concentration of 

















































gene transfer at high concentrations of gp70 was due to inhibition by free gp70. We 
purified stocks from free gp70 by complexation of viruses with charged polymers, as 
previously described (refer to Chapter 5). Briefly, we induced aggregation of viruses into 
polyelectrolyte complexes by adding the cationic polymer Polybrene and the anionic 
polymer chondroitin sulfate C to virus stocks. Then, we pelleted the complexes, 
decanted the supernatant and resupended the pellet to its original volume in fresh cell 
culture medium. We transduced cells with purified virus stocks and found that the 
efficiency of gene transfer increased significantly with all the stocks (compare Figures 
6.2 and 6.3). However, gene transfer was still maximal at low concentrations of gp70 
and decreased at high concentrations of gp70 (Figure 6.3). These results suggested that 
an excess envelope proteins associated with virus particles hinders gene transfer when 
cells are exposed to undiluted virus stocks.  
To investigate the mechanism by which increasing the number of envelope 
proteins per virus particle reduced transduction, we selected purified virus stocks from 
four TELCeB6-A clones that expressed different concentrations of gp70, but similar 
concentrations of p30: clones 1-18, 2-17, 2-18 and 2-44 (Table 6.1). In Figure 6.3, the 
stock from clone 1-18 is at the left of the peak, the stock from clone 2-17 is at the peak 
and the stocks from clones 2-18 and 2-45 are at the right of the peak.  
Given that increasing the concentration of gp70 enhanced transduction with very 
diluted stocks (Figure 6.1) but decreased transduction with undiluted stocks (Figure 6.3), 
we decided to examine in more detail the relationship between the level of gene transfer 
and the concentration of virus particles from each of the four selected stocks. We 
brought a range of volumes of each virus stock (0 to 100 µL) to 100 µL with fresh 
medium and then used the solutions to transduce NIH 3T3 cells.  When using stocks 
with a low number of gp70 per virus (produced by clone 1-18), gene transfer increased 
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 1.00 ± 0.07 
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 1.00 ± 0.08 
 





16.77 ± 3.66 
 
1.1 ± 0.10 
 





22.32 ±  4.90 
 
1.04 ±  0.07 
 
3.38 x 107 ±  0.20 x 107 
 
a: Virus produced by TELCeB6-A clones cells was purified by complexation with 
polymers. Purified virus was analyzed for its concentration of p30 and gp70 by ELISA.  
The number of gp70 per virus was determined as the ratio of gp70 to p30. Values are 
the means ± SD for three replicates. 
b: Virus produced by TELCeB6-A clones cells was purified by complexation with 
polymers. Purified virus was analyzed for its concentration of p30 Values are the means 
± SD for three replicates. 

























Figure 6.3 Transduction with purified virus stocks is maximal at low concentrations of 
gp70. Virus stocks purified by complexation with polymers were brought to 8 µg/mL of 
PB, then used to transduce NIH 3T3 fibroblasts. The efficiency of gene transfer was 
normalized with the concentration of p30 in the stocks. Each point shows the mean ± 
standard deviation of three replicates.  
 


































































Figure 6.4 Low concentrations of viruses displaying high numbers of envelope proteins 
are required to achieve maximal gene transfer. Virus stocks produced by TELCeB6-A 
clones 1-18 ( ), 2-17 ( ), 2-18 ( ) and 2-44 ( ) were purified by complexation with 
polymers, then diluted in fresh medium and used to transduce NIH 3T3 cells. The 
efficiency of gene transfer was quantified. Each point shows the mean ± standard 








































stocks with higher numbers of gp70 per virus (produced by clones 2-17, 2-18 and 2-44), 
the relationship between virus dose and gene transfer was linear only when low doses of 
virus were used (20 to 40 µL per well).  When higher doses of virus were used, 
transduction reached a plateau and remained virtually constant (Figure 6.4). Moreover, 
this plateau developed earlier as the number of envelope proteins per virus increased 
(Figure 6.4). 
This limit in gene transfer at high concentrations of virus-associated gp70 could 
be due to a decrease in the number of cells susceptible to transduction or to a decrease 
in the susceptibility of individual cells to multiple transduction events. To assess these 
possibilities, we conducted a parallel experiment to that from Figure 6.4, where we 
quantified the fraction of cells transduced as a function of virus concentration. 
Transduction with only 20 to 40 µL of the virus stocks was sufficient to achieve almost 
100% transduction, regardless of the number of envelope proteins per virus (Figure 6.5). 
Remarkably, when using the stock from clone 1-18, the level of expression of the 
transgene continued to increase in spite of having reached 100% transduction (compare 
Figures 6.4 and 6.5). This indicated that when the number of envelope proteins per virus 
was low, each cell integrated more copies of the transgene than when the number of 
envelope proteins per virus was high. 
To assess if these findings were specific to NIH 3T3 target cells, we examined if 
high concentrations of virus-associated gp70 would limit transduction to other cell lines. 
We brought a range of volumes (0 to 100 µL) of virus stock produced by clones 1-18, 2-
17 and 2-44 to 100 µL with fresh medium and then used these solutions to transduce 
human rhabdomyosarcoma (TE671) and human adenocarcinoma (Hela) cells. As with 
NIH 3T3, the efficiency of transduction increased with increasing concentrations of virus 




















Figure 6.5 Low concentrations of viruses displaying high numbers of envelope proteins 
are required to transduce 100% of the cells. Virus stocks produced by TELCeB6-A 
clones 1-18 ( ), 2-17 ( ), 2-18 ( ) and 2-44 ( ) were purified by complexation with 
polymers, then diluted in fresh medium and used to transduce NIH 3T3 cells. The 
percentage of lacZ+ cells was quantified. Each point shows the mean ± standard 





































































Figure 6.6 High concentrations of virus-associated gp70 limit gene transfer to TE671 
cells. Virus produced by TELCeB6-A clones 1-18 ( ), 2-17 ( ),and 2-44 ( )  were 
purified by complexation with polymers, then diluted in fresh medium and used to 



























































Figure 6.7 High concentrations of virus-associated gp70 limit gene transfer to Hela cells. 
Virus produced by TELCeB6-A clones 1-18 ( ), 2-17 ( ) were purified by complexation 
with polymers, then diluted in fresh medium and used to transduce Hela cells. Each 






































earlier than the plateaus observed with NIH 3T3 cells (compare Figure 6.4 and Figures 
6.6-6.7). In the case of Hela cells, transduction was the highest when the number of 
envelope proteins per virus was the lowest (clone 1-18). In the case of TE671 cells, 
gene transfer was the highest when the number of envelope proteins per virus was the 
second lowest (clone 2-17). These results suggested that there is a concentration of 
virus-associated gp70 that maximizes transduction and that this level depends on the 
specific target cell line. 
Based on these findings, we hypothesized that a high number of envelope 
proteins per virus was saturating cell receptors and therefore limiting the number of 
transduction events per target cell. To test this hypothesis, we transduced NIH 3T3 cells 
with a mixture of 20 µL of amphotropic GFP virus and 80 µL of amphotropic LacZ virus 
produced by either clone 1-18, clone 2-17 or clone 2-44. As controls, we transduced 
cells with a mixture of 20 µL of amphotropic GFP virus and 80 µL of fresh medium or 
with a mixture of 20 µL of amphotropic GFP virus and 80 µL of non-enveloped LacZ 
viruses. We observed the cells that were transduced with the GFP virus by 
immunofluorescence and quantified the percentage of GFP-positive cells using image 
analysis software. We found that as the number of amphotropic envelope proteins per 
lacZ virus increased, the efficiency of transduction with amphotropic GFP-virus 
decreased (Figures 6.8 and 6.10). To examine if high concentrations of virus-associated 
amphotropic envelope could also inhibit gene transfer with viruses displaying a different 
envelope, we repeated the previous experiment but used ecotropic GFP virus instead of 
amphotropic GFP virus. We found that the efficiency of transduction with ecotropic GFP 
did not vary as a function of the number of amphotropic envelope proteins per lacZ virus 
(P < 0.5) (Figures 6.9 and 6.10). These results suggested that high concentrations of 



























Figure 6.8 High concentrations of virus-associated amphotropic envelope block 
transduction with amphotropic viruses. NIH 3T3 were transduced with 20 µL of a stock of 
amphotropic GFP-viruses and 80 µL of a stock of amphotropic LacZ-virus produced by 
TELCeB6-A clones 1-18, 2-17 or 2-44. As controls, cells were transduced with 20 µL of 
a stock of amphotropic GFP-viruses and 80 µL of fresh medium (MED), or with 20 µL of 
a stock of amphotropic GFP-viruses and 80 µL of non-enveloped viruses produced by 
TELCeB6 packaging cells (BALD). Fluorescent images of GFP+ cells were taken. Note: 






















Figure 6.9 High concentrations of virus-associated amphotropic envelope do not block 
transduction with ecotropic viruses.  NIH 3T3 were transduced with 20 µL of a stock of 
ecotropic GFP-viruses and 80 µL of a stock of amphotropic LacZ-virus produced by 
TELCeB6-A clones 1-18, 2-17 or 2-44. As controls, cells were transduced with 20 µL of 
a stock of ecotropic GFP-viruses and 80 µL of fresh medium (MED), or with 20 µL of a 
stock of ecotropic GFP-viruses and 80 µL of non-enveloped viruses produced by 
TELCeB6 packaging cells (BALD). Fluorescent images of GFP+ cells were taken. Note: 
































Figure 6.10 High concentrations of virus-associated amphotropic envelope block 
transduction with amphotropic viruses, but not with ecotropic viruses. NIH 3T3 were 
transduced with 20 µL of a stock of amphotropic GFP-viruses and 80 µL of a stock of 
amphotropic LacZ-virus produced by TELCeB6-A clones 1-18, 2-17 or 2-44. As controls, 
cells were transduced with 20 µL of a stock of amphotropic GFP-viruses and 80 µL of 
fresh medium (MED), or with 20 µL of a stock of amphotropic GFP-viruses and 80 µL of 
non-enveloped viruses produced by TELCeB6 packaging cells (BALD). The same 
experiment was conducted using ecotropic GFP-virus instead of amphotropic GFP-virus. 
The percentage of fluorescence in wells transduced with amphotropic GFP virus (black 
bars) or with ecotropic GFP virus (white bars) was quantified by image analysis 
software. All the stocks used were purified by complexation with polymers. Each point 
shows the mean ± standard deviation of three replicates. Statistically significant 
differences (p ≤ 0.05) from MED are denoted with an asterisk. 
 
 































surface receptors from interacting with subsequent virus particles that are pseudotyped 
with the same envelope protein.   
In all our previous experiments, we purified virus stocks from free gp70 by 
inducing aggregation of the viruses into high molecular weight polyelectrolyte 
complexes. We have shown that viruses within these complexes sediment and are 
delivered to the cells more rapidly than by simple diffusion, while free retroviruses in 
conventional transductions are transported to cells by diffusion, a slow process 
compared to the rate that viruses lose their bioactivity [35]. Increasing the flux of viruses 
to cells by complexation with polymers has been shown to result in substantial 
enhancement of transduction (refer to Chapter 3) [34]. However, it was not clear if 
increasing the rate of virus transport assisted transduction when the number of envelope 
proteins per virus was high. Since it appeared that only a small fraction of the viruses 
that reached the cells were able to complete transduction in our system, we 
hypothesized that at low concentrations of virus-associated gp70, increasing the rate of 
binding of viruses to cells would not enhance transduction. 
To test this hypothesis, we purified virus stocks produced from clones 1-18, 2-17, 
2-18 and 2-44 by low speed centrifugation. Viruses purified by this method are not 
complexed with any agent and their transport is subject to diffusion limitations. To 
compare the kinetics of binding of viruses purified by complexation with polymers with 
that of viruses purified by low speed centrifugation, we incubated the purified stocks over 
NIH 3T3 cells. At various times we measured the concentration of viral capsid protein 
(p30) that remained in solution. We found that within a half-life of a virus (8 hours), 17% 
of the virus purified by low speed centrifugation and 74% of the viruses purified by 
complexation with polymers had disappeared from solution and had adsorbed to the 
surface of the cells (Figure 6.11). Then, we compared the efficiencies of transduction 
























Figure 6.11 Purification by complexation with polymers increases the flux of viruses to 
cells.  Virus stocks produced by TELCeB6-A clone 1-18 were purified by complexation 
with polymers ( ) of by low speed centrifugation ( ).  Purified stocks were brought to 8 
µg/mL of PB, then added to NIH 3T3 cells. At various times after the start of 
transduction, samples of the supernatant were collected and their concentration of p30 
quantified by ELISA. Each point shows the mean ± standard deviation of three 




































































per virus was low (clones 1-18 and 2-17), viruses purified by complexation with polymers 
achieved higher transduction than viruses purified by low speed centrifugation. However, 
when the number of envelope proteins was high (clones 2-18 and 2-44), viruses purified 
by complexation with polymers and viruses purified by low speed centrifugation achieved 
similar levels of transduction (Figure 6.12). These results indicated that, at high 
concentrations of virus-associated gp70, increasing the flux of viruses to the surface of 
the cells did not enhance gene transfer.  
 
6.5 Discussion 
In this study we examined how varying the number of envelope proteins per virus 
particle affects the efficiency of transduction. We found that virus titer, measured by 
transducing cells with diluted virus stocks, increased as the number of envelope proteins 
per virus particle increased. In contrast, when transducing cells with undiluted virus 
stocks, gene transfer was maximal when the number of envelope proteins per virus was 
low and drastically decreased with increasing numbers of envelope proteins per virus.  
Our results from titer are in agreement with previous studies [18] and indicate 
that individual virus particles displaying high concentrations of gp70 were able to 
efficiently transduce cells in diluted stocks. However, undiluted stocks contained high 
levels of free gp70 (refer to Appendix A1) that strongly inhibited infection when applied 
directly to cells.  Free gp70 complicated our efforts to examine the relationship between 
gene transfer and the number of envelope proteins per virus, so we purified the stocks 
from this inhibitor using a previously described polymer complexation method (refer to 
Chapter 5). To examine the relationship between gene transfer and the number of 
envelope proteins per virus, we used purified virus to transduce NIH 3T3, Hela, and 
TE671 cells.  We were surprised to find that transduction with undiluted and purified 





















Figure 6.12 At high concentrations of virus-associated gp70, increasing the flux of 
viruses to cells does not enhance gene transfer.  Virus stocks produced by TELCeB6-A 
clones 1-18, 2-17, 2-18 or 2-44 were purified by complexation with polymers (black bars) 
of by low speed centrifugation (white bars).  Purified stocks were brought to 8 µg/mL of 
PB, then added to NIH 3T3 cells. Two days later, the efficiency of gene transfer was 
quantified. Each point shows the mean ± standard deviation of three replicates.  
 



































Titer has been commonly used to predict the efficiency of gene transfer in gene 
therapy protocols. Here we show that titer can be a misleading parameter, as it accounts 
for the efficiency of transduction with virus stocks that had been diluted several thousand 
fold in fresh medium, such that each cell is likely to encounter at most one virus particle 
throughout the transduction experiment. In contrast, during transduction with undiluted 
stocks, an individual cell may encounter many viruses within a short period of time, 
which may regulate its susceptibility to transduction or to multiple transduction events.  
We found that when cells were transduced with high doses of purified 
amphotropic virus, further transduction by amphotropic retroviruses, but not ecotropic 
retroviruses, was blocked.  These results suggest that high concentrations of envelope 
proteins that are associated with a virus particle block or otherwise prevent cell surface 
receptors from interacting with subsequent virus particles that are pseudotyped with the 
same envelope protein. We did not examine the specific mechanism by which the 
receptor-envelope interaction was compromised, but possible mechanisms to consider 
include saturation and inactivation of cell receptors.  
Saturation of cell receptors may occur because each individual virus particle may 
bind to more receptors than necessary for transduction. A virus particle requires several 
envelope-receptor interactions in order to mediate efficient fusion. Envelope proteins 
form oligomers and cooperatively bind to cell receptors [22, 23]. Given that receptors 
also form oligomers and appear to mobilize and create multiple binding sites for a virus 
particle [26, 36], it is possible that more receptors than required for fusion colocalize at 
the site of binding of a virus. Considering this setup, when envelope proteins of a single 
virus are in excess, more envelope-receptor interactions than those strictly necessary for 
fusion may take place. In a previous study, we assumed that each retrovirus in a stock 
produced by pooled clones of TELCeB6-A contained about 200-400 envelope proteins, 
in analogy with human immunodeficiency virus type 1 [18, 37-39]. Based on this 
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assumption, we estimated that about 105 envelope proteins were delivered per cell (refer 
to Chapter 5). In the present study, the number of number of envelope proteins per virus 
varied by more than 20-fold, yet the titers of the stocks remained high, on the order of 
106-107 CFU/mL (Table 6.1). If we consider that an infectious virus from a stock with low 
concentrations of gp70 displays 200 envelope proteins, we could estimate that 106 or 
more envelope proteins were delivered per cell when stocks with the highest 
concentrations of gp70 were used. Given that NIH 3T3 cells express about 105 
amphotropic receptors per cell [40], these approximate calculations suggest that cellular 
receptors could be saturated after binding to only few viruses. 
Upon binding to gp70, receptors on the cell surface internalize and colocalize 
with gp70 in intracellular compartments [41, 42]. Replenishment of receptors on the cell 
surface can take several hours, as it has been shown that receptor interference can last 
24-48 hours in hematopoietic stem cells [16, 28]. Given that retroviruses decay rapidly, 
with a half life between 6 and 8 hours [43], it is possible that by the time receptors are 
replenished at the cell surface, the viruses remaining in the medium had lost their ability 
to transduce. 
In addition to saturation, it is possible that receptors are deactivated and become 
unable to mediate virus fusion. The amphotropic receptor is a sodium-dependent 
phosphate transporter [44, 45] and its level of expression is likely regulated to maintain 
homeostasis. In the presence of high extracellular concentrations of phosphate, 
receptors remain present at the surface of the cell, yet are deactivated and not able to 
mediate phosphate uptake or viral transduction [46, 47]. Conversely, in the presence of 
low concentrations of phosphate, receptors are activated [46, 48]. This activation-
deactivation pattern in response to the extracellular phosphate is determined by changes 
in the structural organization of the receptors and by changes in the organization of the 
actin cytoskeleton of the target cells [46]. It is possible that high concentrations of gp70 
 214
are sensed in manner analogous to that of high concentrations of phosphate, and trigger 
deactivation of receptors. 
We speculate that varying the concentration of virus-associated gp70 can be 
used to increase the efficiency of transduction or to limit the number of transduction 
events per target cell. A major concern in the field of gene therapy is that proviral genes 
can integrate within sequences of functional genes and lead to major physiological 
disorders [1]. Restricting the number of integration events by increasing the 
concentration of virus-associated gp70 could decrease the probability of insertional 
mutagenesis. However, we should consider that our results were obtained on NIH 3T3 
cells, which express high concentrations of amphotropic receptors and are easy to 
transduce. Cell lines with lower levels of receptors could benefit from lower expression of 
gp70, as multiple fusion events may be necessary before a single integration occurs.  
The number of envelope proteins per virus that is suitable for a given application 
appears to depend on several factors, such as the type of target cells, the concentration 
of viruses in the stock, the method used to purify or concentrate the stock, and the flux of 
viruses to the cells. The concentration of virus-associated gp70 that achieved maximal 
transduction was different for NIH 3T3, TE671 and Hela cells. These differences can be 
due to variability in the number and regulation of receptors on the surface of the 
particular target cell. Also, it is possible that receptors from different cells mobilize more 
or less efficiently to the binding site of a virus or that the efficiency of post-binding steps 
of transduction varies depending on the cell.  
The concentration of viruses and the method used to process a virus stock can 
also determine the outcome of transduction. Processing of virus stocks is commonly 
used to enhance gene transfer and usually encompasses purification and concentration 
procedures [34, 49-54]. In our system, concentration of the stocks might have not 
increased gene transfer, as maximal transduction was achieved with diluted stocks. On 
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the contrary, purification increased transduction by eliminating a major inhibitor, namely 
free gp70. Given that processing of the stocks usually results in loss of a fraction of the 
viruses, the need to concentrate and purify should be carefully evaluated.   
The efficiency of gene transfer is also dependent on the flux of viruses to target 
cells [34]. Viruses lose their ability to transduce with a short half-life (6-8 hours), and 
their transport is slow, mainly driven by diffusion [35, 43, 55]. As a result, most viruses 
lose their ability to transduce before reaching the target cells. Increasing the rate of 
transport of viruses overcomes this limitation. It enables more viruses to bind to the 
surface of the cells before losing their bioactivity, thereby increasing the efficiency of 
transduction. However, in this study we showed that increasing the flux of viruses only 
enhanced gene transfer when the number of envelope proteins per virus was low. This 
suggests that methods to accelerate the transport of viruses may not always be 
necessary. 
In summary, the results from this study highlight the importance of using accurate 
parameters to predict and control the efficiency of gene transfer. We propose that one of 
these parameters is the number of envelope proteins per virus particle. In order to use it 
appropriately, we need to better understand the mechanism by which gp70 controls the 
efficiency of transduction. In light of this, future studies should focus on characterizing 
the behavior of cell receptors with varying concentrations of viral envelope proteins. 
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CONCLUSIONS AND SUGGESTIONS FOR FUTURE RESEARCH 
 
7.1 Summary of results 
In chapter two, we developed a method that substantially enhances the efficiency 
of retroviral-mediated gene transfer. The method consists of the combined addition of 
equal weight concentrations of the cationic polymer Polybrene and the anionic polymer 
chondroitin sulfate C to retrovirus stocks prior to transduction. We found that these 
polymers aggregate with virus particles and form high molecular weight retrovirus-
polymer complexes that can be pelleted by low speed centrifugation.  The pelleted 
complexes contained most of the virus particles, but few other proteins. We were 
surprised to find that the viruses in the complexes remained bioactive and could be used 
to transduce cells.  When we concentrated the virus stocks by resuspending the virus-
polymer complexes in one-eighth the original volume, gene transfer to NIH 3T3 murine 
fibroblasts increased 10 to 20-fold over the original retrovirus stock that had not been 
concentrated.   
While conducting these experiments, we found that polymers enhanced gene 
transfer even when the stocks were not pelleted and concentrated. In addition, we 
observed granular precipitates on the surface of the target cells, which suggested that 
the complexes were sedimenting onto the cells.  
In chapter three, we investigated the mechanism by which the polymers enhance 
gene transfer without the need for concentration. We found that addition of oppositely 
charged polymers (Polybrene and chondroitin sulfate C) to virus stocks enhanced gene 
transfer by increasing the flux of active viruses to the cells.  Virus-polymer complexes 
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formed that did not reduce the stability of the viruses yet were large enough to sediment, 
delivering the viruses to the cells more rapidly than by simple diffusion.  The size of the 
complexes, the rate of sedimentation, and the levels of gene transfer increased with 
increasing concentrations of polymers. Interestingly, we found that association of the 
viruses with the polymer complexes did not hinder their ability to complete post-binding 
steps of transduction.   
In chapter four, we investigated the possibility of flocculating viruses using 
different combinations of charged polymers. For each combination we tested, viruses 
associated with polyelectrolyte complexes and significantly enhanced transduction. The 
anionic polymer and the viruses appeared to bind to most of the cationic polymer, 
thereby neutralizing the excess of positive charge in the medium. Based on these 
findings and the observation that viruses are located mainly at the surface of the 
complexes, we suggested a mechanism for flocculation. We proposed that oppositely 
charged polymers aggregate and form hydrophobic cores. When the cationic polymer is 
added in excess of the anionic polymer, molecules of the polycation are displayed at the 
surface of theses cores, and serve as anchors for binding of viruses to the complexes.   
While investigating the mechanism by which combinations of oppositely charged 
polymers flocculate viruses, we found that it is possible to flocculate and concentrate 
viruses using a single species of cationic polymer. Viruses concentrated after double 
flocculation remained as part of polymer complexes and were rapidly transported to the 
cells. In contrast, viruses concentrated after single flocculation disaggregated from the 
complexes and behaved as free viruses. We concluded that concentration by 
flocculation with a single polymer species is an effective alternative for applications for 
which high concentrations of polymers are undesirable or for which higher rates of virus 
adsorption due to sedimentation are not necessary. 
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In chapter five, we examined the possibility of purifying stocks of retroviruses 
from inhibitors of transduction by inducing formation of virus-polymer complexes, 
pelleting the complexes and resuspending the pellet to its original volume in fresh cell 
culture medium. We used virus stocks that contained high levels of inhibitory activity that 
was most likely due to free viral envelope protein. We found that the pelleted complexes 
incorporated more than 70% of the virus particles but less than 0.4% of all other proteins 
and no detectable inhibitory activity.  Purified virus transduced cells up to 186-fold more 
efficiently than virus that was not purified. Interestingly, when high doses of purified virus 
were used, gene transfer reached a maximum plateau level, most likely because 
particle-associated amphotropic envelope proteins had saturated the cellular receptors 
for the virus.  
In chapter six, we studied the relationship between the number of amphotropic 
envelope proteins associated per virus particle and the efficiency of transduction. We 
produced virus stocks that differed only in their concentrations of envelope proteins. 
Given that stocks containing high concentrations of virus-associated envelope protein 
also contained high concentrations of free envelope inhibitor, we purified the stocks by 
complexation with charged polymers. Using purified stocks, we found that low 
concentrations of virus-associated envelope achieved the highest efficiencies of 
transduction, most likely by allowing multiple integrations of the transgene per target cell. 
In contrast, high concentrations of virus-associated amphotropic envelope inhibited 
transduction in a receptor dependent manner.  
 
7.2 Conclusions 
1) Aggregation of viruses into complexes of oppositely charged polymers dramatically 
increases the efficiency of retroviral-mediated gene transfer by overcoming major 
barriers of transduction. Virus-polymer complexes sediment, increasing the 
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number of active viruses that are delivered to the cells, and are easily concentrated 
and purified by low speed centrifugation and resuspension in fresh medium (refer 
to Appendix A2 for a detailed protocol of this method). 
2) It is possible to concentrate virus stocks by inducing aggregation of viruses with a 
single species of cationic polymer, while only incorporating trace amounts of the 
polymer to the processed stock. Viruses concentrated by this means are subject to 
diffusion limitations, but can be effectively used in applications where an excess of 
polymers is undesirable. It is important to note that more research is necessary to 
characterize flocculation with a single polymer for its ability to purify viruses from 
inhibitors of transduction.  
3) Purified virus stocks can be used in smaller quantities than unprocessed stocks to 
achieve a desired level of gene transfer. Also, purification reduces uncertainties 
about the relationship between the amount of virus used and the number of genes 
transferred, which should simplify efforts to predict the outcome of retrovirus 
transduction protocols.  
4) The efficiency of gene transfer, and potentially the number of transgene copies 
delivered per target cell, can be modulated by varying the number of envelope 
proteins that protrude from a virus particle.   
 
7.3 Suggestions for future research 
1) Given that double flocculation of viruses with oppositely charged polymers is a 
promising means to overcome major extracellular barriers of retroviral-mediated 
gene transfer, future research should focus on determining the effect that high 
concentrations of charged polymers may have on target cells ex vivo and in vivo. In 
our model system, polymers were not toxic, but their applicability to more sensitive 
cells or directly in vivo has not been evaluated. Moreover, it is not clear if viruses 
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disaggregate from the polyelectrolyte complexes before fusing with the target cells 
or if the polymers are co-internalized with the viruses.  
2) In order to better understand why viruses are selectively incorporated into 
polyelectrolyte complexes and how viruses within complexes can efficiently 
accomplish post-binding steps of transduction, it is necessary to characterize the 
physicochemical properties of the virus-polymer aggregates. Future research 
should focus on quantifying the size, charge and composition of the complexes. In 
addition, future research should examine the kinetics of flocculation and the 
stability of the complexes depending on the medium they are suspended in.  
3) Flocculation with a single species of cationic polymer appears as an effective 
alternative to dual flocculation for concentrating virus stocks, which minimizes the 
concentration of polymers that remain associated with virus particles. Future 
research should examine the selectivity of a single polymer for aggregating virus 
particles and not other components of the medium. More specifically, it should test 
the possibility of purifying virus stocks from inhibitors or undesirable impurities by 
single flocculation.  
4) We developed and evaluated a method for concentrating and purifying stocks of 
retroviruses and lentiviruses and we showed it is rapid, easy and efficient at small 
scale.  Future research should evaluate dual flocculation and single flocculation as 
methods for large scale processing of virus stocks. 
5) Flocculation of retroviruses with polymers can have a wide variety of applications, 
which should be investigated in the future. For example, flocculation could be used 
to detect the presence of viruses in different media (e.g. in blood serum).  
6) Our results indicate that it is possible to enhance gene transfer by regulating the 
number of envelope proteins per virus particle. Given that these results were based 
on transduction of cells that express high concentrations of receptors, future 
 225
research should examine the possibility of enhancing gene transfer by this means 
to cells that express low concentrations of receptors and are difficult to transduce 
(e.g stem cells). 
7)  Our results suggest that it may be possible to restrict the number of transgene 
copies delivered per target cell by increasing the number of envelope proteins per 
virus particle. Since limiting the number of transgenes per cell can reduce the risk 
of insertional mutagenesis, future research should further explore this possibility 
using target cells that are relevant to gene therapies. 
8) Our results indicate that when the number of envelope proteins per virus particle is 
high, transduction is limited due to a reduction in availability of functional receptors 
for viruses pseudotyped with the same envelope. Future research should 
investigate the mechanism by which receptors block transduction in response to 
high concentrations of virus-associated gp70.  A better understanding of this 
mechanism would permit developing therapies to block infection or strategies to 






THE CONCENTRATION OF FREE ENVELOPE PROTEINS IS PROPORTIONAL TO 




The total number of viral envelope proteins (gp70) present in a virus stock 
corresponds to the sum of envelope proteins that are not associated with viruses (free 
gp70) and envelope proteins that protrude from the surface of virus particles (virus-
associated gp70). In this section, we examined the relationship between the total 
number of gp70, free gp70 and virus-associated gp70. 
In Chapter 6, we constructed a panel of several clonal amphotropic murine 
leukemia virus packaging cell lines, each of which was derived from the same parental 
cell line (TELCeB6 cells).  These packaging cell lines (TELCeB6-A) differed only in the 
amount of envelope protein they expressed.  We produced virus stocks from these 
clonal cell lines and measured the fraction of gp70 that was free or that was associated 
with viruses in each stock using two different methods: (1) ultracentrifugation and (2) 
complexation of viruses with polymers.  
Ultracentrifugation. To determine how the concentration of free gp70 varied 
with varying concentrations of total gp70, 9 mL of virus stocks were centrifuged over 2 
mL of 20% sucrose cushion for 90 min at 40000 rpm (200000g) and 4°C. Eight milliliters 
of the supernatant were collected. Upon ultracentrifugation, the virus capsid protein was 
not detected in the supernatant (data not shown), indicating that all the particles had 
been pelleted. However, the concentration of free gp70 remaining in the supernatant 
increased with increasing concentrations of gp70 in the original virus stock (Figure A2.1). 
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This correlation appeared to be linear (R2 = 0.89) and, by regression, we estimated that 
27 ± 5% (P = 0.005) of the total gp70 in the stocks was free. 
Complexation of viruses with polymers. In Chapter 5, we showed that virus 
stocks could be purified from free gp70 by inducing association of virus particles into 
polymer complexes. Briefly, stocks were brought to equal weight concentrations (80 
µg/mL) of PB and CSC by adding, in immediate succession, appropriate volumes of 
aqueous stock solutions (20 mg/mL) of the polymers and vortexing the mixture. The 
mixture was incubated for 20 min at 37°C, then centrifuged at 10000g for 5 min. The 
supernatant was decanted and the pellet was resuspended to the original volume in 
fresh cell culture medium. We purified virus stocks produced by TELCeB6-A clones 
using this procedure, then compared the concentrations of viral capsid protein (p30) and 
gp70 in the original and the purified stocks. The pellet concentrated 87% (R2 = 0.77) of 
the original content of p30 (Figure A2.2). Differences in expression of p30 from stock to 
stock were most likely due to differences in the confluency of packaging cells when the 
virus was harvested. The concentration of virus-associated gp70 in the resuspended 
pellet directly correlated with the concentration of total gp70 in the original stock (Figure 
A2.3). Assuming a linear correlation (R2 = 0.89), we estimated that 67 ± 4% (P = 0.000) 
of gp70 was associated with virus particles, which is consistent with the results from 
ultracentrifugation.  
We concluded that the average number of free envelope proteins was 
proportional to the number of envelope proteins incorporated per virus particle and to the 
amount of envelope protein that was expressed by the cells that produced them. In our 
















Figure A1.1 The concentration of free gp70 in a virus stock is proportional to the 
concentration of virus-associated gp70. Virus stocks produced by various TELCeB6-A 
clones were ultracentrifuged, then the concentration of gp70 in the original stock and in 
the supernatant (free gp70) were measured by ELISA. Each point shows the mean ± 
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Figure A1.2 Recovery of p30 upon purification by complexation with polymers. Virus 
stocks produced by various TELCeB6-A clones were brought to 80 µg/mL of PB and 
CSC, incubated at 37°C for 20 min, then centrifuged for 5 min at 10000g. The pellets 
were resuspended to the original volume in fresh medium. The concentrations of p30 in 
the original stocks and the resuspended pellets were measured by ELISA. Each point 
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Figure A1.3 The concentration of virus-associated gp70 in purified stocks is proportional 
to the total concentration of gp70 in original stocks. Virus stocks produced by various 
TELCeB6-A clones were brought to 80 µg/mL of PB and CSC, incubated at 37°C for 20 
min, then centrifuged for 5 min at 10000g. The pellets were resuspended to the original 
volume in fresh medium. The concentrations of gp70 in the original stocks and the 
resuspended pellets were measured by ELISA. The concentrations of gp70 were 
normalized with the concentrations of p30. Each point shows the mean ± standard 
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PROTOCOL FOR RETROVIRUS / LENTIVIRUS CONCENTRATION, PURIFICATION, 




1. Chondroitin sulfate C (CSC): Chondroitin 6-sulfate sodium salt from shark cartilage 
(Sigma-Aldrich, catalog # C4384) 
2. Polybrene (PB):  Hexadimethrine bromide (Sigma-Aldrich, catalog # H9268) 
 
Procedure 
A. Preparation of stock solutions of PB and CSC (250X concentrate) 
1. Prepare separate stock solutions for each polymer. Dissolve each polymer in 
distilled water (20 mg/mL), then filter-sterilize it using a 0.45 µm-pore filter. Store 
these stock solutions at 4°C. 
We recommend that fresh stock solutions be prepared each month.  Use of stock 
solutions older than one month may lead to lower recoveries of virus and lower 
levels of gene transfer. 
 
B. Concentration and purification of retrovirus or lentivirus stocks 
1. Bring the stock of retrovirus (or lentivirus) to 80 µg/mL of PB and 80 µg/mL of 
CSC by adding, in immediate succession, appropriate volumes of the stock 
solutions of PB and CSC (1/250th of the final volume) to the virus stock.  Mix by 
vortexing quickly or by pipetting up and down. 
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Polymer concentrations have been optimized for stocks of amphotropic retrovirus 
produced by the ψ-CRIP packaging cell line (derived from NIH 3T3) and the 
TELCeB6 packaging cell line (derived from TE671). Equal weight concentrations 
of both polymers have been shown to achieve optimal gene transfer [1].  We 
recommend that new users determine the optimum concentration of polymers for 
their experimental system by measuring the dose response of gene transfer as a 
function of polymer concentration while maintaining a 1:1 ratio of PB:CSC (see  
section D for sample optimization protocol). 
2. Incubate this solution at 37°C for 20 min.  During this time PB and CSC 
aggregate with virus particles and form virus-polymer complexes. 
We have found that incubation times of 5 to 20 minutes work well with 
amphotropic retrovirus stocks produced by the ψ-CRIP packaging cell line.  The 
optimum time required to incubate viruses with polymers to form virus-polymer 
complexes may vary among different virus production systems.  Most likely, 20 
minutes will be more than adequate for most systems.  The incubation time is to 
ensure that as many virus particles as possible have become associated with 
polymer complexes before the complexes are centrifuged and resuspended in 
fresh medium. 
Do not allow the virus stock to become too basic (pH > 7.8) because retrovirus 
stability declines rapidly if the pH becomes too high..  This should not be a 
problem as long as incubation times are kept short (not significantly longer than 
20 min). 
3. Centrifuge the solution at 10,000g for 5 min.  A visible pellet (the virus-polymer 
complexes) should be visible at the bottom of the tube. 
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Under these conditions, which have been optimized for the centrifugation of virus 
in microcentrifuge tubes (1.5 mL) using a table-top centrifuge (e.g., Eppendorf 
5417C), we routinely recover 80% of the virus particles.  It is possible that the 
optimum centrifugation speeds and times may vary if larger volumes of virus are 
centrifuged, or if different rotors or centrifuges are used. 
4. Remove the supernatant from the pellet. 
When using microcentrifuge tubes, the pellet is compact and firmly adherent to 
the side of the tube, but could detach if agitated. To aspirate the supernatant, tilt 
the tube to avoid aspirating the pellet or touching the pellet with the tip of the 
pipette or aspirator.  If necessary, re-centrifuge to re-form the pellet at the bottom 
of the tube.. 
5. Add fresh cell culture medium to the pellet. Resuspend the pellet by pipetting up 
and down until visible aggregates disappear. 
The volume of fresh medium that is added to the pellet depends on the fold-
concentration desired.  For example, to concentrate 1 mL of virus 10-fold, pellet 
the virus, then resuspend in 100 µL of fresh medium.  To purify 1 mL of virus 
and/or resuspend it in a new type of cell culture medium without concentrating it, 
resuspend the pellet with fresh medium to its original volume (1 mL). 
When using microcentrifuge tubes, it is easier to resuspend the pellet using a 
small diameter pipette tip and small volumes of resuspension medium (50-100 
µL) to help break up the pellet. If you wish to resuspend the pellet to a larger 
volume, it is helpful to first resuspend the pellet in a small volume (50-100 µL) 




To determine the percentage recovery of virus particles in the pellet, resuspend 
the pellet to the original volume in fresh medium, then measure the concentration 
of viral capsid protein by ELISA and compare it to that of the original stock 
solution. Measurements of titer increase several fold [1] when using the 
resuspended pellet and therefore cannot be used to accurately assess the 
percentage recovery of virus particles. 
 
C. Example transduction protocol:  Transduction of NIH 3T3 murine fibroblasts with 
virus-polymer complexes 
Day 1 
1. Plate 5000 NIH 3T3 cells per well in a 96-well plate. Incubate the plate overnight 
at 37°C and 10% CO2. 
Day 2 
1. Prepare virus stocks using the concentration/purification procedure: 
i. To purify the virus without concentrating it, bring 400 µL of virus stock in a 
microcentrifuge tube to equal weight concentrations of PB and CSC.  
Follow steps B2 to B5 and resuspend the pellet to its original volume in 
fresh medium. 
We generally bring the concentration of PB and CSC to 80 µg/mL; 
however, new users should determine the polymer concentrations that 
are optimal in their hands; in addition, optimum polymer concentrations 
should also be determined any time a new cell type or virus is used. 
 
ii. To concentrate the virus 8-fold, bring (2) 1480 µL volumes of virus stock 
in microcentrifuge tubes to equal weight concentrations of PB and CSC.  
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Follow steps B2 to B5.  Resuspend each pellet in 185 µL of fresh 
medium, then combine into a single tube for a total volume of 370 µL of 
concentrated virus-polymer complexes. 
We generally bring the concentration of PB and CSC to 80 µg/mL; 
however, the optimal concentration of polymers used should be 
determined for each new virus-cell system as described below.  It is also 
important to determine to what extent the virus should be concentrated in 
order to obtain the highest levels of gene transfer.  
2. Carefully remove the medium from the cells by aspiration or by inverting the plate 
over sterile paper towels.  
3. Add 100 µL per well of the virus-polymer complexes to triplicate wells.  As a 
control, add 100 µL per well of untreated virus stock to triplicate wells. Add fresh 
medium to the rest of the wells. 
4. Incubate the plate for two days at 37°C and 10% CO2. 
Precipitates will be visible on the surface of the target cells within a few minutes after 
the start of transduction and will accumulate over several hours.  These structures 
are virus-polymer complexes that have sedimented onto the surfaces of the cells [1, 
2]. The presence of virus-polymer complexes on cells has been shown to not be 
cytotoxic for a number of target cell lines (including NIH 3T3, Hela, RIE) and to not 
interfere with post-binding steps of gene transfer [2].  Nevertheless, we recommend 
that appropriate control experiments are conducted to verify that the virus-polymer 
complexes do not adversely affect cell function. 
Day 4 
Quantify the efficiency of gene transfer by measuring the level of β-galactosidase 




D.  Optimization of polymer concentrations  
1. Add equal weight concentrations of PB and CSC ranging from 20 to 320 µg/mL 
of both polymers to stocks of retrovirus. For example, add 20, 40, 80, 120, 160, 
and 320 µg/mL of both polymers to 400 µl of virus stock in microcentrifuge tubes. 
2. Follow steps B2 to B4 for each tube, then resuspend each pellet in 400 µl (the 
original volume) of fresh medium. 
3. Transduce NIH 3T3 target cells plated the previous day in 96-well plates by 
adding 100 µl per well of each resuspended pellet to triplicate wells. As a control, 
add 100 µl per well of untreated virus stock. (see the part C for additional details). 
4. Two days later, measure the level of β-Gal activity in lysates of transduced cells 
[1].  Plot β-Gal activity (which is proportional to the number of genes transferred) 
as a function of the concentration of PB and CSC that was added to the virus 
stock.  Determine what polymer concentration results in the highest levels of 
gene transfer (usually in the range of 40 to 120 µg/mL). 
 
 
